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HISTORICAL OVERVIEW
When an individual’s kidneys fail, there are three treatment options: hemodialysis, 
peritoneal dialysis or kidney transplantation. A successful kidney transplantation results in 
the best patient survival and a better quality of life compared to the two other treatment 
modalities.1 Kidney transplantation is therefore the preferred therapy for renal failure. 
The first deceased donor kidney transplantation in the United States was performed 
in 1950 by Lawler and colleagues on Ruth Tucker, a 44-year-old woman with polycystic 
kidney disease.2 Although the kidney transplant was rejected ten months later because 
no immunosuppressive therapy was available at the time, the intervening time allowed 
Tucker’s remaining native kidney (it was an orthotopic transplantation) to recover and she 
lived for another five years.2 At the same time in France, Küss, Hamburger, and others also 
performed a number of kidney transplantations.3-6
In 1954 the first successful kidney transplantation with a living kidney donor was 
performed between identical twins in Boston at the Peter Bent Brigham Hospital.7, 8 A kidney 
was transplanted from Ronald Herrick to his brother Richard Herrick. The transplantation 
kept Richard alive for eight more years. Joseph Murray who performed the procedure and 
is famous for his quote: “If you’re going to worry about what people say, you’re never going 
to make any progress”, received the Nobel Prize for Medicine in 1990 for “his discoveries 
concerning organ transplantation in the treatment of human disease”. Because Ronald and 
Richard were identical twins no immunologic problems occurred (the failure of the graft 
was caused by a recurrence of his primary kidney disease). 
However, it was not until the development of immunosuppressive (drug) therapy, that 
kidney transplantation between non-genetically identical individuals became possible.9 In 
the absence of such treatment, the recipient’s immune system will treat the transplanted 
organ as ‘strange’ and reject it. Pharmacologic suppression of the immune system is for 
this reason crucial. 
Currently, immunosuppressive therapy for the prevention of acute rejection after kidney 
transplantation mostly consists of the combination of a calcineurin inhibitor (CNI), either 
ciclosporine or tacrolimus, plus mycophenolic acid (MPA), and glucocorticoids with or 
without induction therapy with an interleukin (IL)-2 receptor blocker or a T-lymphocyte 
depleting agent. With immunosuppressive drug combination therapy, patient and kidney 
allograft survival have greatly improved.10,11 However, prolonged use of immunosuppressive 
drugs leads to considerable toxicity, including an increased rate of infections and 
malignancies, as well as drug-specific toxicity.
Calcineurin inhibitors:
Pharmacokinetics, pharmacodynamics and pharmacogenetics
In the last three decades the incidence of acute rejection among kidney transplant 
recipients has been reduced dramatically as a result of the introduction of a number of 
immunosuppressive drugs. Nowadays, renal allografts are infrequently lost as a result of 
uncontrollable acute rejection. Perhaps more than any other class of immunosuppressive 
drugs, the CNIs cyclosporine and tacrolimus have contributed to the decreased incidence of 
acute rejection. Cyclosporine revolutionized the transplant field following its introduction 
in the late 1970’s. Fifteen years later tacrolimus entered the transplantation arena and 
is nowadays the preferred CNI. With tacrolimus-based immunosuppressive therapy, 
acute rejection rates during the first post- transplant year have now fallen below 20% 
and one-year graft survival has risen to above 90%. However, despite the remarkable 
improvement of the short-term transplantation results, the introduction of modern 
immunosuppressive drug therapy has not resulted in a comparable improvement of the 
long-term transplantation outcomes.12
 
There are numerous reasons for the disappointing long-term kidney transplant survival. 
The majority of kidney transplants is lost by death of the recipient with a functioning 
kidney allograft. In addition, many kidney transplants are lost because of recurrence of 
the primary kidney disease. A third important cause of chronic kidney transplant loss, is 
the poorly understood entity named “chronic allograft nephropathy”. For many years this 
was considered to be caused by the chronic use of CNIs, that are notorious for their acute 
nephrotoxic effects.13-15 However, the presumed chronic nephrotoxicity of CNIs is currently 
subject of much debate and several investigators believe that it is not an important cause 
for chronic kidney transplant loss and is in fact a misdiagnosis of immunologically-mediated 
damage to the transplant.16, 17
The search for new immunosuppressive compounds that are less toxic but equally 
effective as the CNIs has been disappointing. Over the last few years, the development 
of a number of promising immunosuppressive drugs was aborted because of unexpected 
toxicity, lack of efficacy or both [e.g. fingolimod (FTY720), sotrastaurin (AEB071), and 
tofacitinib (CP69,550)]. It is therefore to be expected that the current gold standard 
immunosuppressive drug regimen of a CNI plus MPA will be here to stay for the next few 
years.
Pharmacokinetics of tacrolimus
Tacrolimus is a macrolide antibiotic with a molecular weight of 806. Tacrolimus is produced 
by Streptomyces Tsukubaenis and is highly lipophilic and therefore poorly soluble in 
water.18 The main mechanism of action of tacrolimus is the inhibition of T-lymphocyte 
signal transduction and interleukin (IL)-2 transcription by inhibiting the enzyme calcineurin. 
After entering the T-cell, tacrolimus binds to FK-binding protein (FKBP)-12, after which the 
tacrolimus-FKBP-12 complex binds to and inhibits calcineurin. By inhibiting calcineurin, 
tacrolimus prevents the dephosphorylation and activation of the nuclear factor of activated 
T-cells (NFAT). This eventually leads to the inhibition of the transcription of several genes 
important for T-cell activation and proliferation such as IL-2, IL-4 and gamma interferon. 
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The pharmacokinetics of tacrolimus are characterized by a highly variable, unpredictable, 
and in general, poor oral bioavailability. The oral bioavailability averages around 30%, but 
can be as low as 5% or as high as 90%. Tacrolimus distributes extensively into tissues 
and the cellular fraction of blood, where it is mainly distributed in erythrocytes and 
leucocytes. More than 90% of tacrolimus present in plasma is protein-bound. Besides a 
low oral bioavailability, the pharmacokinetics of tacrolimus are characterized by marked 
interindividual differences in first-pass metabolism and systemic clearance. The elimination 
half-life after oral intake of tacrolimus is between 8 and 12 hours. Following metabolism, 
tacrolimus is mainly excreted into bile (>90%).19 The intestinal and hepatic metabolism 
of tacrolimus is mediated by the cytochrome P450 ( CYP) isoenzymes 3A4 and 3A5. In 
addition, tacrolimus is a substrate of the drug transporter ATP-binding cassette (ABC) 
protein B1 (ABCB1, formerly known as permeability glycoprotein or P-gp).20
Pharmacokinetics of ciclosporine
Cyclosporine is an 11-amino acid cyclic peptide produced by the fungus Tolypocladium 
inflatum Gams.21 Like tacrolimus, ciclosporine is a calcineurin inhibitor. Tacrolimus is 
however 10 to 100 time more potent at the molecular level.22 Ciclosporine also has a 
different receptor than tacrolimus and binds to the intracellular protein cyclophilin-A with 
subsequent inhibition of the activation of calcineurin, again preventing IL-2 production 
by T-lymphocytes.23 Ciclosporine has a high variability in its pharmacokinetics. The oral 
bioavailability of ciclosporine is 25-30%.24 After oral administration the peak concentration 
in blood (Cmax) occurs at around two hours with a highly variable half-life of between 5 to 
10 hours.25 Ciclosporine in blood is distributed between erythrocytes and leukocytes with 
only about 4% in the plasma of which 70% is protein-bound.26 Ciclosporine is metabolized 
by CYP3A4 and CYP3A5 expressed in the intestine and liver. It is also a substrate for ABCB1 
expressed on the lymphocytes. 
Therapeutic Drug Monitoring
Besides marked interindividual differences in its pharmacokinetics, the clinical use 
of calcineurin inhibitors is further complicated by their narrow therapeutic window. 
Calcineurin inhibitors are considered to be critical dose drugs and in most transplant centers 
the dose of these drugs is adjusted according to whole blood concentrations, a practice 
known as therapeutic drug monitoring (TDM). The target whole blood concentrations 
aimed for depend on various factors including the perceived immunological risk, type of 
organ transplanted, and co-medication used. Different analytical methods can be used to 
determine tacrolimus or ciclosporine whole blood concentrations. The most commonly 
used quantitative procedure for TDM for calcineurin inhibitors is that of the micro particle 
enzyme-linked immunoassay (MEIA). However, liquid chromatography with mass 
spectrometric detection (LC-MS) has been implemented as an alternative technology for 
monitoring.27-29
Pharmacogenetics of Calcineurin inhibitors
The clinical use of calcineurin inhibitors is complicated further by a high between-patient 
variability in their pharmacokinetics. In recent years it has become clear that much of 
the interindividual differences in the pharmacokinetics of CNIs results from variability in 
the activity of the metabolizing enzymes cytochrome P450 (CYP) 3A4 and CYP3A5.30 In 
addition, several studies have established the importance of the drug transporter ABCB1 
in the disposition of CNIs. The encoding genes of CYP3A4, CYP3A5, and ABCB1 contain 
numerous single-nucleotide polymorphisms (SNPs) and these polymorphisms have been 
the subject of a considerable number of studies as they may explain the differences in 
calcineurin pharmacokinetics between patients.
CYP3A
The CYP enzyme family consists of more than 50 isoenzymes that are responsible for the 
oxidative metabolism of many endogenous and exogenous compounds.31
 
The CYP3A 
subfamily (chromosome 7q21-q22.1), which represents the majority of CYP proteins in 
human liver, metabolizes more than 50% of all drugs currently in use (including tacrolimus 
and ciclosporine). The CYP3A locus consists of four genes and two pseudogenes: CYP3A4, 
CYP3A5, CYP3A7, CYP3A43, CYP3AP1, and CYP3AP2. A large number of SNPs has been 
identified in most of these genes (see http://www.imm.ki.se/CYPalleles). CYP3A4 and CYP3A5 
have largely overlapping substrate specificities and, based on the amount of protein, are 
considered the most important CYP3A family members. CYP3A4 is constitutively expressed 
in liver, jejunum, colon, kidney and pancreas, but marked interindividual differences in its 
activity exist, which may vary by up to 40-fold.3 2 For stable kidney transplant recipients, a 
ten-fold variation in enterocyte CYP3A4 content was reported.33
 
CYP3A5 is also present in 
the liver, kidney and small intestine, although its expression is even more variable, and in 
general much lower, compared with CYP3A4. In Caucasian livers, the CYP3A5 protein was 
only detectable in 10-40% of all samples.34 However, CYP3A5 may account for up to 50% 
of total hepatic CYP3A content in some individuals. The functional significance of the other 
two CYP3A family members, CYP3A7 and CYP3A43 is thought to be limited.35
 
In the last decade SNPs have been identified in the CYP3A4 and CYP3A5 genes. 
The CYP3A4*1B polymorphism located in the promoter region of the CYP3A4 gene, 
has been associated with an increased expression of CYP3A4 protein.36
 
However, the 
clinical relevance of this polymorphism is not yet clarified.37,38 Besides the CYP3A4*1B 
polymorphism, the newly discovered CYP3A4*22 in intron 6 of CYP3A4 SNP may explain 
part of the variability in CNI pharmacokinetics.39 The CYP3A4*22T-variant (C>T) allele was 
associated with decreased hepatic CYP3A4 mRNA expression and with decreased CYP3A4 
enzymatic activity. The CYP3A4*22 allele is found with a relatively high allelic frequency of 
3-4% in the Caucasian population. 
At present however, the best-studied SNP is the CYP3A5*3 SNP in intron 3 of the 
CYP3A5 gene, genomic 6986A>G, which shows 100% linkage with the absence of CYP3A5 
protein. The CYP3A5*3 polymorphism has been shown to cause alternative splicing and 
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protein truncation, resulting in the absence of functional CYP3A5 protein.30
 
At least 
one CYP3A5*1 (or wild-type) allele is required for expression of CYP3A5 30,34,40 and 
therefore mostly two groups are defined: CYP3A5 expressers (CYP3A5*1/*1 plus *1/*3) 
and CYP3A5 non-expressers (CYP3A5*3/*3). The frequencies of CYP3A5*1 wild-type allele 
are: 5-16% in Caucasians, 15% in Japanese, 35% in Chinese, 51% in Asians and 60-85% 
in African-Americans.30 In recent years, a variety of studies have clearly demonstrated 
that renal transplant recipients carrying the CYP3A5*3 allele and who are therefore 
expected to lack functional CYP3A5 protein, require a significantly lower tacrolimus dose 
to reach target concentrations compared with patients homozygous for the wild-type 
allele (CYP3A5 expressers).37,41-43 A higher tacrolimus dose requirement has also been 
observed for CYP3A5 expressers receiving a heart-, or lung transplant.44 Because patients 
expressing CYP3A5 need higher tacrolimus doses to reach target concentrations, they may 
be at an increased risk of under-immunosuppression, especially in the early phase after 
transplantation, and the subsequent development of acute rejection. Several authors have 
therefore suggested that the tacrolimus starting dose in these patients should be twice as 
high as that of CYP3A5 non-expressers.45 
ABCB1
ABCB1 is encoded by the ABCB1 gene located on chromosome 7q21.1 and belongs to 
the family of the ABC membrane transporters (subfamily B). ABCB1 is an ATP-dependent 
transporter capable of pumping many endogenous substances, as well as a wide variety of 
drugs (including tacrolimus and ciclosporine), from the cytoplasm or cell membrane to the 
extracellular space.31,46,47 Physiologically, ABCB1 is expressed in the kidney (brush border of 
proximal tubular cells), the liver (at the canalicular surface of hepatocytes), pancreas, and 
at the apical surface of mature enterocytes in the small intestine and colon.48
 
The specific 
tissue expression of ABCB1 suggests that the protein functions as a protective barrier, by 
actively extruding xenobiotics and metabolites from the cell interior into bile, urine or gut 
lumen. ABCB1 is also expressed on various leukocytes, including T and B-lymphocytes and 
dendritic cells.49,50
 
More than 25 SNPs have been discovered in ABCB1. The best-studied 
SNP is the 3435C>T transition located in exon 26. This is a silent SNP, meaning that it does 
not lead to an amino acid change. However, it was recently demonstrated that this variant 
allele leads to an ABCB1 protein with an altered conformation and function that may have 
arisen as a result of an altered timing of translational folding.48
 
Furthermore, Wang and 
colleagues demonstrated that the 3435C>T variant affects ABCB1 mRNA stability, although 
this finding has been questioned by others.48,51
 
The ABCB1 3435C>T SNP is in strong 
linkage disequilibrium with the 1236C>T (in exon 12) and the 2677G>T/A (in exon 
21; Ala893Ser/Thr) SNPs.52
 
The effect of SNPs in ABCB1 on tacrolimus dose-requirement, 
appears to be smaller when compared with the effects of genetic variation in CYP3A5.44,53-56 
Perhaps even more important than its relation to pharmacokinetics is the effect of 
genetic variation on transplantation outcome. Identification of functional SNPs in genes 
encoding for drug metabolizing enzymes has great potential to influence the drug efficacy 
and safety profile. CYP3A5 expressers might have underexposure of tacrolimus, which can 
result in more early acute rejection. 
In chapter 2 we report our studies on the relationship of single-nucleotide polymorphisms 
in CYP3A and ABCB1 and the pharmacokinetics and pharmacodynamics of calcineurin 
inhibitors.
Next to the interpatient variability, also the intrapatient variability (the variability in one 
patient) is a problem with the use of calcineurin inhibitors. A high intrapatient variability 
might put patients at risk for periods of over- or underimmunosuppression and might 
therefore lead to graft loss after transplantation. Only few studies have investigated 
this hypothesis. A study of Kahan et al.21 studied this for ciclosporine and found that 
the incidence of chronic rejection was higher (40%) in patients with a high intrapatient 
variability compared to patient with a low intrapatient variability (rejection rate 24%). 
Borra et al.57 studied this for tacrolimus and mycophenolic acid. They have found that 
a high intrapatient variability in the clearance of tacrolimus was a significant risk factor 
for treatment failure, a composite end point of graft loss, biopsy-proven chronic allograft 
nephropathy or a doubling of the plasma creatinine concentration. The impact of intra-
patient variability in tacrolimus clearance in heart transplant adult recipients has not been 
studied. 
In chapter 3 paragraph 3.2 we report our studies on the correlation between progression 
of graft vascular disease and intrapatient variability of tacrolimus in heart transplant 
patients. 
As the pharmacogenetics plays a role in the pharmacokinetics of tacrolimus, the 
intrapatient variability might also be influenced by pharmacogenetics. Yong Chung have 
concluded that the CYP3A5 genotype in tacrolimus treated patients is correlated to the 
intrapatient variability.58 This observation might be explained by the fact that in patients 
without functional CYP3A5 enzyme the metabolism of tacrolimus depends exclusively on 
CYP3A4 and is therefore more sensitive to induction and inhibition. 
In chapter 3 paragraph 3.1 we report our studies on the impact of CYP3A5 genotype and 
the intrapatient variability of tacrolimus in kidney transplant recipients.
A maximum efficacy with a minimum toxicity is the ultimate goal of immunosuppressive 
therapy in kidney transplantation. Although pharmacogenetics might influence the 
blood concentrations of calcineurin inhibitors the first questions that should be asked, 
is what blood concentrations should we achieve? It is surprising that the concentration-
effect relationship for tacrolimus has been poorly defined. As mentioned previously 
TDM for tacrolimus is universally applied. To justify the use of TDM a concentration-
effect relationship between tacrolimus and its effect (the prevention of acute rejection) 
should be present. However, a reliable association between tacrolimus exposure and 
pharmacodynamic effects is still missing. 
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In chapter 4 we report our studies on whether the currently used and empirically defined 
tacrolimus target concentrations are related to the incidence of acute rejection. 
Mycophenolic Acid: 
PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS
Mycophenolic acid (MPA) was subsequently isolated from Penicillium stoloniferum. 
MPA is a selective, noncompetitive and reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH).59 This enzyme catalyse the rate-limiting step in the de novo 
guanosine synthesis. In contrast to other cells, lymphocytes cannot rely on the salvage 
pathway as an alternative supply of guanosine nucleotides. MPA therefore selectively 
leads to inhibition of T- and B-lymphocyte proliferation.60 
Mycophenolic acid (MPA) has complex pharmacokinetics.61 After administration 
mycophenolate mofetil, which is a pro-drug, is extensively hydrolyzed to active MPA.62 
MPA binds for more than 95% to albumin.59 Uridine diphosphat glucuronosyltransferases 
(UGTs) metabolise MPA via glucuronidation.63 7-O-mycophenolic acid glucuronide (MPAG) 
is the main metabolite and is not immunologically active.64 Two other metabolites of MPA 
are formed, 7-O-glucoside and the pharmacologically active acyl glucuronide (AcMPAG). 
By enterohepatic circulation of MPAG a secondary plasma peak of MPA is formed.65 
MPAG is excreted into the bile via the multidrug resistance-associated protein (MRP2, 
encoded by ABCC2), which is expressed in the canalicular membrane of hepatocytes.66 
Other data suggest that organic anion transporting proteins (OATPs), encoded by solute 
carrier organic anion (SLCO1) genes, localized in the sinusoidal membrane of hepatocytes 
are involved in MPA and/or MPAG uptake in hepatocytes and therefore might affect MPA 
pharmacokinetics.67 Over 95% of orally administered MPA is removed from the body by 
the kidneys as MPAG.
Mycophenolic acid pharmacogenetics and side effects
The interindividual differences in MPA pharmacokinetics can be caused by differences in the 
genetic composition of drug-metabolizing enzymes and drug transporters. Over the years 
numerous SNPs of the genes encoding for UGT isoenzymes, MRP2 and IMPDH have been 
reported. The use of MPA in clinical practice is complicated by the frequent occurrence 
of gastrointestinal adverse effects, such as nausea, abdominal cramps, and especially 
diarrhea. Diarrhea has been shown to reduce the quality of life of transplanted patients 
and is an important reason for noncompliance or discontinuation of MPA therapy.68 The 
pathogenesis of MPA-related diarrhea in renal transplant recipients is unknown. A direct 
toxic effect of MPA or MPAG on enterocytes may be an explanation. Differences in the 
expression or function of drug-transporting enzymes present in the apical membrane 
of the intestine could lead to high local concentrations of MPA or MPAG at the level of 
the intestinal epithelium and thus predispose certain patients to develop gastrointestinal 
side effects. Sawamoto et. al. 69 demonstrated that MPA is a substrate for ABCB1. More 
recently, these in-vitro findings were corroborated by an experimental in-vivo study 
in mice. Studying ABCB1 knockout mice, Wang et al. 70 observed that the MPA levels in 
plasma and tissue of these mice were markedly increased compared with wild-type mice, 
again suggesting that MPA is an ABCB1 substrate. Among the OATP transporters, OATP1B1 
(SLCO1B1) and OATP1B3 (SLCO1B3) are the major OATPs expressed on hepatocytes. In 
addition, OATPs are also expressed in the kidney and intestine.71 The OATPs are believed 
to be involved in the uptake of MPAG from the blood into hepatocytes .72 Polymorphisms 
leading to altered OATP activity may therefore affect MPA pharmacokinetics. 
In chapter 5 paragraph 5.1 we report our studies on whether genetic polymorphisms 
in ABCB1 and SLCO are related to MPA pharmacokinetics and the occurrence of MPA-
related diarrhea after kidney transplantation. In chapter 5 paragraph 5.2 we report our 
studies on whether other SNPs were related to the side effects anemia and leucopenia 
of MPA. 
The overall aim of this thesis was to explore ways of individualization of immunosuppressive 
therapy in transplant recipients. 
The Aim of the thesis was to investigate:
1. Do the SNPs in CYP3A and ABCB1 influence ciclosporine pharmacokinetics and 
pharmacodynamics? (Chapter 2.1)
2. Does the CYP3A4*22 C>T SNP influences tacrolimus pharmacokinetics? (Chapter 2.2)
3. Does the CYP3A4*22 C>T SNP affects the efficacy and toxicity of ciclosporine? 
(Chapter 2.3)
4. Do SNPs in CYP3A and ABCB1 influence the cyclosporine-mediated nephrotoxicity? 
(Chapter 2.4)
5. Does the ABCB1 3435C>T variant allele cause increased intra-lymphocytic tacrolimus 
accumulation? (Chapter 2.5)
6. Do CYP3A5 expressers have a higher within-patient variability in the apparent oral 
clearance of Tac? (Chapter 3.1)
7. Is a high within-patient variability in the apparent oral clearance of Tac a risk factor 
for the subsequent development of transplant coronary artery disease? (Chapter 
3.2)
8. What is the concentration-effect relationship between the currently accepted 
tacrolimus predose target concentrations and early acute rejection after kidney 
transplantation? (Chapter 4.1)
9. Do SNPs in SLCO1B and ABCB1 influence the occurrence of MPA-related diarrhea? 
(Chapter 5.1)
10. Do SNPs in IL12A, CYP2C8 and HUS1 affect the occurrence of MPA-related anemia 
and leucopenia? (Chapter 5.2)
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ABSTRACT
The association of CYP3A5, CYP3A4 and ABCB1 SNPs with ciclosporin (CsA) pharmacokinetics 
is controversial. The authors studied the influence of these SNPs on CsA pharmacokinetics, 
as well as on the incidence of biopsy-proven acute rejection (BPAR), and renal function 
after kidney transplantation. One-hundred-seventy-one patients participating in an 
international, randomized-controlled trial were genotyped for CYP3A5*3, CYP3A4*1B 
and the ABCB1 1236 C>T, 2677 G>T/A, and 3435 C>T SNPs. The patients were treated 
with CsA, mycophenolate mofetil and glucocorticoids. CsA was dosed to reach pre-
dose concentrations (C
0
) or two hours post-dose concentrations (C
2
). Pharmacokinetic 
parameters were measured on days 3 and 10, months 1, 3, 6 and 12 after transplantation. 
Renal function was assessed by measuring serum creatinine and calculating the creatinine 
clearance. The incidence of BPAR and delayed-graft function (DGF) was recorded. CYP3A5, 
CYP3A4 and ABCB1 genotype were not associated with dose-adjusted CsA C
0
 or C
2
. The 
incidence of BPAR in this cohort was 16% and was comparable between the different ABCB1 
genotype groups. No significant difference in the incidence of BPAR was found between 
CYP3A5 expressers (10%) and non-expressers (18%), p = 0.24. Nor was there a difference 
in the incidence of BPAR between CYP3A4*1 homozygotes (5%) vs. CYP3A4*1B carriers 
(18%), p = 0.13. There were no differences with regard to creatinine clearance between the 
different CYP3A and ABCB1 genotype groups. According to the results, determination of 
CYP3A and ABCB1 SNPs pre-transplantation is not helpful in determining the CsA starting 
dose and does not aid in predicting the risk of BPAR or worse renal function in an individual 
patient. 
INTRODUCTION
The calcineurin inhibitor (CNI) ciclosporin (CsA) is an immunosuppressive agent used for the 
prevention of acute rejection after solid organ transplantation 1. CsA blood concentrations 
have been shown to correlate with its efficacy (i.e. the absence of acute rejection) and 
toxicity 2. However, a large interindividual pharmacokinetic variability and a narrow 
therapeutic window complicate the use of CsA. Therefore, therapeutic drug monitoring 
(TDM) is routinely performed for this agent after transplantation. 
Ciclosporin is a substrate of the efflux transporter adenosine triphosphate (ATP) 
binding cassette (ABC) protein (ABCB1), which is encoded by the ABCB1 gene. ABCB1 is 
a transmembrane transporter which is capable of pumping a wide variety of substances, 
including CsA, from the cytoplasm to the exterior of the cell 3. Ciclosporin is metabolized by 
the cytochrome P450 (CYP) isoenzymes CYP3A4 and CYP3A5. Both ABCB1 and the CYP3A 
isoenzymes are expressed in the human intestine where they act synergistically as a barrier 
to limit the bioavailability of CsA. ABCB1 limits its absorption by active extrusion from the 
enterocyte interior back into the gut lumen, whereas exposure to CsA is reduced further 
by CYP3A-mediated metabolism in the enterocyte 3. Hepatic CYP3A and biliary ABCB1 are 
responsible for the systemic clearance and elimination of CsA, respectively.
In the last decade several single-nucleotide polymorphisms (SNPs) have been identified in 
the CYP3A5, CYP3A4, and ABCB1 genes. Several investigators have studied the association 
between these SNPs and the pharmacokinetics of CsA [reviewed in reference 9]. Although 
several studies have demonstrated that SNPs in ABCB1 influence the PK of drugs such as 
digoxin, simvasatin and atorvastatin, the effect of these SNPs on CsA disposition is less 
clearly defined 10-16. For example, we reported a significant, albeit small, effect of the 
CYP3A4*1B SNP on CsA oral clearance 17, whereas other investigators did not observe 
an association. Similar conflicting results have been reported with regard to CYP3A5*3 
and various ABCB1 SNPs 9, 14, 18-24. Importantly, only limited data exist on the association 
of genetic variation in CYP3A and ABCB1 and the efficacy and toxicity of CsA treatment 
in transplanted patients. Several studies did not observe an association between SNPs in 
CYP3A or ABCB1 and the incidence of acute rejection after kidney transplantation 14, 19, 25. 
Interestingly, in two recent studies an association between ABCB1 genotype and the risk of 
developing clinically-defined CsA-associated nephrotoxicity, the most dreaded side-effect 
of CsA, was reported 1 
An important limitation of the majority of published genetic association studies in 
transplantation is that they were of a retrospective design, included limited numbers 
of patients, and that transplant recipients were not always uniformly treated. The aim 
of the present study was to investigate prospectively the association between CYP3A4, 
CYP3A5 and ABCB1 SNPs and CsA pharmacokinetics, as well as the relation of these 
genetic polymorphisms to the efficacy of CsA therapy and graft function after kidney 
transplantation. All patients reported in the current study participated in a randomized-
controlled clinical trial (the so-called FDCC trial) 26. The current pharmacogenetic sub-study 
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was performed as an integral part of this immunosuppressive drug trial allowing for an 
in-depth analysis of the association between genetic variability and CsA pharmacokinetics 
efficacy and adverse events.
PATIENTS AND METHODS
Patients and study design
The patients in this study were de novo kidney transplant recipients who participated in 
the Fixed-Dose vs. Concentration-Controlled trial. In the FDCC study, immunosuppressive 
therapy consisted of a CNI (either CsA or tacrolimus [Tac]) plus glucocorticoids and MMF. MMF 
treatment was either fixed-dose with patients randomised to the FD arm initially receiving 
1000 mg MMF twice daily, or the MMF dose was adjusted on the basis of mycophenolic 
acid blood concentrations in patients randomised to the concentration-controlled arm. The 
choice of CsA or Tac and the target blood concentrations were in accordance with each 
center’s protocol. Standard CNI and corticosteroid tapering regimens were left to the 
discretion of the investigators. Induction therapy with either anti-interleukin-2 receptor 
monoclonal antibody treatment or antithymocyte globulin was allowed. The study design 
and main results of the FDCC trial were published recently 26. At the initiation of the study a 
pharmacogenetic sub-study was planned, and in the centers participating in this sub-study 
all patients provided two written informed consents, one for the FDCC study and one for 
the pharmacogenetic sub-study. The ethics committees of all participating centers and the 
relevant authorities in the participating countries approved the study protocol.
For this pharmacogenetic sub-study, data were available for 171 kidney transplant 
patients treated with CsA, MMF, and glucocorticoids. CsA dose was titrated to pre-dose 
concentrations (C
0
) or to two hours post-dose concentrations (C
2
) or both, according to local 
practice. Standard CNI and glucocorticoid tapering regimens were left to the discretion of 
the investigators. The use of drugs interfering with CsA PK, such as erythromycin, itraconazol 
etc. were not allowed. Induction therapy with either anti-interleukin-2 receptor monoclonal 
antibody treatment was allowed. The patients were instructed to take their evening dose of 
CsA exactly 12 hours before their morning dose.
C
0
 and/or C
2
 were measured on days 3 and 10, week 4, and months 3, 6 and 12 after 
transplantation, and whenever deemed necessary by the attending physician. Creatinine 
clearance was calculated by the Cockcroft-Gault formula 27. Delayed graft function (DGF) was 
defined as the need for dialysis within the first week after transplantation. Biopsy-proven 
acute rejection (BPAR) was defined as any histologically confirmed episode for which a Banff 
score of 1 (mild, grades IA and IIA), 2 (moderate, grades IB and IIB), or 3 (severe, grade III) 
was recorded. The patients with panel reactive antibodies (PRA) above 50% within 6 months 
before study entry were excluded from the study. In the FDCC study, donor deoxyribonucleic 
acid (DNA) was not collected and no protocol kidney biopsies were performed. 
Drug concentration measurements
Ciclosporin C
0
 and C
2
 were determined in whole blood in local laboratories in each of 
the participating centers by the use of immunoassays [CsA FPIA assay (AxSYM Abbott 
Laboratories) and Emit 2000 (Syva Company, Dade Behring Inc., Cupertino, CA)]. 
Proficiency testing was ensured by participation of all centers in the United Kingdom 
Quality Assessment Scheme (Prof. Holt, St George’s, University of London, London United 
Kingdom). Dose-adjusted CsA concentrations were calculated by dividing the C
0 
or the C
2
 
by the corresponding 24-h dose on a milligrams per kilogram basis. Mycophenolic acid 
(MPA) plasma concentrations were measured at three time points: before (pre-dose 
concentration), and 30 and 120 min after oral MMF administration. The MPA abbreviated 
AUC from 0 to 12 hr (AUC0–12) was calculated from these three MPA concentrations 
(unpublished data).
Genotype analysis 
The patients were genotyped for CYP3A4*1B, CYP3A5*3 and for ABCB1 1236C>T (exon 
12), 2677G>T/A (exon 21), and 3435C>T (exon 26). Genomic DNA was isolated from 200 
µL ethylenediaminetetraacetic acid-treated whole blood using a MagnaPure LC (Roche 
Diagnostics GmbH, Mannheim, Germany). Polymerase chain reaction (PCR)-restriction 
fragment length polymorphism (RFLP) analysis for CYP3A5*3 was performed as described 
previously 28-29. Other rare CYP3A5 alleles which result in the absence of functional CYP3A5 
protein, such as CYP3A5*6 4, were not determined in the current study due to the low 
allele frequency of 0.1% in Caucasians 29. Patients not carrying the CYP3A5*3 allele were 
therefore assigned the CYP3A5*1/*1 genotype by default. Genotyping for the CYP3A4 
–392A>G (CYP3A4*1/*1B) SNP and for ABCB1 1236C>T, 2677G>T/A and 3435C>T was 
performed as described previously 21. 
For the present analysis, patients carrying one CYP3A5*1 allele were combined with 
CYP3A5*1 homozygotes (“CYP3A5 expressers”) and were compared against CYP3A5*3 
homozygotes, the “CYP3A5 nonexpressers”. Likewise, CYP3A4*1A homozygotes were 
analyzed against the CYP3A4*1B carriers.
Statistical analysis
Student’s t-test was used to compare means between groups at a single point in time. For 
the univariate analysis of the associations between categorical data (e.g. the incidence of 
acute rejection) we used Pearson’s Chi Square test or Fisher’s exact test, as appropriate. 
To identify risk factors for the development of BPAR a binary logistic regression was 
performed. To estimate the overall effect of CYP3A5, CYP3A4 and ABCB1 genotype on the 
outcome variables CsA daily dose and dose-adjusted CsA C
0 
and C
2
 we used mixed model 
analysis of variance (ANOVA). For all analyses, SPSS for Windows version 16.0 was used 
(SPSS, Chicago, IL, USA). 
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RESULTS 
The characteristics of the 171 patients included in this study are summarized in Table 1. 
The allele frequencies of the various CYP3A4, CYP3A5 and ABCB1 SNPs were in Hardy-
Weinberg equilibrium when analysed according to ethnic background (Caucasian, Black or 
Asian), except for ABCB1 3435C>T in Caucasians (Chi Square test, p = 0.035)
Table 1. Patient characteristics
Sex (male / female) 105 / 66
Age (years)† 49.0 ± 11.9
First / Second Transplant 159 (93%) / 12 (7%)
Living / deceased donor 43 (25%) / 128 ( 75%)
CsA monitoring C
0
/C
2
/both 40 (23%)/ 25 (16%)/ 106 (62%)
FD / CC MMF therapy 94 (55%) / 77 ( 45%)
Induction therapy‡ 96 (56%)
Primary kidney disease 
Diabetic nephropathy 9 (5 %)
Glomerulonephritis 46 (27%)
Hypertensive nephropathy 18 (11%)
Obstructive/reflux nephropathy 12 (7%)
Other 41 (24%) 
Polycystic kidney disease 31 (18%)
Pyelonephritis / interstitial nephritis 5 (3%)
Unknown 9 (5%)
HLA mismatches§ 2.9 
Panel reactive antibodies
less than 10% /10% or greater 155 (93%) / 12 (7%)
Ethnicity
Asian 6 (3%)
Black 3 (2%)
Caucasian 150 (88%)
Other 12 (7%)
† Mean ± SD
‡ All of the 96 patients who received induction therapy were treated with antibodies against the IL-2 receptor 
and none was treated with anti-thymocyte globulin. 
§ Mean
FD, Fixed-dose; CC, Concentration-controlled; MMF, Mycophenolate mofetil
CsA pharmacokinetics and CYP3A and ABCB1 genotype 
The daily dose of CsA and CsA exposure (measured as either C
0
 or C
2
) on days 3 and 
10, month 1, 3, and 12 was comparable between patients carrying the CYP3A5*1 allele 
and CYP3A5 nonexpressers (data not shown). When we investigated CsA dose-adjusted 
concentrations, no statistically significant differences were observed between CYP3A5 
expressers and non-expressers throughout the first post-transplant year as shown in 
Figure 2 (C
2
). No statistically significant differences between CYP3A4*1A homozygotes and 
CYP3A4*1B carriers were observed with regard to CsA daily dose, CsA exposure or dose-
adjusted CsA concentrations (Figure 1). The C
0
 revealed the same results, but the data are 
not shown.
Figure 1
Mean ciclosporine (CsA) dose-adjusted pre-dose concentrations C
2
 according to CYP3A4 genotype. The closed 
circles represent the CYP3A4*1 homozygotes whereas the open circles represent the CYP3A4*1B carriers. 
Figure 2
Mean CsA dose-adjusted C
2
 according to CYP3A5 genotype. The closed circles represent the CYP3A5 expressers 
whereas the open circles represent the CYP3A5 non-expressers.
Values are depicted as means. The error bars represent the corresponding 95% confidence intervals. 
Also the ABCB1 SNPs did not show a statistically significant association with CsA daily 
dose, CsA exposure or dose-adjusted CsA concentrations (data not shown). Next, we 
investigated the effects of unambiguous ABCB1 haplotypes on CsA pharmacokinetics. 
For this analysis we compared patients that were homozygous for the 1236C, 2677G and 
3435C alleles (ABCB1 CGC haplotype) with patients homozygous for ABCB1 1236T, 2677T 
and 3435T alleles (ABCB1 TTT haplotype). The ABCB1 CGC haplotype was present in 28 
patients (16%) and the ABCB1 TTT haplotype was present in 20 patients (12%). There were 
no significant differences between the two haplotype groups with regard to CsA dose-
adjusted C
0 
or C
2 
(data not shown)
 
throughout the first post-transplant year. Finally, we 
performed an analysis combining the two ABCB1 haplotypes with either the CYP3A5 or the 
CYP3A4 genotype to account for any interaction between ABCB1 and CYP3A. No significant 
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differences were observed between these various genotype groups with regard to CsA 
dose-adjusted C
0
 and C
2.
 
Clinical outcomes and CYP3A and ABCB1 genotype 
Patient and graft survival
Of the 171 patients included in this study, 3 patients died during the first year after 
transplantation (overall one-year patient survival 98.2%). One patient died on day 21 
after transplantation as a result of a myocardial infarction, one patient died of sepsis on 
day 41 after transplantation, and one patient died as a result of stroke on day 320 after 
transplantation. Throughout the first post-transplant year, 9 patients lost their graft, due to 
various causes (including one acute rejection), resulting in an overall graft survival of 94.7 
%. Graft loss occurred at a median time of 55 days (range 8 to 338 days). Patient survival or 
graft loss was not associated with CYP3A5, CYP3A4 or ABCB1 genotype 15, 30
Acute Rejection
The overall incidence of biopsy-proven acute rejection (BPAR) in this cohort of 171 patients 
was 16% (28 patients). Of the 28 patients with BPAR, 12 had grade 1 according to the 
Banff ’97 classification and 16 patients had a grade 2 acute rejection. No difference in the 
incidence of BPAR was observed between CYP3A5 expressers and non-expressers: 10% vs. 
18%, respectively (p = 0.24). Likewise, patients carrying the CYP3A4*1B variant allele had 
an incidence of BPAR which was not statistically different compared to that of CYP3A4*1 
homozygotes: 5% vs. 18%, respectively (p = 0.13). In addition, no differences with regard to 
the severity of BPAR were observed between the different genotype groups. The incidence 
of BPAR was not related to ABCB1 genotype when individual SNPs or haplotypes were 
analyzed (Table 2). Finally, ABCB1 haplotypes stratified to CYP3A4 or CYP3A5 genotype 
were not related to the risk of acute rejection (data not shown). 
The median time to BPAR was 50 days post-transplantation (range: 3 to 181 days), with 
five BPARs occurring within the first ten days after transplantation. The mean CsA C
0
 on 
day 3 after transplantation of these 5 patients was not different from that of patients who 
did not experience BPAR before day 10 after transplantation: 354 vs. 314 ng/mL (p = 0.63). 
The mean C
2
 was also not different between these patients (993 vs. 1137 ng/mL, p = 0.54). 
In addition, on day 3 after transplantation, the MPA area-under the concentration time-
curve (MPA AUC
0-12 h
) was not statistically significantly lower in patients experiencing an 
early episode of BPAR compared with those who did not have BPAR within the first 10 
days after transplantation: 25.5 vs. 32.3 mg/L per hour (p = 0.19). In order to identify risk 
factors for BPAR we performed a binary logistic regression analysis (incorporating variables 
such as induction therapy, total number of HLA mismatches, exposure to CsA, PRA, 
CYP3A5, CYP3A4 and ABCB1 genotype). Only PRA was identified as a risk factor for the 
development of BPAR. Patients with PRA >10% had a significantly higher risk of developing 
BPAR compared to patients with PRA <10% (OR: 8.8, 95% CI: 2.0-39.5; p < 0.005). 
Delayed Graft Function
DGF occurred in 44 of the 171 patients (26%). On day 3 after transplantation the mean CsA 
C
0
 was not different between the patients with DGF and the patients who did not experience 
DGF: 291 vs. 324 ng/mL (p = 0.31). However, the mean CsA C
2
 on day 3 between these 
patients did differ: 778 vs. 1233 ng/mL for patients with and without DGF, respectively (p < 
0.0001). DGF occurred in 13/39 (33%) patients expressing CYP3A5 vs. 31/132 (23%) in CYP3A5 
nonexpressers (p = 0.216). The incidence of DGF was higher (p = 0.014) in patients carrying 
the CYP3A4*1B gene (10/21; 48%) compared to the CYP3A4*1 homozygotes (34/150; 23%). 
We compared the association of the different ABCB1 genotypes to incidence of DGF, as 
shown in Table 2. When we performed binary logistic regression analysis [incorporating 
the covariates gender, (donor) age, CYP3A4, CYP3A5, and ABCB1 genotype, primary kidney 
disease and cold ischemia time], only longer cold ischemia time (OR: 1,11 95% CI: 1.04 – 1.18; 
p = 0.001) and higher donor age (OR: 1.05 95% CI: 1.01-1.08; P = 0.013) were significantly 
related to the risk of DGF.
Creatinine clearance 
Throughout the first post-transplant year, the mean creatinine clearance increased from 31.6 
mL/min on day 3 to 66.7 mL/min on year 1, respectively. When comparing all the patients the 
mean creatinine clearance was not associated with CYP3A5 or CYP3A4 genotype (data not 
shown). However, statistically significant differences in creatinine clearance on day 10 were 
observed for the different ABCB1 genotypes (Table 3). A significant difference was also found 
for CYP3A4 combined with the different ABCB1 haplotypes. On day 10 after transplantation, 
CYP3A4*1 homozygotes with the ABCB1 TTT haplotype had a creatinine clearance that was 
significantly higher compared with CYP3A4*1 homozygotes with the ABCB1 CGC haplotype: 
58.4 mL/min vs. 21.4 mL/min, respectively (p = 0.004). At week 4 CYP3A4*1B carriers with 
the ABCB1 CGC haplotype showed a significantly higher creatinine clearance compared to 
CYP3A4*1B carriers with ABCB1 TTT haplotype: 65,2 mL/min vs. 41,2 mL/min respectively 
(p = 0.044). 
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However, when we exclude the patients with DGF different results were observed. Table 3 
shows the analysis of ABCB1 genotype and creatinine clearance for patients with immediate 
graft function. The creatinine clearance did not show significant differences between 
ABCB1 genotypes anymore. However, according to the CYP3A4 genotype the creatinine 
clearance was statistically higher in CYP3A4*1B carriers (n = 11) compared to CYP3A4*1 
homozygotes (n = 114) on day 10 (69.90 vs. 53.91 mL/min; P = 0.035), month 1 (79.53 vs. 
61.51 mL/min (P = 0.013) ) and month 6 (84.26 vs. 66.60 mL/min (P = 0.041) ), as depicted 
in figure 3. The creatinine clearance in the different CYP3A5 genotypes did not statistically 
differ when adjusted for DGF. However, when we performed a logistic regression analysis 
on month 12 to identify the factors that were associated with a lower creatinine clearance 
at month 12 after transplantation [including the co-variates: gender, (donor) age, CYP3A4, 
CYP3A5 genotype, primary kidney disease, cold ischemia time, delayed graft function and 
BPAR], only a higher donor age (p = 0.024) was significantly related to a lower creatinine 
clearance, and the previously observed influence of CYP3A4 genotype was no longer 
statistically significant (p = 0.094). 
Figure 3
Mean creatinine clearance according to CYP3A4 
genotype. The closed circles represent the CYP3A4*1 
homozygotes (patients without DGF) whereas the 
open circles represent the CYP3A4*1B carriers 
without DGF.
Values are depicted as means. The error bars 
represent the corresponding 95% confidence 
intervals. 
D ISCUSSION 
To our knowledge this is the second prospective trial to investigate the association 
between CYP3A and ABCB1 genotype and CsA exposure 19. Based on our present findings 
we conclude that polymorphic expression of CYP3A4, CYP3A5 and ABCB1 cannot explain 
the high interindividual pharmacokinetic variability of CsA. In a previous study 1 among 
kidney and heart transplant recipients, we observed a slightly higher CsA clearance in 
patients carrying the CYP3A4*1B allele compared to CYP3A4*1 homozygotes. We believe 
that the apparent discrepancies between the current study and our previous study can 
be explained by the fact that in the study published in 2004 more elaborate CsA blood 
sampling was performed (i.e. AUC during the absorption phase) and a more precise 
pharmacokinetic analysis was used (nonlinear mixed-effects modelling). However, we feel 
that the effect of the CYP3A4*1B polymorphism, if any, is unlikely to be clinically relevant. 
Other studies have also failed to identify clinically significant effects of CYP3A4 SNPs on 
CsA exposure 14, 21.
Possibly, polymorphisms in other genes encoding for proteins involved in the transport 
or metabolism of CsA are responsible for this as yet unexplained variability. For example, 
the Pregnane X receptor (PXR), which regulates ABCB1 expression appears to influence 
the bioavailability of CsA 31 32, which has also been shown for Tac 33. However, results from 
a recently published study 34 have demonstrated that PXR does not appear to be very 
important in this respect. The large variation in dose-adjusted CsA concentrations suggests 
that factors other than genotype, must be considered to explain the variability in CsA 
pharmacokinetics 35. 
In the current prospective study we have shown that the different genotypes do not lead 
to an increased incidence of acute rejection in kidney transplant patients who are treated 
with an immunosuppressive regimen consisting of CsA, MMF and glucocorticoids with or 
without anti-interleukin-2 receptor antibody treatment. This result was to be expected 
as the CsA concentrations did not differ significantly between these different genotypes. 
With regard to the risk of developing DGF, logistic regression analysis showed that only 
cold ischemia time and donor age were related to the risk of DGF, which has also been 
reported by other authors 19, 36-38. In contrast to our results, Cattaneo et al 19 reported that 
carriers of T allelic variants in ABCB1 2677G>T/A and 3435C>T SNPs had a higher risk for 
DGF. They suggested that DGF in T allelic variant carriers might be the consequence of 
severe reperfusion injury, sustained by increased intra-lymphocytic CsA concentrations. 
However, it is questionable if intra-lymphocytic CsA accumulation leads to more DGF. It 
would be more logical to assume an effect of accumulation of CsA in renal tubular cells, 
in order to explain differences in DGF incidence. Hauser et al 23 observed that for renal 
transplant recipients the ABCB1 genotype of the donor but not of the recipient, was a risk 
factor the occurrence of clinically-defined CsA-related nephrotoxicity. Obviously, it is the 
genotype of the donor that determines intragraft ABCB1 expression and possibly intrarenal 
accumulation of CsA. Unfortunately, donor DNA was not collected in the present study.
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With regard to renal transplant function, we found no association with CYP3A or ABCB1 
genotype. Only a higher donor age was identified as a risk factor for a lower creatinine 
clearance. This finding is in line with the recent findings of Naesens et al. who showed 
that that the age of the kidney transplant donor is a major determinant of its susceptibility 
to Tac-mediated nephrotoxicity, with kidneys from older donors have the most rapid 
deterioration of function 39-40 Future studies should take into account the role of genetic 
factors influencing metabolism and transportation of CNIs in both acceptor and donor.
CONCLUSION
The data from this prospective study provide evidence that the pharmacokinetics of CsA 
are not influenced by genetic variation in the metabolizing enzymes CYP3A4 and CYP3A5 
or the drug transporter ABCB1. In addition, the incidence of BPAR and renal function were 
not associated with polymorphisms in these genes. Determination of CYP3A and ABCB1 
SNPs pre-transplantation is therefore not of help in determining the CsA starting dose 
and does not appear to identify patients at high risk of experiencing acute rejection or 
nephrotoxicity. Further research should be performed to determine other risk factors for 
developing CsA-induced nephrotoxicity, including the role of the genotype of the kidney 
donor. 
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ABSTRACT
Background Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. 
Tac pharmacokinetics varies considerably between individuals, which complicates its 
use to prevent rejection after kidney transplantation. This variability might be caused by 
genetic polymorphisms in key metabolizing enzymes. METHODS: We evaluated the impact 
of a newly discovered single nucleotide polymorphism (SNP) in CYP3A4 (rs35599367C>T) 
on Tac pharmacokinetics in 185 renal transplant recipients that participated in an 
international randomized-controlled clinical trial (FDCC-study). RESULTS: We showed 
that the overall Tac daily dose requirement was on average 33% lower for T-variant allele 
carriers compared to CC patients to reach the same predose blood concentrations (CI
95% 
-46% to -20%; p=0.018). When combined with CYP3A5*3 genotype, the CYP3A4 intron 
6 SNP was also associated with the risk of supratherapeutic Tac levels (>15 ng/mL) 
during the first days following surgery, with OR=8.7 for CYP3A4 T-variant allele carriers 
plus CYP3A5*3/*3 (p=0.027) and OR=4.2 for CYP3A4 CC-homozygotes plus CYP3A5*3/*3 
(p=0.002), compared to CYP3A4 CC homozygotes having at least one CYP3A5*1 allele. 
Overall increase in Tac dose-adjusted trough blood concentration was +179% for CYP3A4 
T-variant allele carriers with CYP3A5*3/*3 (p<0.001), +101% for CYP3A4 CC-homozygotes 
with CYP3A5*3/*3 (p<0.001) and +64% for CYP3A4 T-variant allele carriers with CYP3A5*1 
(p=0.020), as compared to CYP3A4 CC-homozygotes with CYP3A5*1. CONCLUSION: 
The CYP3A4 rs35599367C>T polymorphism is associated with a significantly altered Tac 
metabolism and therefore increases the risk of supratherapeutic Tac concentrations early 
after transplantation. Analysis of this CYP3A4 allelic variant may help identifying patients 
at risk of Tac overexposure. 
INTRODUCTION
CYP3A4 is the most abundant CYP enzyme in human liver and intestine and is responsible for 
the oxidative metabolism of approximately 45-60% of all prescribed drugs 1. CYP3A4 activity 
varies widely in the population with a 10-100 fold inter-individual variability 2-5. A recent study 
identified a functional single nucleotide polymorphism (SNP) in CYP3A4 intron 6, which was 
associated with decreased CYP3A4 expression and activity. This SNP was correlated with statin 
dose requirement for lipid level control 6. 
The immunosuppressive drug tacrolimus (Tac) is extensively metabolized by CYP3A4 and 
CYP3A5 7-9. The CYP3A5*3 allele, encoding absence of CYP3A5 10, was earlier associated with 
Tac predose concentrations (C
0
) and Tac dose requirements. The CYP3A5 genotype explains 
a major part of the Tac pharmacokinetic interindividual variability: carriers of two CYP3A5*3 
non-functional alleles require a significantly lower Tac dosage (about 50%) than patients 
carrying a CYP3A5*1 active allele among kidney, liver, lung, and heart transplant recipients 
to reach identical C
0
 concentrations 11-19. However, the clinical benefit of CYP3A5-based Tac 
dosing remains debatable 20-21. The polymorphic drug transporter ABCB1 is also involved in Tac 
disposition. Variants have been associated with Tac drug disposition, although contradictory 
results have been published 22. 
No studies performed to date have been able to identify SNPs in CYP3A4 that could account 
for a substantial part of inter-individual variability in CYP3A4 activity. A newly discovered 
CYP3A4 SNP in intron 6 (rs35599367 C>T), may explain this. 6. Main goal of our study was 
therefore to test specifically the hypothesis that this new CYP3A4 SNP is correlated with an 
increased Tac exposure on a standard dosages, and might predict lower dose requirement in 
kidney transplant patients.
MATERIALS AND METHODS
Patients and study design
Patients were de novo kidney transplant recipients participating in a phase IV, open, 
prospective, randomized controlled, international multi-center trial comparing fixed-dose (FD) 
mycophenolate mofetil (MMF) treatment with concentration-controlled (CC) treatment (the 
‘FDCC-study’) 23. The randomization to FD or CC regimen was done in blocks of eight patients 
per center. Patients were randomized centrally, through an automated telephone system, in 
a one-to-one ratio. Parallel to the main study, also a pharmacogenetic substudy was started. 
The role of genetic polymorphisms in UGT1A9 for MMF metabolism 24, in UGT2B7 for Acyl-
MPAG 25, and in CYP3A5 and ABCB1 for Tac exposure and acute rejection 26 in the FDCC-study 
have been published earlier. Patients provided separate written informed consents for both 
the FDCC-study and the substudy. The study protocol was approved by the ethics committees 
of all participating centers and relevant authorities in the participating countries.
Immunosuppressive therapy consisted of calcineurin inhibitor (CNI) and corticosteroids. 
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The choice of Tac or cyclosporine (CsA), and the target blood concentrations for each 
individual drug, were in accordance with each center’s protocol. Tac treatment started 
within 48 hours prior to transplantation and was administrated orally. Therapeutic drug 
monitoring was routinely performed, and centers were free to aim for the target levels 
they considered appropriate. Retrospective analysis showed that all centers started Tac 
aiming for target levels 7-15 ng/mL, tapering to 5-12 ng/mL at month 3, and 4-10 ng/
mL at month 12. Corticosteroid tapering was recommended but not mandatory and 
tapering regimens were left to the discretion of the investigators. In general, centers used 
higher dosages in the first 2 weeks (20-25 mg prednisolone equivalent daily), lower doses 
thereafter (15 mg on week 4, 5 mg at month 3) and low dose or no prednisolone between 
months 6 and 12. More details are reported in the original publication of the FDCC-study 
23. Genetic data were accessible for 185 kidney transplant recipients treated with Tac. 
However, pharmacokinetic data were not available for all patients at all time points. Tac 
predose concentrations (C
0
) were measured on days 3, 10 and months 1, 3, 6 and 12 after 
transplantation, and whenever deemed necessary by the attending physician. Donor DNA 
was not collected and no protocol kidney biopsies were performed. Delayed graft function 
(DGF) was defined as the need for dialysis within the first week after transplantation. 
Biopsy-proven acute rejection (BPAR) was defined as any histologically confirmed episode 
with a Banff score of 1 or more. All biopsy samples were assessed locally by a pathologist.
Drug concentration measurement 
Tac C
0
 was determined in whole blood in local laboratories in each participating center by 
use of immunoassays, like the Tac II microparticulate enzyme immunoassay (MEIA; Abbott 
Laboratories, Abbott Park, IL, USA) and enzyme multiplied immunoassay technique (Emit 
2000; Syva Company, Dade Behring Inc., Cupertino, CA, USA). The specificities of both 
assays were comparable and high correlations existed between immunoassays and high-
performance liquid chromatography 27-28. Although immunoassays slightly overestimate 
Tac concentrations due to concurrent measurement of metabolites, this methodology was 
feasible to assess differences in Tac concentrations regarding CYP3A5 genotype 16. A limited 
number of centers used LC-MS/MS to measure Tac concentrations. Proficiency testing was 
ensured by participation of all centers in the UK Quality Assessment Scheme (Dr Holt, 
St George’s Hospital Medical School, London, UK). Dose-adjusted predose concentrations 
were calculated by dividing the C
0
 by the corresponding 24-h dose on a mg/kg basis.
Genotype analysis
Genomic DNA was isolated from 200 µl EDTA whole blood using MagnaPure LC (Roche 
Diagnostics GmbH, Mannheim, Germany). Allelic discrimination reaction was realized 
using TaqMan® (Applied Biosystems, CA, USA) genotyping assays (C__59013445_10) for 
CYP3A4 intron 6 C>T genotype on a ABI PRISM 7500® Fast real-time PCR Systems (Applied 
Biosystems, CA, USA) using 50 ng genomic DNA. CYP3A5*3 and ABCB1 1236C>T, 2677G>T/A 
and 3435C>T analysis were performed as described earlier 26-29.
Statistical analysis
Statistical analyses were performed using Predictive Analytics Software (PASW) statistics, 
version 17.0 for Windows (IL, USA). Tac C
0
 and dose-adjusted C
0
 were normalized by 
logarithmic transformation. Log distributions were confirmed to be normally distributed 
by Kolmogorov–Smirnov tests. When only 2 genotype groups were compared, Student’s 
independent t-tests were performed to compare means between groups at single time 
points. With more groups, analyses of variance (ANOVA) were performed under the null 
hypothesis that means of compared groups were equal. When differences between means 
were significant, post-hoc analysis consisted of a priori polynomial linear contrast test to 
assess any potential linear trend according to genotype classification. The corresponding 
linear contrast does test probability of a positive linear trend of the dependent variable 
across the ordered level of genotype classifications. Differences between groups were 
assumed for p-values <0.05. For univariate analysis of associations between categorical 
data (e.g. incidence of acute rejection), Fisher’s exact test or Pearson’s χ2 test were used. 
Tac daily dose and dose-adjusted C
0
 were compared between genotypes by mixed-model 
analysis based on the maximum likelihood ratio with patient genotype status as fixed 
factor and time after transplantation as repeated measurement. Sex, ethnicity and age of 
patients were introduced as random effects to adjust for these co-variables. No structure 
was imposed on variances and covariances between and within times of follow up of the 
repeated Tac measurements. We assumed levels of covariables (sex, ethnicity and age) 
uncorrelated and have a constant variance across time of follow up. Coefficients estimated 
from the mixed-model analysis of variance were back-transformed by taking their antilog, 
to become interpretable as percent differences in geometric mean values of untransformed 
outcomes. Multiple logistic regression analysis was carried out according to criteria defined 
by McMaster 30, with fixed Tac supratherapeutic threshold at 15 ng/mL. Genotype-specific 
odds ratios (OR) and 95% confidence intervals were computed using backward stepwise 
analysis based on maximum likelihood ratios to assess the impact of genotype on risk 
Tac plasma concentrations >15 ng/mL with p-values <0.05 being considered statistically 
significant for entry and p-values <0.10 for staying in the model. For these analyses, each 
genotype was coded as a ‘dummy variable’.
RESULTS
CYP3A4 intron 6 genotype and tacrolimus exposure
Patient characteristics are reported in table 1. In total, 173 had the CC genotype, 11 the CT 
genotype and 1 patient was homozygous TT variant, resulting in a minor allele frequency 
of 3.5% in our study. The observed genotype distribution is in accordance with Hardy-
Weinberg equilibrium (χ2 test; p=0.25). Heterozygous CT and homozygous TT variants 
were grouped and analyzed together as T-variant allele carriers, against CC homozygous 
patients. We did not observe linkage disequilibrium between CYP3A4 intron 6 SNP and 
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either CYP3A5*3 or CYP3A4*1B alleles (χ2 =0.24 and 1.36, p=1.0 and 0.46, respectively).
Table 1: Patient demographics
All patients
CYP3A4 intron 6 
homozygous CC
CYP3A4 intron 6 allele 
T carriers (CT plus TT)
p-value
N 185 173 12 -
Sex (male/female) 112 (60.5%) 73(39.5%) 108 (62.4%) 65(37.6%) 4 (33.3%) 8 (66.7%) 0.07
Age (years)a 47.9 ± 13.8 47.7 ± 14.0 51.8 ± 11.3 0.32
Weight (Kg)a 72.6 ± 14.0 72.8 ± 14.3 71.1 ± 10.4 0.69
Transplantation number 0.80
First 156 (84.3%) 145 (83.8%) 11 (91.7%) -
Second 19 (10.3%) 18 (10.4%) 1 (8.3%) -
Third or more 5 (2.7%) 5 (2.9%) 0 (0.0%) -
Missing information 5 (2.7%) 5 (2.9%) 0 (0.0%) -
Living/deceased donor 71 (38.4%) 114 (61.6%) 66 (38.2%) 107 (61.8%) 5 (41.7%) 7 (58.3%) 0.81
FD/CC MMF therapy 98 (53.0%) 87 (47.0%) 92 (53.2%) 81 (46.8%) 6 (50.0%) 6 (50.0%) 0.83
Induction therapy b 67 (36.2%) 62 (35.8%) 5 (41.5%) 0.69
Primary kidney disease 0.29
Diabetic nephropathy 16 (8.6%) 15 (8.7%) 1 (8.3%) -
Glomerulonephritis 51 (27.6%) 48 (27.7%) 3 (25.0%) -
Hypertensive nephropathy 18 (9.7%) 18 (10.4%) 0 (0.0%) -
Obstructive/reflux 
nephropathy 9 (4.9%) 8 (4.6%) 1 (8.3%) -
Other 42 (22.7%) 42 (24.3%) 0 (0.0%) -
Polycystic kidney disease 29 (15.7%) 24 (13.9%) 5 (41.7%) -
Pyelonephritis/interstitial 
nephritis 9 (4.9%) 8 (4.6%) 1 (8.3%) -
Unknown 9 (4.9%) 8 (4.6%) 1 (8.3%) -
HLA mismatches c 2.9 (3.0) 2.9 (3.0) 3.2 (3.0) 0.55
Panel reactive antibodies
<10% / ≥10 % 167 (90.3%) 18(9.7%) 155 (89.6%) 18(10.4%) 12 (100.0%) 0(0.0%) 0.24
Ethnicity 0.65
Asian 9 (4.9%) 9 (5.2%) 0 (0.0%) -
Black 8 (4.3%) 8 (4.6%) 0 (0.0%) -
Caucasian 164 (88.6%) 152 (87.9%) 12 (100.0%) -
Other 4 (2.2%) 4 (2.3%) 0 (0.0%) -
CC, concentration-controlled; FD, fixed-dose; HLA, Human Leucocyte Antigen; MMF, mycophenolate mofetyl.
a Mean ± SD
b All patients who receive induction therapy were treated with antibody against the IL-2 receptor and none was 
treated with anti-thymocyte globulin.
cMean (median)
Tac daily dose on day 3 after transplantation (without adjustments made based on TDM) 
was comparable between the two CYP3A4 intron 6 genotype groups: 13.3 versus 13.0 
mg/day for homozygous CC wild-type patients and carriers of at least one T-variant allele, 
respectively (p=0.84, figure 1a, table 2). However, with these comparable dosages, Tac 
C
0
 was higher for T-variant carriers compared to CC patients: 20.5 versus 14.9 ng/mL, 
respectively (p=0.05, figure 1b, table 2). Later time points revealed that differences in C
0
 
between both groups were no longer observed (p>0.05, figure 1b, table 2), but that carriers 
of at least one T-variant allele required significantly lower Tac doses than CC patients from 
day 10 to month 6 to reach this C
0
 (figure 1a, table 2). The same trends were observed 
when dose was adjusted for weight (table 2). Repeated measurement in mixed-model 
analysis demonstrated overall daily Tac dose requirement (adjusted for covariates age, 
gender and ethnicity) to be on average 33% lower for T-variant allele carriers (CI
95%
 -46% 
to -20%; p=0.018) compared to CC patients. As a result, calculated Tac dose-adjusted C
0
 
was lower for CC patients compared to CT/TT patients. These differences were statistically 
different at day 10 and month 1 after transplantation (figure 1c, table 2), but not at later 
time points, which might be explained by a decrease in the number of subjects, resulting 
in a larger CI
95%
. The mixed-model for repeated measurements revealed that overall Tac 
dose-adjusted C
0
 (adjusted for covariates [age, gender and ethnicity]) was on average 47% 
higher T-variant allele carriers (CI
95% 
8-100%; p=0.001) compared to homozygous wild-type 
patients. For ABCB1, neither 2677G>T/A nor 1236C>T was associated with differences in 
Tac pharmacokinetic parameters during the whole study. By contrast, as reported (26), the 
3435C>T SNP was significantly associated with Tac dose and dose-corrected Tac exposure 
in a linear mixed-model when CYP3A4 genotype was not taken into account. When ABCB1 
haplotypes were generated, no differences were observed in Tac dose and dose-corrected 
Tac exposure between the ABCB1 CGC (n=26) and TTT haplotype groups (n=20) (data not 
shown).
Figure 1. 
A) Tacrolimus daily dose, B) tacrolimus predose concentration (C0), C) dose-corrected tacrolimus C0 according 
to the genetic status of patients for the CYP3A4 intron 6 C>T SNP at different time points and D) Dose-corrected 
tacrolimus C0 according to the genetic status of patients for the CYP3A4 intron 6 C>T and CYP3A5*3 SNPs at 
different time points. Data are represented as means (±SEM). *=p<0.05; **=p<0.01, ***=p<0.001.
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Table 2: Tacrolimus dose, predose concentration (C
0
) and dose-corrected predose concentration (C
0
/Dose) 
according to the CYP3A4 intron 6 C>T SNP genotype.
Tacrolimus 
dose (mg/day)
CYP3A4 intron 6 
homozygous CC
n
CYP3A4 intron 6 allele T 
carriers (CT plus TT)
n p-value
Day 3 13.3 [12.6-13.9] 136 13.0 [11.7-14.3] 9 0.84
Day 10 12.9 [11.9-13.9] 134 9.2 [7.2-11.7] 10 0.05
Month 1 11.2 [10.4-11.9] 137 6.6 [5.5-7.7] 10 <0.001
Month 3 7.5 [6.8-8.2] 131 5.2 [4.3-6.1] 11 <0.001
Month 6 6.2 [5.5-6.8] 120 4.5 [3.7-5.3] 10 0.004
Month 12 5.2 [4.7-5.8] 112 4.6 [3.1-6.1] 9 0.55
Weight-adjusted Tacrolimus dose (mg/day per kg b.w,)
Day 3 0.181 [0.174-0.189] 135 0.193 [0.178-0.207] 9 0.45
Day 10 0.176 [0.162-0.190] 133 0.134 [0.101-0.168] 10 0.10
Month 1 0.156 [0.15-0.166] 136 0.097 [0.078-0.116] 10 0.004
Month 3 0.105 [0.095-0.115] 130 0.076 [0.061-0.091] 11 0.10
Month 6 0.087 [0.078-0.097] 119 0.066 [0.054-0.079] 10 0.25
Month 12 0.072 [0.063-0.081] 111 0.069 [0.041-0.097] 9 0.84
Tacrolimus C
0
 (ng/mL)*
Day 3 14.9 [13.8-16.0] 144 20.5 [15.2-27.7] 8 0.05
Day 10 11.5 [10.9-12.1] 133 13.2 [11.3-15.5] 9 0.21
Month 1 12.5 [11.8-13.2] 145 12.8 [10.9-15.0] 11 0.81
Month 3 10.2 [9.8-10.8] 145 11.0 [9.7-12.4] 11 0.47
Month 6 8.6 [8.1-9.2] 125 9.1 [7.6-11.0] 10 0.63
Month 12 7.2 [6.5-7.9] 110 9.5 [6.9-13.1] 8 0.12
Tacrolimus C
0
/Dose (ng/mL per mg/kg)*
Day 3 84.7 [78.2-91.8] 125 108.7 [82.9-142.6] 8 0.14
Day 10 74.3 [67.3-82.0] 120 101.3 [86.5-118.6] 8 0.006
Month 1 87.5 [80.3-95.4] 128 136.6 [107.9-173.1] 10 0.006
Month 3 112.2 [101.0-124.6] 124 154.2 [117.6-202.3] 10 0.10
Month 6 121.3 [106.4-138.3] 105 144.3 [111.7-186.3] 9 0.26
Month 12 114.7 [100.7-130.5] 98 171.8 [120.2-245.5] 8 0.09
Creatinine clearance (mL/min)
Day 3 35.8 [31.7-39.9] 151 42.0 [20.1-63.8] 10 0.47
Day 10 45.1 [41.2-49.0] 148 47.4 [29.0-65.7] 11 0.77
Month 1 55.6 [52.0-59.3] 148 57.3 [42.1-72.5] 11 0.82
Month 3 60.1 [56.3-63.9] 144 66.2 [50.9-81.5] 11 0.40
Month 6 63.7 [59.8-67.7] 130 66.1 [50.0-82.3] 10 0.74
Month 12 65.6 [61.5-69.6] 114 59.1 [41.3-76.9] 9 0.40
* Values are expressed as geometric means with 95% confidence interval range in brackets
CYP3A4 intron 6 genotype, CYP3A5*3 and ABCB1 3435C>T combined effects
Subsequently, we investigated combined effects of CYP3A4 intron 6 genotype, ABCB1 
3435C>T and CYP3A5*3 allelic status. Patients carrying at least one CYP3A5*1 allele 
(CYP3A5 expressers) were compared with CYP3A5*3/*3 nonexpressers. In a mixed-model 
analysis, adjusted for covariates age, gender and ethnicity, including ABCB1 3435C>T, 
CYP3A5*3 and CYP3A4 intron 6 genotype status as fixed effects, all investigated SNPs 
correlated significantly with dose-corrected Tac exposure. The overall Tac dose-adjusted C
0
 
was 43% higher among CYP3A4 intron 6 CT/TT patients (CI
95%
 13-88%; p<0.001) compared 
CC patients, and 43.3% lower among CYP3A5 expressers compared to nonexpressers (CI
95%
 
-52.7 to -32.1%; p=0.001). Regarding ABCB1 3435TT individuals, patients with the ABCB1 
3435CT and 3435CC genotypes had an overall Tac dose-adjusted C
0
 that was 14.3% (CI
95%
 
-26.2 to -0.5%; p=0.042) and 20.9% (CI
95%
 -32.7 to -7.1%; p=0.003) lower, respectively. 
However, only CYP3A4 intron 6 and CYP3A5 genotypes correlated significantly with Tac 
dose requirement as ABCB1 3435C>T genotype status did not appear as a significant fixed 
effect anymore in the mixed-model. In this final model, Tac dose requirement was 25% 
lower for T-variant allele carriers (CI
95%
 -43 to -7%; p=0.04) compared to CC patients, and 
63.7% higher in patients who expressed CYP3A5 compared with nonexpressers (CI
95%
 39.1 
to 88.2%; p<0.001).
As effects of CYP3A4 intron 6 and CYP3A5*3 SNPs appear independent, we generated 
groups of combined genotypes, with Group 1 containing CYP3A5 nonexpressers and 
CYP3A4 intron 6 T-variant carriers (poor metabolizers); Group 2 contains CYP3A5 
nonexpressers and CYP3A4 intron 6 C-allele homozygotes (intermediate-1 metabolizers); 
Group 3 clustered CYP3A5 expressers carrying the CYP3A4 intron 6 T-allele (intermediate-2 
metabolizers) and Group 4 merged CYP3A5 expressers with CYP3A4 intron 6 CC wild-
types (extensive metabolizers) (table 3). Tac C
0
 was significantly different among groups 
of genotypes at first visits (table 4). Tac daily dose requirement, based on reaching target 
Tac C
0
 by TDM, was significantly different from day 10, and this remained significant (table 
4). The same significant differences were observed when dose was adjusted for weight 
(table 4). Tac dose-adjusted C
0
 was significantly different among groups at all time points 
(figure 1d, table 4). This was a linear trend in function of genotype category classification 
either for Tac predose concentrations at day 3 (Group 1 > Group 2 > Group 3 > Group 4, 
p<0.004; table 4) or for Tac dose requirement from day 10 to month 12 (Group 1 < Group 2 
< Group 3 < Group 4, p=0.001; table 4). This trend was also observed for dose-adjusted Tac 
C
0
 and showed high statistical significance at all investigated time points (Group 1 > Group 
2 > Group 3 > Group 4, p=0.006; table 4). The mixed-model analysis revealed an overall 
increase in Tac dose-adjusted trough blood concentrations of +179.3% for poor (p<0.001), 
+101.4% for intermediate-1 (p<0.001) and +64.4% for intermediate-2 (p=0.020) clusters as 
compared to extensive metabolizers. 
Table 3: CYP3A4/CYP3A5 haplotype classification.
CYP3A4 intron 6 CT or TT CYP3A4 intron 6 CC
CYP3A5*1 non carriers
Group 1 Group 2
Poor metabolizers
n= 10 (5.4%)
Intermediate-1 metabolizers
n= 142 (76.8%)
CYP3A5*1 carriers
Group 3 Group 4
Intermediate-2 metabolizers
n= 2 (1.1%)
Extensive metabolizers
n= 31 (16.8%)
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Table 4: Tacrolimus dose, predose concentration and dose-corrected predose concentration according to the 
combined CYP3A4 intron 6 C>T SNP and CYP3A5 genotype.
Tacrolimus dose (mg/day) Group 1 n Group 2 n Group 3 n Group 4 n
p-value
ANOVA
p-value
Polynominal#
Day 3 13.0 [10.9-15.1] 7 13.1 [12.4-13.8] 111 13.0 [0.3-25.7] 3 14.0 [12.0-15.9] 25 0.78 -
Day 10 8.3 [5.9-10.6] 8 11.8 [10.8-12.8] 109 13.0 [0.3-25.7] 2 17.6 [15.0-20.2] 25 <0.001 <0.001
Month 1 6.5 [5.0-8.0] 8 10.3 [9.5-11.0] 112 7.0 [-5.7-19.7] 2 15.2 [13.1-17.2] 25 <0.001 <0.001
Month 3 5.0 [3.8-6.2] 9 6.7 [6.2-7.3] 105 6.0 [6.0-6.0] 2 10.5 [8.5-12.6] 26 <0.001 0.001
Month 6 4.3 [3.2-5.3] 8 5.3 [4.8-5.9] 97 5.5 [-0.9-11.9] 2 9.7 [7.9-11.6] 23 <0.001 <0.001
Month 12 3.9 [2.9-4.9] 8 4.6 [4.1-5.1] 91 10.0 1 7.9 [6.2-9.6] 21 <0.001 <0.001
Weight-adjusted Tacrolimus dose (mg/day per kg b.w,)
Day 3 0.190 [0.173-0.207] 7 0.178 [0.171-0.185] 110 0.201 [0.012-0.222] 2 0.197 [0.172-0.222] 25 0.18 -
Day 10 0.118 [0.089-0.146] 8 0.160 [0.147-0.174] 108 0.201 [0.012-0.390] 2 0.245 [0.212-0.277] 25 <0.001 <0.001
Month 1 0.094 [0.070-0.118] 8 0.143 [0.132-0.154] 111 0.108 [-0.084-0.300] 2 0.212 [0.189-0.235] 25 <0.001 <0.001
Month 3 0.072 [0.054-0.089] 9 0.093 [0.084-0.102] 104 0.093 [0.089-0.096] 2 0.152 [0.122-0.183] 26 <0.001 0.001
Month 6 0.062 [0.048-0.075] 8 0.074 [0.065-0.082] 96 0.085 [-0.010-0.180] 2 0.142 [0.112-0.173] 23 <0.001 <0.001
Month 12 0.058 [0.042-0.074] 8 0.062 [0.054-0.070] 90 0.155 1 0.114 [0.088-0.140] 21 <0.001 <0.001
Tacrolimus C0 (ng/mL)*
Day 3 21.5 [14.2-32.5] 7 15.8 [14.7-17.1] 118 14.9 1 11.2 [9.1-13.7] 26 <0.001 0.004
Day 10 13.0 [10.5-16.0] 8 11.7 [11.0-12.4] 110 15.3 1 10.8 [9.3-12.5] 23 0.40 -
Month 1 12.8 [10.2-16.2] 9 12.7 [12.0-13.4] 120 12.4 [7.9-19.7] 2 11.5 [9.7-13.6] 25 0.62 -
Month 3 11.1 [8.9-13.0] 10 10.4 [9.9-11.0] 120 9.3 1 9.4 [8.4-10.5] 25 0.36 -
Month 6 9.1 [7.1-11.7] 9 8.7 [8.1-9.3] 105 9.0 1 8.2 [6.9-9.9] 20 0.90 -
Month 12 9.5 [6.4-14.0] 8 7.2 [6.6-8.0] 91 - 0 6.8 [5.1-9.0] 19 0.27 -
Tacrolimus C0/Dose (ng/mL per mg/kg)*
Day 3 113.6 [78.4-164.7] 7 91.7 [83.9-100.3] 100 80.1 1 61.6 [53.3-71.1] 25 <0.001 0.006
Day 10 104.3 [84.5-128.9] 7 83.0 [74.6-92.3] 97 82.2 1 46.6 [39.8-54.4] 23 <0.001 0.003
Month 1 142.3 [100.9-200.6] 8 97.5 [89.3-106.3] 103 116.2 [12.3-1100.0] 2 56.2 [46.8-67.4] 25 <0.001 <0.001
Month 3 123.3 [115.9-226.2] 9 127.9 [114.9-142.3] 100 100.0 1 65.0 [52.3-80.7] 24 <0.001 <0.001
Month 6 148.3 [105.3-208.7] 8 140.2 [123.0-159.9] 86 116.1 1 62.8 [46.4-85.0] 19 <0.001 0.001
Month 12 171.8 [111.7-276.8] 8 131.2 [116.4-147.8] 80 - 0 63.0 [42.3-93.9] 18 <0.001 <0.001
Creatinine clearance
Day 3 43.9 [16.4-71.3] 8 36.1 [31.6-40.6] 125 34.3 [-202.9-271.4] 2 34.6 [23.6-45.2] 26 0.85 -
Day 10 49.0 [25.9-72.0] 9 44.1 [39.8-48.3] 123 40.2 [-64.8-145.2] 2 50.0 [39.4-60.7] 25 0.67 -
Month 1 59.1 [40.0-78.2] 9 55.2 [51.1-59.2] 123 49.2 [19.5-78.9] 2 58.0 [48.8-67.2] 25 0.88 -
Month 3 67.6 [50.8-84.4] 10 60.0 [56.0-63.9] 118 52.5 1 60.9 [49.1-72.7] 26 0.77 -
Month 6 68.1 [50.5-85.8] 9 63.5 [59.2-67.7] 107 48.5 1 64.9 [53.6-76.1] 23 0.84 -
Month 12 60.9 [40.8-81.0] 8 65.4 [61.1-69.8] 94 45.0 1 66.1 [55.1-77.1] 20 0.75 -
* Values are expressed as geometric means with 95% confidence interval range in bracket
# The corresponding linear contrast tested the probability of a positive linear trend of the dependant variable 
across the ordered level of the genotype classification (a priori polynomial linear contrast test) 
Patients from Group 1 and 2 had a geometric mean of Tac C
0
 at day 3 above the consensus 
supratherapeutic threshold (15 ng/mL): 21.5 ng/mL for group 1 and 15.8 ng/mL for group 
2. Logistic regression models showed that the risk of presenting supratherapeutic Tac C
0
 at 
day 3 was significantly higher for Group 1 (OR=8.3 CI
95%
 [1.3–57.0], p=0.027) and Group 2 
(OR=4.7; CI
95%
 [1.9–13.4], p=0.002), respectively, compared to Group 4 (Figure 2). Group 3 
was excluded from analysis as data on Tac C
0
 were available for only one patient (Tac C
0
 = 
14.9 ng/mL). No significant differences were observed regarding risk of Tac C
0
 <10 ng/mL 
across the different genotype clusters (data not shown).
Figure 2. Percentage of patients within each CYP3A metabolizer cluster stratified by Tac C
0
 levels at day 3 below 
or above the 15 ng/mL supratherapeutic threshold.
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CYP3A4 genotype, delayed graft function, creatinine clearance and acute 
rejection
DGF was observed in 38/185 patients, of which two carried the CYP3A4 intron 6 T-variant 
allele. No statistically significant difference in incidence of DGF between variant carriers and 
CC patients was observed (χ2=0.12, p= 0.72). Also no significant differences in creatinine 
clearance were observed between variant carriers and CC patients (table 2). No differences 
were observed regarding creatinine clearance or incidence of DGF between groups of 
combined genotypes for CYP3A4/5 SNPs (table 4 and 5, respectively). Biopsy proven 
acute rejection (BPAR) occurred in 37/185 patients, of which 4 carried the CYP3A4 intron 
6 variant, but no statistically significant differences in BPAR incidence between variant 
carriers and CC patients was observed (χ2=1.42, p=0.23). Similarly, we did not find any 
statistically significant differences in the incidence of either DGF or BPAR among different 
clusters of generated genotypes according to CYP3A4 intron 6 and CYP3A5*3 allelic status 
(χ2=0.51 and 4.52, p=0.96 and 0.18, respectively).
DISCUSSION
In this study, we showed for the first time that the new CYP3A4 intron 6 C>T SNP (rs35599367) 
is associated with a lower Tac dose requirement, in agreement with the reduced function 
of this CYP3A4 variant and thus expected reduced clearance of Tac 6. We demonstrate 
that de novo kidney transplant recipients who carry at least one T-variant allele required 
significantly lower Tac doses to reach target Tac C
0 
when compared to homozygous wild-
type patients. During the first year after transplantation, T variant allele carriers required 
on average 33% lower Tac dose than homozygous CC patients. 
Our findings are in agreement with the recent report of Wang et al. addressing the 
functional defect caused by this SNP 6. These authors showed that the intron 6 C>T SNP 
rs35599367 is significantly linked to reduced CYP3A4 mRNA expression and enzyme activity 
in human livers, being thus far the only CYP3A4 SNP with relative high allele frequency in 
Caucasians showing such a large effect. A recent paper by Jacobson et. al described three 
other CYP3A4 polymorphisms with respect to Tac pharmacokinetics 31, but these were only 
observed in Africans. In our study, only eight patients were of African origin, which is why 
we did not include the Jacobson SNPs. 
Using CYP3A4/5 combined genotypes, the significance of the observed effects on Tac 
pharmacokinetics is increased compared to the CYP3A4 or CYP3A5 genotype alone. This 
effect was allele-dose dependent and the magnitude was quantitatively influenced by 
genotype classification: Tac dose requirement was lowest for poor metabolizers, followed 
by intermediate-1, intermediate-2 and then extensive metabolizers at all time points 
(p=0.001), except day 3 (p=0.78). This latter observation reflects that at this time point, 
no dose adjustments were made based on TDM and dosing thus was independent from 
genotype or metabolizer status. Similarly, Tac dose-adjusted C
0
 was significantly affected 
by CYP3A4/5 combined genotype and followed the order extensive < intermediate-2 < 
intermediate-1 < poor metabolizers, demonstrating that poor metabolizers require lower 
doses to achieve target Tac C
0
 when compared to other groups at all time points, also at 
day 3 after transplantation. This suggests that this classification might lead to a better 
prediction of optimal Tac starting dose for immunosuppressive therapy. 
The risk of supratherapeutic Tac C
0
 (>15 ng/mL) on day 3 was significantly higher for poor 
and intermediate-1 metabolizers when compared to extensive metabolizers. This was even 
more pronounced among poor metabolizers compared to intermediate-1 metabolizers. We 
observed that both poor and intermediate-1 metabolizers had mean Tac C
0
 at day 3 >15 ng/
mL (21.5 and 15.8 ng/mL, respectively). We have reported earlier that a significantly larger 
proportion of patients carrying the CYP3A5*1 allele had Tac C
0
 <10 ng/mL 26. When genetic 
status for CYP3A4 intron 6 SNP was taken into account, no significant differences were 
observed regarding the risk of presenting Tac concentration below this threshold (data not 
shown). However, as recently suggested by several authors, it is likely that clinicians are 
able to target C
0
 above this threshold rapidly after transplantation by performing simple 
concentration-controlled Tac dose adjustments without consideration of CYP3A5 status 
20. In the present study, 15% of patients presented Tac C
0
 <10 ng/mL at day 3, whereas 2 
patients had Tac C
0
 <5 ng/mL. Approximately 50% of patients presented Tac C
0
 above 15 
ng/mL. Neither subtherapeutic Tac C
0
 at day 3 nor CYP3A5*1 allele were associated with 
BPAR within 1 month after surgery (data not shown), in accordance with previous studies 
16,26, 32-34. We found that relatively many patients (50%) overshooted the Tac exposure 
upper limit and relatively few patients (15%) had Tac exposures <10 ng/mL, indicating 
that overexposure is a more frequently encountered problem than underexposure. This 
may be especially relevant in patients suffering from DGF. Regarding ABCB1, we found the 
3435C>T SNP independently associated with Tac dose-adjusted C
0
. The influence of this 
SNP (14.3% and 20.9% lower for heterozygotes and homozygotes, respectively) was modest 
when compared to the effects of CYP3A4 and CYP3A5 polymorphisms, and disappeared 
in a mixed-model analysis in which CYP3A4 and CYP3A5 genotype were included. The 
relatively minor contribution of ABCB1 polymorphism on Tac pharmacokinetics is in line 
with previous investigations 35-37.
The present study has limitations. Although most participating centers used immunoassays 
to measure Tac concentrations, some centers applied LC-MS/MS. In an additional mixed-
model analysis in which we adjusted for Tac assay, the effect of CYP3A4 intron 6 genotype 
was still significant, both for Tac daily dose (-20% for T-variant allele carriers, p=0.007) as for 
Tac dose-adjusted C
0 
(+37% for T-variant allele carriers, p<0.001). Secondly, corticosteroids 
are known to influence Tac exposure 38-39. As corticosteroid tapering was recommended 
but not mandatory, there may have been differences in corticosteroid regimens used in the 
different centers. This may have influenced the analysis. If all patients had been treated 
with the same dose, the influence of genotype may have been stronger through reduction 
of uncontrolled variability generated by different tapering regimens. The corticosteroid 
dose could unfortunately not be included in the mixed-model analysis because different 
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formulations with different immunosuppressive potencies were used. Third, diabetic 
gastro-intestinal motility disorders can affect Tac pharmacokinetics. Although diabetic 
gastropathy may alter the curve of the Tac AUC during a dosing interval, Tac predose 
concentrations are in general much less affected 40 and we therefore believe that the 
influence of diabetes on the outcomes of the present study is limited. Fourth, there were 
occasionally data missing, which increased with follow-up. To overcome this, we have 
performed mixed-model analysis, which compensates for missing records. Nevertheless, a 
more complete data set may have provided stronger associations. Finally, we realize that 
our findings are significant with a 95% confidence level. Therefore, our results need to be 
confirmed with independent cohorts. 
In conclusion, we have shown that the new genetic CYP3A4 intron 6 polymorphism 6 was 
associated with reduced Tac clearance in our patient cohort. Therefore, pretransplantation 
genotyping of the CYP3A4 intron 6 C>T SNP, along with CYP3A5*3, could potentially benefit 
patients by reducing initial Tac doses among CYP3A poor metabolizers and thereby reduce 
the risk of reaching supratherapeutic Tac concentrations. 
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ABSTRACT
Objective Cyclosporine A (CsA) is a substrate of cytochrome P450 3A4 (CYP3A4). Recently, 
a newly discovered SNP in CYP3A4 (rs35599367 C>T), defining the CYP3A4*22 allele, has 
been linked to reduced hepatic expression and activity of CYP3A4. In the present study, the 
clinical impact of this SNP was investigated in a cohort of patients receiving a CsA-based 
immunosuppressive regimen. 
Materials and methods 172 de novo kidney transplant recipients, receiving CsA/MMF as 
immunosuppressive therapy and participating in the FDCC study, were genotyped for the 
new CYP3A4*22 allele. CsA C
0
 and/or C
2 
levels were measured on days 3 and 10, and on 
months 1, 3, 6 and 12 after transplantation. Plasma creatinine concentrations, delayed 
graft function (DGF) and biopsy-proven acute rejection (BPAR) were recorded. 
Results The CYP3A4*22 allele was significantly associated with a higher risk of DGF compared 
to CYP3A4*1/*1 patients after adjustment for known risk factors (odds ratio (OR)=6.34, 
confidence interval (CI
95%
) (1.38-29.3, p=0.015). Mixed-model analysis demonstrated that 
the overall creatinine clearance was 20% lower in CYP3A4*22 allele carriers compared 
to CYP3A4*1/*1 patients [CI
95%
 (-33.1 to -7.2%, p=0.002]. For ABCB1 3435C>T, T-variant 
carriers had a decreased risk of developing DGF compared to CC patients (CT: OR=0.30, 
CI
95%
 [0.11-0.77], p=0.011; TT: OR=0.18, CI
95%
 [0.05-0.67], p=0.011).
Conclusion The CYP3A4*22 constitutes a risk factor for DGF and worse creatinine clearance 
in patients receiving CsA-based immunosuppressive therapy. Therefore, pre-transplant 
genotyping for this CYP3A4*22 allele might help clinicians to identify patients at risk of 
DGF and poor renal function when treated with CsA. 
INTRODUCTION
The clinical use of Cyclosporine A (CsA) in suppressing the immune response is hampered 
by its narrow therapeutic index and its highly variable and relatively unpredictable 
pharmacokinetics 1. Therapeutic drug monitoring has therefore been adopted by most 
transplant physicians as a means to improve the efficacy of CsA treatment and to reduce 
toxicity. CsA is extensively metabolized by CYP3A 2, but drug transporters are also involved 
in the disposition of CsA. One of them is ABCB1 (or P-glycoprotein), encoded by the ABCB1 
gene 3. 
CYP3A4 is the most abundant CYP enzyme in human liver and intestine and is responsible 
for the oxidative metabolism of approximately 45% to 60% of all currently prescribed drugs 
4. CYP3A4 activity and protein content vary widely in the population, with a 10 to 100-
fold inter-individual variability 5-8. Studies aiming to unravel the genetic basis of variable 
CYP3A4 expression and/or activity failed thus far to identify nonsynonymous single-
nucleotide polymorphisms (SNP) that could explain these inter-individual differences in 
pharmacokinetics. Genetic variants of CYP3A4 that change amino acids are rare [9] and 
therefore can only account for a small portion of the observed variability. The most common 
CYP3A4 variant allele is a promoter variant: CYP3A4*1B. This first described CYP3A4 variant 
allele contains a nucleotide variation in the putative nifedipine response element 10. The 
CYP3A4*1B allele was in initial studies associated with an increased CYP3A4 activity, but 
subsequent studies reported inconsistent results 5, 10-13. 
A recent study identified a new functional SNP located in CYP3A4 intron 6 (rs35599367 
C>T), defining the CYP3A4*22 allele (http://www.cypalleles.ki.se/), for which the T-variant 
allele was associated with both decreased hepatic CYP3A4 mRNA expression and with 
decreased CYP3A4 enzymatic activity 14. This SNP also proved to have clinical implications, 
since it correlated with statin dose requirement for optimal lipid level control 14. The 
CYP3A4*22 allele is found with a relatively high allelic frequency of 3-4% in the Caucasian 
population, strengthening its potential contribution to differential CYP3A4 activity. We 
have previously demonstrated in two independent studies that the CYP3A4*22 allele 
might be clinically relevant when considering calcineurin inhibitor (CNI)-based therapy. 
We observed that kidney transplant recipients who carried the variant allele showed 
higher dose-adjusted CNI predose concentrations and were at a higher risk of reaching 
supratherapeutic whole-blood concentrations 15-16. The goal of the present study was to 
validate the effect of the novel CYP3A4*22 allele on CsA exposure, on dose requirement, 
and on efficacy/toxicity in a large cohort of 172 de novo kidney transplant patients 
participating in a prospective clinical trial.
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MATERIALS AND METHODS
Patients and study design
Patients were de novo kidney transplant recipients who participated in a phase IV, open, 
prospective, randomized, controlled, international, multi-center trial comparing fixed-
dose mycophenolate mofetil (MMF) treatment with concentration-controlled treatment 
(the FDCC trial) 17. At the initiation of the study, a pharmacogenetic substudy was started. 
Pharmacogenetic results regarding the role of UGT1A9 polymorphisms on MMF metabolism 
18, the role of UGT2B7 polymorphisms on acyl-glucuronide metabolite of mycophenolic acid 
(AcylMPAG) plasma concentrations 19, and the role of CYP3A5 and ABCB1 polymorphisms on 
tacrolimus (Tac) and CsA exposure and the risk of acute rejection 20-21 have been published 
earlier. All patients provided 2 written informed consents, one for the original FDCC study 
and one for the pharmacogenetic substudy. The FDCC and the pharmacogenetic (sub)study 
were approved by the ethics committees of all participating centers and relevant authorities 
in the participating countries. In the FDCC study, immunosuppressive therapy consisted of a 
CNI, MMF and corticosteroids. The choice of CsA or Tac and the target blood concentrations 
were in accordance with each center’s protocol. Standard CNI and corticosteroid tapering 
regimens were left to the discretion of the investigators. For this pharmacogenetic study, 
genetic data were available for 172 kidney transplant recipients treated with CsA. However, 
pharmacokinetic data concerning CsA measurements and/or dosage were not available 
for all patients at all time points of follow up. CsA predose concentrations (C
0
) and/or 
2 hours after drug administration (C
2
) were measured on days 3 and 10 and on months 
1, 3, 6, and 12 after transplantation, and whenever deemed necessary by the attending 
physician. In the FDCC study, donor DNA was not collected and no protocol kidney biopsies 
were performed. Creatinine clearance was calculated by the Cockcroft-Gault formula 22. 
Delayed graft function (DGF) was defined as the need for dialysis within the first week after 
transplantation. Biopsy-proven acute rejection (BPAR) was defined as any histologically 
confirmed episode for which a Banff score of 1 (mild, grades IA and IIA), 2 (moderate, grades 
IB and IIB), or 3 (severe, grade III) was recorded. The patients with panel reactive antibodies 
(PRA) above 50% within 6 months before study entry were excluded from the study. 
Drug concentration measurements
CsA C
0
 and C
2
 were determined in whole blood in local laboratories in each of the participating 
centers by the use of immunoassays [CsA FPIA assay (AxSYM Abbott Laboratories) and Emit 
2000 (Syva Company, Dade Behring Inc., Cupertino, CA)]. Proficiency testing was ensured 
by participation of all centers in the United Kingdom Quality Assessment Scheme (Prof. 
Holt, St George’s, University of London, London, United Kingdom). Dose-adjusted CsA 
concentrations were calculated by dividing the C
0 
or the C
2
 by the corresponding 24-h dose 
on a milligrams per kilogram basis. 
Genotype analysis
Genomic DNA was isolated from 200 µl ethylenediaminetetraacetic acid-treated whole blood 
using a MagnaPure LC (Roche Diagnostics GmbH, Mannheim, Germany). Allelic discrimination 
analysis was performed for the determination of CYP3A4*22 allelic status (rs35599367). 
Allelic discrimination reaction was realized using TaqMan® (Applied Biosystems, CA, USA) 
genotyping assays (C__59013445_10) on the ABI PRISM 7500® Fast real-time PCR Systems 
(Applied Biosystems, CA, USA). The PCR cycle consisted of an initial step of 1 min at 60 °C, 
followed by a denaturation step at 95 °C for 30 sec and 40 cycles with 95°C for 3 sec and 
60°C for 30 sec. The final post PCR read was made in 1 min at 60°C. The volume for each 
reaction was 11 μl, consisting of 5 μl TaqMan® GTXpress™ Master Mix, 0.125 μl of TaqMan® 
SNP genotyping assay (80x), containing the primers (64 μM) and the probes (16 μM), and 
10ng genomic DNA. CYP3A5*3, CYP3A4*1B and ABCB1 3435C>T analysis were performed as 
described earlier 20.
Statistical analysis
Statistical analyses were performed using the Predictive Analytics Software (PASW) statistics, 
version 17.0 for Windows (IL, USA). CsA C
0
 and dose-adjusted C
0
 were normalized by a 
logarithmic transformation. The log and other pharmacokinetic parameters distributions were 
then confirmed to be normally distributed by the Kolmogorov–Smirnov test. As only 2 groups 
of genotype were compared, Student’s independent t-tests were performed to compare 
means between groups at a single time point under the null hypothesis that the means of 
the compared groups were equal. For the univariate analysis of the association between 
categorical data (e.g. the incidence of acute rejection) we used Pearson’s Chi Square test or 
Fisher’s exact test, as appropriate. To estimate the overall effect of genotype on the outcome 
variables, mixed-model analysis were performed. Creatinine clearance was compared 
between genotypes by mixed-model based on the maximum likelihood ratio with the patient 
genotype status as fixed factors and the time after transplantation as repeated measurement. 
Sex, ethnicity and age of the donor and the recipient were introduced as random effects in 
the model in order to adjust the model for these co-variables. No structure was imposed on 
the variances and on the covariances between and within times of follow up of the repeated 
CsA measurements. Also, it was assumed that levels of covariables are uncorrelated and have 
a constant variance across time of follow up. Multiple logistic regression analysis was carried 
out to assess the influence of genotypes and other co-variables on the risk of DGF. Genotype-
specific odds ratio (OR) and 95% confidence intervals were computed using backward 
stepwise analysis based on the maximum likelihood ratio with a p-value of less than 0.05 
being considered statistically significant for entry and a p-value of less than 0.10 for remaining 
in the model. For these analyses, each genotype was coded as a distinct ‘dummy variable’. 
Potential confounders considered for these analyses included sex, age of the donor and the 
recipient, primary kidney disease, PRA, and cold ischemia time. Subsequently, we also ran 
the analysis by taking into account the potential influence of other functional SNPs including 
CYP3A4*1B, CYP3A5*3 and ABCB1 3435C>T. 
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RESULTS
CYP3A4 intron 6 genotype, CsA exposure, and clinical outcomes
The characteristics of the 172 patients included in the study are reported in Table 1. 
Of these patients, 161 had the CYP3A4*1/*1 genotype, 11 were heterozygous for the 
CYP3A4*22 variant allele, whereas no variant homozygotes were found. In total, this gives 
an allelic frequency of 3.2%. The observed genotype distribution was in accordance with 
Hardy-Weinberg equilibrium (χ2 = 0.19; p = 0.66). 
Table 1: Demographics of the study population
All patients CYP3A4*1/*1 CYP3A4*22 carriers p-value
N 172 161 11 -
Sex (male/female) 106 (61.6%)/66 (38.4%) 96 (59.6%)/65 (40.4%) 10 (90.9%)/1 (9.1%) 0.053
Age (year)a 49 ± 12 49 ± 12 52 ± 13 0.47
Weight (kg)a 73 ± 15 73 ± 15 76 ± 10 0.43
Transplantation number 0.04
First 159 (92.4%) 151 (93.8%) 8 (72.7%)
Second 13 (7.6%) 10 (6.2%) 3 (27.3%)
Living/deceased donor 43 (25.0%)/129 (75.0%) 40 (24.8%)/121 (75.2%) 3 (27.3%)/8 (72.7%) 1.0
FD/CC MMF therapy 93 (54.1%)/79 (45.9%) 87 (54.0%)/74 (46.0%) 6 (54.5%)/5 (45.5%) 1.0
Induction therapyb 97 (56.4%) 93 (57.8%) 4 (36.4%) 0.21
Primary kidney disease 0.47
Diabetic nephropathy 9 (5.2%) 9 (5.6%) 0 (0.0%) -
Glomerulonephritis 48 (27.9%) 46 (28.6%) 2 (18.2%) -
Obstructive/reflux 
nephropathy 12 (7.0%) 12 (7.0%) 0 (0.0%) -
Polycystic kidney disease 31 (18.0 %) 27 (16.8%) 4 (36.4%) -
Pyelonephritis/interstitial 
nephritis
10 (2.9%) 8 (2.5%) 2 (9.1%) -
Hypertensive nephropathy 17 (9.9%) 16 (9.9%) 1 (9.1%) -
Other 36 (20.9%) 34 (21.1%) 2 (18.2 %) -
Unknown 9 (5.2%) 9 (5.6%) 0 (0.0%) -
HLA mismatchesc 2.8 (3.0) 2.9 (3.0) 2.5 (3.0) 0.49
Panel reactive antibodies
<10% / ≥10 % 160 (93.0%)/12 (7.0%) 150 (93.2%)/11 (6.8%) 10 (90.9%)/1 (9.1%) 0.57
Ethnicity 1.0
Asian 6 (3.5%) 6 (3.7%) 0 (0.0%) -
Black 3 (1.7%) 3 (1.9%) 0 (0.0%) -
Caucasian 151 (87.8%) 140 (87.0%) 11 (100.0%) -
Other 12 (7.0%) 12 (7.4%) 0 (0.0%) -
Cold ischemia time (hr) 13.1 ± 8.6 13.2 ± 8.8 9.8 ± 6.0 0.22
Donor age (year) 47.7 ± 14.9 47.8 ± 14.8 45.3 ± 17.6 0.58
We did not observe any linkage disequilibrium between the CYP3A4*22 and either the 
CYP3A4*1B or the CYP3A5*3 allele (χ2=0.46 and 2.6; p=0.73 and 0.25, D=2.4x10-3 and 
4.1x10-3; r2=2.6x10-3 and 4.8x10-3, respectively). (Because of low minor allelic frequencies 
for the three SNPs, only 3 gametic types are found in the population. As a consequence, 
Lewontin D’ is equal to 1 for both LD assessments and there is thus no need to invoke a low 
recombination rate and a complete LD to explain that value 23). 
Table 2: Cyclosporine dose, predose (C
0
) and 2 hours after drug administration (C
2
) concentrations, dose-
corrected C
0
 (C
0
/Dose) and C
2
 (C
2
/Dose) according to the CYP3A4*22 allelic status.
Cyclosporine dose (mg/day) CYP3A4*1/*1 n CYP3A4*22 carriers n p-value
Day 3 537  [499-574] 156 545 [389-670] 11 0.91
Day 10 495 [463-526] 151 516 [377-655] 11 0.73
Month 1 374 [354-394] 131 344 [248-441] 9 0.47
Month 3 255 [240-270] 108 250 [176-324] 6 0.87
Month 6 230 [217-244] 98 230 [196-264] 5 0.99
Month 12 213 [202-225] 93 210 [193-227] 5 0.90
Cyclosporine C
0
 (ng/ml)*
Day 3 276 [251-303] 118 283 [211-380] 11 0.87
Day 10 278 [253-305] 122 282.9 [198-405] 10 0.92
Month 1 244 [223-267] 103 269 [189-382] 8 0.56
Month 3 158 [145-173] 82 158 [72-346] 6 1.00
Month 6 136 [124-148] 75 123 [107-142] 5 0.57
Month 12 128 [117-140] 69 145 [120-175] 5 0.47
Cyclosporine C
2
 (ng/ml)
Day 3 1122 [1031-1212] 99 1331 [816-1846] 7 0.25
Day 10 1334 [1240-1428] 113 1680 [1040-2320] 6 0.11
Month 1 1299 [1200-1399] 101 1188 [486-1890] 5 0.63
Month 3 938 [856-1021] 86 919 [405-1434] 5 0.92
Month 6 847 [782-913] 80 796 [593-998] 5 0.70
Month 12 767 [708-827] 71 858 [621-1095] 5 0.43
Cyclosporine C
0
/Dose (ng/ml per mg/kg)*
Day 3 37 [34-40] 116 43 [33-55] 11 0.27
Day 10 42 [39-45] 120 45 [39-51] 10 0.65
Month 1 50 [45-55] 103 59 [44-80] 8 0.36
Month 3 47 [43-51] 82 48 [26-89] 6 0.90
Month 6 44 [40-49] 75 41 [28-59] 5 0.61
Month 12 46 [41-51] 69 52 [38-71] 5 0.54
Cyclosporine C
2
/Dose (ng/ml per mg/kg)
Day 3 148 [136-160] 99 154 [101-206] 7 0.82
Day 10 194 [180-207] 112 203 [138-268] 6 0.76
Month 1 254 [234-273] 101 203 [86-320] 5 0.26
Month 3 264 [240-289] 86 251 [137-366] 5 0.80
Month 6 264 [243-285] 80 268 [166-370] 5 0.92
Month 12 261 [239-283] 71 309 [210-408] 5 0.27
Creatinine clearance (ml/min)
Day 3 32 [28-36] 160 28 [11-46] 11 0.67
Day 10 46 [42-51] 154 45 [24-65] 11 0.89
Month 1 85 [55-62] 131 53 [37-69] 9 0.47
Month 3 66 [62-70] 106 43 [35-51] 6 0.007
Month 6 67 [63-71] 98 53 [37-70] 5 0.15
Month 12 68 [64-73] 93 49 [37-61] 5 0.06
* Values are expressed as geometric means with 95% confidence interval range in brackets
All CsA pharmacokinetic parameters were comparable between the two CYP3A4*22 
genotype groups at all time points (Table 2). Regarding dose-adjusted parameters, similar 
results were observed without weight normalization (data not shown). 
Biopsy-proven acute rejection occurred in 28 of the 172 patients (16%). Of these 28 
patients, three carried a CYP3A4*22 allele, whereas the remaining 25 were homozygous 
wild-type. No statistically significant difference in the incidence of BPAR between variant 
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allele carriers and homozygotes for the reference allele was observed (χ2=1.04, p=0.39, 
Table 3). 
Table 3: Influence of CYP3A4*22 allele on delayed graft function (DGF) and biopsy-proven acute rejection 
(BPAR).
CYP3A4*1/*1 CYP3A4*22 carriers χ2 p-value
Delayed Graft Function (DGF)
Yes 39 5
2.44 0.15
No 122 6
Biopsy Proven Acute Rejection (BPAR)
Yes 25 3
1.04 0.39
No 136 8
Delayed graft function was observed in 44 of the 172 patients (26%), of which five carried 
a CYP3A4 intron 6 variant allele. The difference observed in the proportion of patients 
experiencing DGF between T-allele variant carriers (46%) and homozygotes for the 
reference allele (24%) groups was in itself not significant (χ2=2.44, p=0.15, OR=2.6, Table 
3). However, when multiple binary logistic regression analysis was performed to assess 
the influence of patient genotype along with different co-variables [gender, age of the 
donor and the recipient, primary kidney disease, PRA, and cold ischemia time], the risk of 
experiencing DGF was significantly higher in patients that carried the CYP3A4*22 variant 
allele compared to patients homozygous for CC (OR=6.34, CI
95%
 [1.38-29.3], p=0.015, Table 
4). In addition, we observed that the carriers of a T-allele for the ABCB1 3435C>T SNP 
in ABCB1 were less at risk of developing DGF than homozygous patients for the C-allele 
(OR=0.30 for CT, CI
95%
 [0.11-0.77], p=0.011, and OR=0.18 for TT, CI
95%
 [0.05-0.67], p=0.011, 
Table 4). By contrast, neither CYP3A4*1B nor CYP3A5*3 allelic status was associated with 
the risk of DGF. In the logistic regression model, patients with PRA >10% had a significantly 
higher risk of developing DGF compared to patients with PRA <10% (OR=9.63, CI
95%
 
[2.02-45.9], p=0.005, Table 4). Finally, longer cold ischemia time (OR=1.14, CI
95%
 [1.06-
1.21], p<0.001) and higher donor age (OR=1.04, CI
95%
 [1.01-1.08], p=0.006, Table 4) were 
significantly related to the risk of DGF. The risk of DGF was not influenced by CsA C
0 
at 
day 3, recipient age, gender or primary kidney disease. By contrast, it was significantly 
correlated with the CsA C
2
 levels, with higher concentrations being protective (OR=0.997 
CI
95%
=[0.996-0.998], p<0.001). When all non-significant potential confounders (age of the 
recipient, sex and primary kidney disease) along with CsA C
2
 levels were forced into the 
logistic regression model, it did not modify the association between CYP3A4*22 allele 
and the risk of DGF, which was still higher in carriers of the CYP3A4*22 allele with an 
OR of 7.5 CI95%=[0.65-87.5] but no more significant (p=0.11), maybe because C
2
 levels 
were only available for 7 of the 11 CYP3A4*22 allele carriers. There is evidence that a 
prior transplant may predispose to DGF 24 and because among CYP3A4*22 variant allele 
carriers significantly more patients received a second renal transplant as compared with 
the homozygous wild-type group (p=0.04, Table 1), this may have confounded our results. 
However, no association was observed between the number of prior transplants and the 
risk of DGF, neither in the univariate nor in the multiple logistic regression models (data 
not shown). Consistently, when we excluded recipients of a second transplant from our 
analysis, the increased risk of DGF among patients carrying the CYP3A4*22 variant allele 
was still observed (p=0.03) with an OR of 7.66 (CI
95%
=[1.24-47.4]). 
Table 4: Multiple logistic regression modeling for the risk of presenting DGF
Risk factor OR CI
95%
p-value
Reference class* 1 - -
CYP3A4 intron 6 CT 6.34 [1.38-29.3] 0.015
ABCB1 3435CT 0.30 [0.11-0.77] 0.013
ABCB1 3435TT 0.18 [0.05-0.67] 0.011
PRA >10% 9.63 [2.02-45.9] 0.005
Donor age 1.04 [1.01-1.08] 0.006
Cold ischemia time 1.14 [1.06-1.21] <0.001
* CYP3A4 intron 6 CC, ABCB1 3435CC, Panel Reactive Antibodies <10%, Donor age 47.6, Cold ischemia time 
13.1 hours.
Renal function, assessed by calculation of creatinine clearance, was statistically significantly 
lower among CYP3A4*22 allele carriers at 3 months of follow-up compared with wildtype 
patients (p=0.006, Table 2). This difference did not remain significant at later time points 
(p=0.15 and 0.06 at months 6 and 12, respectively). In the FDCC trial the duration of DGF 
was not systematically recorded. Therefore, we chose to study renal function of the whole 
cohort from month 3 onwards as by that time, most patients will likely have recovered from 
DGF or their grafts will have been considered as “never functioning”. Creatinine clearance 
values at earlier time points (i.e. <3 months) may reflect the influence of dialysis in cases 
of DGF and were therefore not considered for the analysis. Repeated measurement in 
mixed-model analysis demonstrated that the overall creatinine clearance was 26% lower 
in CYP3A4*22 variant allele carriers when considering data from the third month onwards 
(CI
95%
 [-41.3 to -11.3%], p=0.001. Figure 1A). We also performed the analyses considering 
the entire 12-month study period after excluding all patients that experienced DGF. Results 
showed that the creatinine clearance did not differ between the two CYP3A4 genotype 
groups at the individual time points anymore (p=0.06 at month 3 and p=0.10 at month 6 
and 12). The overall creatinine clearance throughout the first year after transplantation 
remained 13% lower in DGF-free CYP3A4*22 variant allele carriers although this difference 
was not statistically significantly different (p=0.13, Figure 1B).
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Figure 1: Creatinine clearance (mL/min) according to the genetic status of patients for CYP3A4*22 allelic status 
when considering (A) late follow-up time points in all patients and (B) the entire follow-up time in DGF-free 
patients only. Data are represented as means (±SD). **=p<0.01. Open circles: CYP3A4*22 allele carriers, filled 
circles: CYP3A4*1/*1 homozygotesDISCUSSION
Our study is the first retrospective analysis investigating the association between the newly 
discovered CYP3A4 intron 6 rs35599367 C>T SNP (CYP3A4*22), CsA exposure and response 
to CsA therapy in a prospective trial. We show here that the CYP3A4*22 variant allele is 
a risk factor for DGF and poorer renal function during CsA treatment. As the CYP3A4*22 
allele is not in substantial LD with any Hapmap SNPs and is not referred to in Hapmap, 
association studies using tag SNPs failed to correlate this SNP with differential CYP3A4 
clinical phenotypes. Given the fact that genome-wide human SNP arrays only contain SNPs 
that have a minor allele frequency of more than 5%, the impact of the CYP3A4*22 allele 
will not be detected in GWAS using these genotyping tools. 
We hypothesize that the higher risk of DGF in carriers of the CYP3A4*22 allelic variant 
is real and the consequence of a reduced CYP3A4 activity. The CYP3A4*22 variant allele 
has been functionally linked to reduced CYP3A4 mRNA expression and 6β-testosterone 
hydroxylation in human liver microsomes 14. The exact mechanism underlying the increased 
DGF risk of CYP3A4*22 carriers is at present unclear. Although the nephrotoxicity of CsA 
is well-known, its contribution to the occurrence of DGF after kidney transplantation is 
controversial. Indeed, in the BENEFIT trial, no differences in the incidence of DGF were 
observed between patients treated with CsA and patients who were treated with a CsA-
free protocol 25. In agreement with those results, we showed here an inverse relationship 
between CsA C
2
 levels and the risk of DGF, which might be explained by the fact that the 
physician would have decided to initially lower the CsA dose for patients considered as at 
higher risk of DGF but, hence, argues against an association between CsA exposure and 
risk of DGF (i.e. lower is the CsA C
2,
 higher is the risk). Therefore, the higher risk of DGF 
observed in CYP3A4*22 carriers may not have been caused by an altered metabolism of 
CsA. CYP3A4 plays a role in oxidative stress and its activity is related to the production 
of reactive oxygen species (ROS). Therefore, one explanation might be that the reduced 
CYP3A4 expression of CYP3A4*22 carriers leads to differential levels of ROS. This could 
eventually lead to a worse outcome of ischemia-reperfusion injury and a higher risk of 
DGF, although this remains highly speculative at this moment. On the other hand, a recent 
meta-analysis that aimed to identify the risks and benefits of reduced CNI exposure by 
pooling data from 56 studies (including the above-mentioned BENEFIT trial) demonstrated 
that CNI-sparing strategies were associated with a reduction in DGF rate [26]. Therefore, 
despite the fact that the meta-analysis was conducted irrespective of the CNI used (i.e. Tac 
or CsA), we cannot exclude that the higher risk of DGF in CYP3A4*22 allele carriers was the 
consequence of an altered CYP3A4-mediated oxidative metabolism of CsA. 
In addition to a higher risk of DGF, CYP3A4*22 variant allele carriers had a poorer renal 
function. In contrast to DGF, there is considerable evidence that CsA exposure has an 
impact on long term kidney allograft function 27. Indeed, in the BENEFIT trials, it was shown 
that renal function was better in patients receiving belatacept and no CsA as compared 
to patients who did receive CsA 25, 28-29. These observations may seem contradictory to 
our results as, in the present study, the reduced renal function (and higher risk of DGF) of 
CYP3A4*22 allele carriers was not explained by differences in CsA exposure between the 
different genotype groups. Nonetheless, there remains a possibility that differences may 
have existed between the CYP3A4*22 genotype groups in terms of CsA systemic exposure. 
We showed previously for the CYP3A4*1B allele, that a patient’s genotype does affect CsA 
oral clearance (as determined from an area-under the concentration versus time curve), 
which was not apparent when C
0
 or C
2 
were studied [30]. If overexposure to CsA did indeed 
exist, one would expect an increased incidence of other CsA-related adverse events to 
have occurred in association with the CYP3A4*22 allele, as well. Blood pressure and lipid 
levels were not systematically recorded in the FDCC trial. However, when studying the risk 
of opportunistic infections in binary logistic regression, we observed a trend towards an 
increased risk of experiencing an opportunistic infection in CYP3A4*22 carriers (OR=2.9, 
p=0.09, CI
95%
 [0.85-10.0]). This argues in favour of our hypothesis that patients carrying the 
CYP3A4*22 SNP allele may have been exposed to higher CsA levels and may have suffered 
from over-immunosuppression. 
In addition, CsA levels measured by immunoassays should be interpreted with caution, 
as these assays are known to cross-react with CsA metabolites 31. It is possible that the 
CYP3A4*22 allele influenced the ratio of CsA to its metabolites which was not detected 
because of these analytical issues. A reduced CsA metabolite production in CYP3A4*22 
carriers would result in higher levels of the parent drug, which is considered to exert the 
nephrotoxic effects unlike its metabolites 32-36.
The poorer long-term renal function of CYP3A4*22 carriers may have resulted from their 
increased occurrence of DGF. However, we feel that these two outcome variables were 
independently related to CYP3A4 genotype. First, we showed that, when only later time 
points were considered (i.e. when kidney function for patients that experienced DGF likely 
had recovered), the creatinine clearance was significantly lower for CYP3A4*22 carriers. 
Secondly, when patients experiencing DGF were excluded from the analysis, the overall 
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creatinine clearance remained poorer in CYP3A4*22 carriers although the difference 
between the two genotype groups was numerically smaller and no longer statistically 
significantly different. This may have resulted from a loss of statistical power as 5 out of 
11 CYP3A4*22 carriers suffered from DGF and the number of data available for DGF-free 
CYP3A4*22 variant allele carriers decreased when time of follow-up increased (day 3: n=6; 
day 10: n=6; month 1: n=4, month 3, 6 and 12: n=2). Still, we believe that the association 
between CYP3A4 genotype and renal function should be interpreted with caution, given 
the relatively low number of CYP3A4*22 carriers and hence the possibility of a type II 
statistical error or spurious associations. The observed differences in renal function 
between the different CYP3A4*22 genotype groups are not likely due to differences in 
intra-renal CYP3A4 activity, as CYP3A4 is not expressed in the kidney 37-39. 
We have previously reported that CYP3A4*22 variant allele carriers require lower 
Tac doses to achieve target blood concentrations and are at risk of Tac overexposure as 
compared with homozygous wildtype patients 15, 16. These results are in agreement with 
the idea of a reduced CYP3A4-mediated metabolism in CYP3A4*22 variant allele carriers. In 
contrast to the observation made in the present study, the CYP3A4*22 allele was associated 
with higher CsA dose-adjusted predose concentrations in a cross-sectional study of stable 
renal transplant 16. These discrepancies might be ascribed to differences in study design. 
In our previous study, only 50 patients were included and no more than 5 CYP3A4*22 
carriers were identified. In addition to the restricted cross-sectional design, the small size 
of studied groups could have increased the probability of a spurious association. However, 
and in line with the current study, we observed in our previous cross-sectional study that 
the creatinine clearance was 15.5% lower in patients harboring a CYP3A4*22 allele 16. 
For ABCB1 3435C>T, multivariate analysis showed that the T-variant allele is protective 
for DGF. As the T-allele has been previously associated with decreased expression of ABCB1 
in different organs 40-43, our hypothesis is that patients carrying the T-allele accumulate 
more CsA in body compartments (other than the kidney) where ABCB1 is expressed. The 
transplanted kidney, which expresses the donor genotype, would then be protected from 
drug overexposure. Indeed, it has been shown by Hauser et al. that the ABCB1 genotype 
of the kidney donor was a risk factor for CsA-related nephrotoxicity 44. Unfortunately, 
donor DNA was not collected in the present study. In contrast to our results, Cattaneo 
et al. 45 showed that CsA-treated kidney transplant recipients carrying the 3435T-allelic 
variant had a three-fold increased risk for DGF and a trend to a slower recovery of renal 
function than patients homozygous for the C-allele. Their hypothesis was that oxidative 
stress in grafts transplanted in carriers of the 3435T allele could have been amplified by 
ROS generated in increased amount by infiltrating leukocytes. The underlying assumption 
is that intra-leukocyte CsA concentrations are increased in 3435T allele carriers. However, 
Ansermot et al. did not detect any significant difference in wildtype and variant haplotype 
carriers for 2677G>T/A and 3435C>T SNPs when considering CsA t
max
, t
1/2
, C
max
 and AUC
0-24 
in peripheral blood mononuclear cells (PBMCs) 46. The observation arising from our study 
is corroborated by the data reported earlier by Fellay et al. 47 on the influence of the ABCB1 
3435C>T genotype on anti-HIV drugs distribution. We have previously demonstrated that 
when CYP3A4*22 allelic status was not taken into account, ABCB1 3435C>T SNP was no 
longer a significant covariate for the risk of DGF 20. This indicates that the ABCB1 3435C>T 
recipient genotype has only a weak impact on CsA pharmacokinetics. To fully address this 
issue, further studies which take into account ABCB1 genotype of the donor, along with 
the CYP3A4*22 genotype of the recipient, should be performed. Finally, we confirmed the 
results of previous reports showing that donor age and longer cold ischemia time were 
both related to the risk of developing DGF 45, 48-50. 
In conclusion, we demonstrated in a large cohort of patients that the CYP3A4 intron 6 
SNP, representing the CYP3A4*22 allele, predisposes kidney transplant recipients receiving 
CsA to worse renal function and is associated with an increased risk of DGF. Therefore, pre-
transplant genotyping of the CYP3A4*22 allele could potentially help the clinician to identify 
patients at risk of impaired renal function associated with CsA-based therapy. Prospective 
studies are needed to confirm this contribution of CYP3A4*22 pharmacogenetic screening 
for CsA therapy.
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ABSTRACT
Introduction Tacrolimus has a large inter-individual pharmacokinetic variability and 
quantification of its effect is difficult. It is a substrate of ABCB1, an efflux-pump expressed 
more on CD8+ T cells than on CD4+ T cells. The ABCB1 3435C>T single-nucleotide 
polymorphism (SNP) has been associated with inter-individual differences in ABCB1 
activity and may influence drug efficacy. Here the influence of this SNP on the biological 
effect of tacrolimus was studied. 
Methods Rhodamine (Rh123) efflux was used to study ABCB1 activity, with or without the 
addition of the ABCB1-inhibitor verapamil. Intracellular IL-2 production in T cells was used 
to measure the pharmacodynamic effect of tacrolimus after PMA/ionomycin stimulation 
of whole blood. In addition, the ABCB1 genotype of 36 tacrolimus-treated renal transplant 
patients was related to ABCB1 activity and tacrolimus-efficacy. 
Results The mean Rh123 efflux was higher in CD8+ T cells compared to CD4+ T cells: 40% 
vs. 19% of cells, resp. (p<0.001). Verapamil almost completely blocked Rh123 efflux (to 
1.8% of CD4+ T cells and 0.5% of CD8+ T cells), while tacrolimus did not change Rh123 
efflux. Tacrolimus 10 ng/mL reduced the production of IL-2 in CD4+ and CD8+ T cells by 
28.9% and 45.4% (p < 0.05). Tacrolimus-mediated inhibition of IL-2 was enhanced by 
verapamil (p<0.05). This effect on tacrolimus pharmacodynamics was associated with 
ABCB1 3435C>T SNP in renal transplant patients: verapamil reduced the percentage of IL-2 
producing CD4+ and CD8+ T cells by 14% and 22% in patients with the CC genotype (p < 
0.05) but not in patients with the TT genotype. Moreover, the ratio tacrolimus C
0
 over % 
IL-2 producing CD8+ T cells in CC genotype patients was significantly higher compared to 
TT genotype patients (p<0.05), showing a smaller pharmacodynamic effect in CC genotype 
patients. 
Conclusion The ABCB1 3435C>T SNP influences ABCB1 activity of T cells and the 
pharmacodynamic effect of tacrolimus in kidney transplant patients. 
INTRODUCTION
Combination therapy of the calcineurin inhibitor (CNI) tacrolimus with mycophenolate 
mofetil, with or without glucocorticoids forms the most frequently used immunosuppressive 
regimen after solid organ transplantation 1. Tacrolimus forms a complex with the 
intracellular FKBP12 (FK506 binding protein), which binds and inhibits the phosphatase 
activity of calcineurin 2. This complex subsequently blocks the activation of the nuclear 
factor of activated T cells (NFAT), leading to inhibition of the expression of various cytokines, 
such as interleukin (IL)-2, which decreases inflammatory responses of alloreactive T cells 
2. Tacrolimus has a narrow therapeutic range, a large inter-individual variability in its 
pharmacokinetics, and quantification of its effect is difficult 3. 
CNIs are substrates of ABCB1 (ATP-binding cassette sub-family B member 1, previously 
known as P-glycoprotein (P-gp) or multidrug resistance protein-1 (MDR1) 4, a protein that 
acts as an efflux pump and is encoded by the ABCB1 gene. Physiologically, ABCB1 is expressed 
in the liver, pancreas, on enterocytes in the small intestine and colon, in the blood-brain 
barrier, and in the human kidney. ABCB1 is also found on various leukocytes, including T 
and B lymphocytes 5. The specific tissue expression of ABCB1 suggests that it functions 
as a protective barrier. Its expression in the intestine is thought to limit the absorption 
of xenobiotics, whereas its expression in the biliary tract and kidney may facilitate the 
elimination of metabolic waste products and toxins 5. In addition, ABCB1 removes CNIs 
from the intracellular compartment of lymphocytes, their main therapeutic target 4. 6-7. For 
this reason, the activity of ABCB1 may affect intracellular tacrolimus concentrations and 
inter-individual variability in ABCB1 activity may influence the immunosuppressive effect 
of tacrolimus. The efflux-pump has a higher expression on CD8+ T cells than on CD4+ T cells 
8-10, and hence will influence the intralymphocytic tacrolimus concentrations especially 
in CD8+ T cells. Several single-nucleotide polymorphisms (SNPs) have been identified in 
ABCB1. The SNP that has been studied most is the C to T transition at position 3435 within 
exon 26 (rs1045642), a synonymous SNP. The ABCB1 3435C>T SNP has been associated 
with reduced mRNA expression 11 and stability 12, and more recently, with changes in 
substrate specificity 13. The ABCB1 3435CC genotype is associated with a higher ABCB1 
function compared to the 3435CT and 3435TT genotypes 13. 
Up until now, however, only few reports have been published on the functional 
effects of genetic variation in ABCB1 on immunosuppressant pharmacokinetics and 
pharmacodynamics. Crettol et al 7 have shown in cyclosporine-treated patients that 3435TT 
carriers had 1.7 fold increased intracellular drug concentrations and 1.2 fold increased 
whole blood concentration. To the best of our knowledge no such data exist on the effects 
of this SNP with regard to tacrolimus. Therefore, in the present study, we investigated the 
influence of the ABCB1 3435C>T SNP on the pharmacodynamic effects of tacrolimus in 
vitro and ex vivo in blood from tacrolimus-treated renal transplant patients.
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MATERIAL AND METHODS
Renal transplant patients
For the ex vivo analysis we studied blood samples from 36 renal transplant patients, 
who were treated with a maintenance immunosuppressive regimen of oral tacrolimus 
(Prograft®, Astellas Pharma Inc., Tokyo, Japan) and mycophenolate mofetil (Cellcept®, Roche 
Laboratories, New Jersey, NJ). The number of patients was chosen to have approximately 10 
individuals in each genome group at an expected 3435CT frequency of 50% and a 3435TT 
frequency of 25% 14-15. Tacrolimus doses ranged from 1 to 3 mg twice daily, aiming for 
predose concentrations (C
0
) between 4 and 8 ng/mL, and oral mycophenolate mofetil was 
dosed between 500 and 1000 mg twice daily. Blood samples were collected before drug-
intake in heparin and EDTA-containing vacutainer tubes (BD Vacutainer, Becton Dickinson, 
Plymouth, UK). Tacrolimus concentrations were determined in EDTA whole blood using 
the ACMIA-Flex immunoassay on a Dimension XPand analyzer (Siemens HealthCare 
Diagnostics, Inc, Newark, DE) in accordance with the manufacturers’ instructions. The 
study protocol was approved by the local ethics committee and informed consent was 
obtained from each individual.
Rhodamine 123 assay
For the Rh123 assay peripheral blood mononuclear cells (PBMC) were used. PBMC were 
isolated from heparinized normal human whole blood by density-gradient centrifugation 
over Ficoll-paque (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the 
manufacturer’s protocol. PBMC were rested overnight in RPMI 1640-DM medium (Gibco 
BRL, Paisley, Scotland, UK) supplemented with 2 mmol/L L-glutamine (Gibco BRL), 100 IU/
mL penicillin (Gibco BRL), 100 μg/mL streptomycin (Gibco BRL) and 10% heat inactivated 
fetal bovine serum (FBS) (BioWhittaker, Verviers, Belgium). Next PBMC were loaded for 45 
minutes with Rh123 (0.5 ug/mL; Sigma Aldrich, Steinheim, Germany) at 37 0C and washed 
twice with Rh123-free medium, Rh123-free medium containing 40 μmol/L verapamil 
(Sigma Aldrich) or Rh123-free medium containing 10 ng/mL tacrolimus (Astellas Pharma 
Inc.). Rh123 was allowed to efflux from the cells for two hours at 37 0C before cells were 
washed twice with phosphate buffered saline + 0.5% BSA (bovine serum albumin) at 4,0C. 
PBMC were surface-labeled with antibodies for 20 minutes on ice with the following 
lineage-specific monoclonal antibodies (mAb): CD3-peridinin chlorophyll protein complex 
(PERCP), CD4-pacific blue (PB) and CD8-PE-cyanin7 (PE-CY7; BD Biosciences, San Jose, 
CA). Samples were analyzed on a FACS Canto II flow cytometer (BD Biosciences). At least 
ten thousand gated cell events were acquired from each tube and Rh123 fluorescence 
was measured from 505 to 550 nm using an excitation wave length of 488 nm. Negative 
FMO (fluorescence minus one) control tubes were included. FMO controls were set up by 
leaving out the Rh123 in the staining panel.
Intracellular IL-2 analysis
Two hundred μL heparinized whole blood was spiked for one hour at 37 oC with vehicle 
or verapamil (Sigma-Aldrich) followed by one hour incubation with vehicle or tacrolimus 
in concentrations of 5, 10 or 50 ng/mL (Astellas Pharma Inc., Tokyo, Japan). Samples were 
activated with phorbol-12-myristate-13-acetate 0.8 µM and ionomycin 10 µg/mL (PMA/
ionomycin) (Sigma-Aldrich) for four hours at 37 oC. To retain cytokines within the cells, 
Golgistop (BD Biosciences) was added during stimulation with PMA/ionomycin. After 4 
hours the stimulation was stopped with EDTA, final concentration 2 μmol/L. Cells were fixed 
and lysed for 10 minutes with 4mL FACS lysing solution (BD Biosciences). After washing 
PBMC were permeabilized for 10 minutes with FACS perm solution II (BD Biosciences). 
Thirty minutes surface and intracellular staining was performed simultaneously using CD3-
PERCP, CD4-PB, CD8-PE-CY7, and IL-2-allophycocyanin (APC; BD Biosciences). Samples 
were analyzed on a FACS Canto II flow cytometer and ten thousand gated cell events were 
acquired from each tube. Isotype control IgG1-APC (BD Biosciences) and FMO control 
tubes were included.
Genotype for ABCB1 3435C>T
Genotyping for the ABCB1 3435C>T was performed using Taqman® allelic discrimination 
assays on the ABI Prism 7000 Sequence detection system (Applied Biosystems, California, 
USA). The assay consisted of two allele-specific minor groove binder (MGB) probes, labelled 
with the fluorescent dyes VIC® and FAM™. PCRs were performed in a reaction volume of 
12 µL, containing assay-specific primers, allele-specific Taqman® MGB probes, Abgene 
Absolute™ QPCR Rox Mix and genomic DNA (5 ng). The thermal profile consists of an initial 
denaturation step at 95oC for 15 minutes, followed by 40 cycles of denaturation at 92oC 
for 15 seconds, annealing and extension at 60oC for 1 minute. Genotypes were scored by 
measuring allele-specific fluorescence using the SDS 1.2.3 software (Applied Biosystems).
Analysis of data
Percentage of IL-2 and Rh123 positive cells were generated by data-analysis with Diva 
version 6.0 software (BD Biosciences) and statistical analysis was done using Graph Pad 
Prism 5.0 (Graph Pad Software Inc., La Jolla, CA, USA). 
RESULTS
Tacrolimus inhibits intracellular IL-2 production in T cells
First, the pharmacodynamic effect of tacrolimus was studied by measuring intra-lymphocytic 
IL-2 production after ex vivo stimulation of whole blood from healthy volunteers by PMA/
ionomycin. A typical example of the flow cytometric measurement is given in figure 1A and 
B. Stimulation induced the expression of intracellular IL-2 in 76.9 % of CD4+ and 41.8 % of 
CD8+ T cells (mean, n = 5, figure 1B). Tacrolimus inhibited the percentage of IL-2 producing 
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CD4+ and CD8+ T cells in a dose dependent manner (figure 1C). At 10 ng/mL tacrolimus, the 
inhibition was 34.5% (p<0.05) in CD4+ T cells and 27.3% (p<0.05) in CD8+ T cells, compared 
to no drug. For our next experiments this 10 ng/mL tacrolimus concentration was used to 
study the effect of blocking ABCB1 pump activity by verapamil. 
Figure 1. Inhibition of intracellular IL-2 production by tacrolimus
A) Example dot plots of gating strategy used to measure the interleukin (IL)-2 production in CD4+ T cells and 
CD8+ T cells, after ex vivo stimulation of whole blood from healthy volunteers by phorbol-12-myristate-13-
acetate (PMA)/ionomycin. On the left plot the CD3+ T cells are separated from the PBMC fraction by CD3+ 
monoclonal antibody surface staining. On the right plot the CD3+ T cells are shown and separated into 
CD4+ and CD8+ T cells. B) These plots show the IL-2 expression in CD4+ (above) and CD8+ T cells (below) 
of a fluorescence minus one control (FMO, left), an unstimulated sample (middle) and a PMA/ionomycin 
stimulated sample (right). C) Average percentages of IL-2 producing CD4+ T cells (left) and CD8+ T cells (right) 
for unstimulated samples, PMA/ionomycin stimulated samples and samples incubated with 5, 10 and 50 
ng/mL tacrolimus before stimulation (means + SEM of 5 independent experiments are depicted, * p < 0.05 
compared to stimulated sample).
Effect of verapamil on ABCB1 efflux pump activity
ABCB1 pump activity can be studied by loading PBMC with Rh123 and measuring the efflux 
after incubation of the cells in Rh123 free medium 16-17. Here Rh123 efflux was measured 
by flow cytometry in CD4+ and CD8+ T cells with or without the addition of tacrolimus 
and the ABCB1 inhibitor verapamil. After treatment of cells for 45 minutes with Rh123 
more than 98% of T cells were loaded with dye (figure 2A). Cells were incubated in Rh123-
free medium for two hours in the presence of vehicle, 40 μmol/L verapamil or 10 ng/mL 
tacrolimus. A typical example of Rh123 loading and efflux are shown in figure 2. 
Figure 2. Rh123 efflux inhibited by verapamil 
A) PBMC from healthy volunteers were loaded with rhodamine (Rh) 123 for 45 min. Rh123 uptake by CD4+ and 
CD8+ T cells is shown in the presence of medium, verapamil 40 μmol/L or tacrolimus 10 ng/mL. B) Left plots 
show the efflux of Rh123 after two hrs incubation of the samples in vehicle without Rh123. CD4+ and CD8+ T 
cells effluxed the dye in the presence of vehicle and tacrolimus while verapamil strongly inhibited dye efflux. 
Data are representative of 3 independent experiments.
Figure 3. Inhibition of ABCB1 increases the effect of tacrolimus on T cells
Whole blood from healthy volunteers was stimulated by phorbol-12-myristate-13-acetate/ionomycin for 4 hrs 
and analyzed as shown in figure 1A and 1B. The ABCB1 inhibitor verapamil (40 μmol/L) enhanced the inhibitory 
effect of 10 ng/mL tacrolimus on the interleukin (IL)-2 producing cells by 28.9% (p<0.05) in CD4+ T cells and 
by 45.4% (p<0.05, n=5) in CD8+ T cells. Verapamil alone did not influence the number of IL-2 producing T cells.
In the presence of vehicle, Rh123 was effluxed by 19% of CD4+ T cells (median, range 18-
19%; three independent experiments) and 40% of CD8+ T cells (median, range 37-40%). In 
line with previous studies 9-10, CD8+ T cells had a higher ABCB1 efflux activity compared to 
CD4+ T cells (p<0.001, n=3). Tacrolimus did not influence Rh123 efflux compared to vehicle, 
18% in CD4+ T cells (median, range 16-19%, n=3) and 38% in CD8+ T cells (range 37-39%), 
CD8+
P/I
ver
apa
mil
+P/
I
TAC
+P/
I
TAC
+ve
rap
am
il+P
/I
25
30
35
40
45
50 p < 0.05
p < 0.05
% 
IL-
2 P
ro
du
cin
g C
ell
s
CD4+
P/I
ver
apa
mil
+P/
I
TAC
+P/
I
TAC
+ve
rap
am
il+P
/I
40
60
80
100 p < 0.05
p < 0.05
% 
IL-
2 P
rod
uc
ing
 Ce
lls
Project1:Copy of Layout 1 - Mon Jul 09 16:36:39 2012
Chapter 2.4
84 85
Chapter
2.4
while addition of the ABCB1-inhibitor verapamil almost completely blocked Rh123 efflux 
from CD4+ and CD8+ T cells (efflux in only 1.8% (median, range 1.3-3.7%) and 0.5 % (range 
0.1-1.0%, p<0.05 compared to vehicle). 
Next, we investigated the effect of verapamil on the pharmacodynamic effect of 
tacrolimus. After ex vivo stimulation of whole blood from healthy volunteers the induced 
intracellular IL-2 expression in T cells was measured. In the absence of tacrolimus, the 
addition of verapamil did not influence the percentage of IL-2 producing CD4+ or CD8+ T 
cells (n = 5, p>0.05; figure 3). However, in the presence of 10 ng/mL tacrolimus, verapamil 
enhanced the inhibitory effect of tacrolimus on the IL-2 producing cells by 28.9% (p<0.05) 
in CD4+ T cells and 45.4% (p<0.05, n=5) in CD8+ T cells (figure 3), presumably mediated 
through intra-lymphocytic tacrolimus accumulation.
ABCB1 pump activity in T cells of renal transplant patients
A total of 36 renal allograft patients treated with tacrolimus were enrolled in our study. 
Their mean age was 53.9 years (median 55 years), mean time after transplantation was 48 
months (median 34 months), the ratio of men to women was 18:19 and 35 out of 36 patients 
received concomitant treatment with mycophenolate mofetil and/or corticosteroids while 
one patient received tacrolimus monotherapy. The tacrolimus C
0 
concentrations ranged 
from 2.7 to 13.8 ng/mL (median 6.7 ng/mL). These demographic variables were not 
significantly different across the three genotype groups containing 13 patients with the 
ABCB1 3435CC genotype, 15 with the CT and 8 with the TT genotype. 
Figure 4. In CC genotype renal transplant patients blocking ABCB1-activity enhances the immunosuppressive 
effect of tacrolimus
A) Whole blood from tacrolimus-treated renal transplant patients (n = 36) was stimulated by phorbol-12-
myristate-13-acetate/ionomycin in the presence of verapamil 40 μmol/L. Verapamil decreased the percentage 
of interleukin (IL)-2 producing CD4+ and CD8+ T cells by inhibiting efflux of tacrolimus (means + SEM are 
depicted). B) If the patients from figure 4A are categorized according to their ABCB1 3435C>T genotype 
verapamil reduced the percentage of IL-2 producing cells by 22% in CD8+ T cells and 14% in CD4+ T cells of 
patients with a CC genotype (n=13), whereas no significant effect of verapamil was found in the group of 
patients with a CT (n=15) or TT (n=8) genotype. 
Whole blood from these patients was stimulated with PMA/ionomycin in the presence of 
verapamil or vehicle, and intracellular IL-2 expression was measured. Overall verapamil 
decreased the percentage of IL-2 expressing CD4+ and CD8+ T cells (p<0.01, figure 4A). In 
patients with the CC genotype, verapamil reduced the percentage of IL-2 producing CD4+ 
T cells by 14% (p<0.05) and of IL-2 producing CD8+ T cells by 22% (p<0.0001), whereas no 
significant effect of verapamil was found in patients with the CT or TT genotype (p>0.05; 
figures 4B and 4C). Of note, due to individual variation in some patients IL-2 production 
increased after the addition of verapamil. These exceptions were however not seen in 
the CD8+ T cells of CC genotype patients where the effect of ABCB1-inhibition was the 
strongest.
Ratio tacrolimus C
0
 over IL-2 producing T cells
Another way to show the influence of the ABCB1 3435C>T genotype on the pharmacodynamic 
effect of tacrolimus is to correlate tacrolimus whole blood concentrations with inhibition 
of IL-2 production by T cells, in the three genotype groups. This is illustrated in figure 
5 where the ratio tacrolimus C
0
 over percentage of IL-2 producing T cells was studied. 
In patients with the CC genotype this ratio was significantly higher (p<0.05) compared 
to the TT genotype indicating that in CC-genotype patients, tacrolimus has a smaller 
pharmacodynamic effect (Figure 5).
Figure 5. CC genotype patients need more tacrolimus for inhibition of IL-2 production in T cells
The ratio between tacrolimus C
0
 and percentage of IL-2 producing T cells after whole blood stimulation with 
phorbol-12-myristate-13-acetate/ionomycin is plotted on the Y-axis for the three different ABCB1 3435C>T 
genotype groups.
DISCUSSION
Tacrolimus is a substrate for the ABCB1 efflux pump 5. Here we hypothesized that the 
3435C>T SNP in the ABCB1 gene can modulate the immunosuppressive activity of 
tacrolimus by altering the activity of the pump. The data from the Rh123 efflux assay 
demonstrated that the functionality of the ABCB1 pump can be inhibited by the ABCB1 
inhibitor verapamil, especially in CD8+ T cells (figure 2). Other studies have also shown 
higher functionality of ABCB1 in CD8+ T cells compared to CD4+ T cells 18-20. The T cells with 
the highest ABCB1 efflux activity are memory CD4+ and CD8+ T cells 9, 21, a population with 
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low susceptibility to tacrolimus 22 and important in the transplantation setting since they 
are pivotal for allo-reactivity 23-26.
Moreover, in vitro in whole blood from healthy volunteers we saw that verapamil 
augmented the biological effect of tacrolimus, i.e. inhibition of IL-2 production in T cells 
(Figure 3). Although this study is the first to relate ABCB1 activity to tacrolimus efflux and 
its pharmacodynamic effect, the inhibition of ABCB1 by verapamil has been extensively 
reported elsewhere 27-28, especially in anti-cancer drug treatment. Verapamil is extensively 
used as an ABCB1 inhibitor in clinical trials 27-28, it increases the AUC of different anti-cancer 
drugs 29-32 and recently Neerati et al. showed that the ABCB1 inhibition by verapamil results 
in increased AUC and peak plasma concentrations of phenytoin, another ABCB1 substrate 33. 
Tacrolimus intracellular concentrations have been reported to be a more reliable 
marker of its immunosuppressive efficacy compared to whole blood concentrations 34. 
Therefore we hypothesized that intracellular tacrolimus concentrations and its effect on 
T cells are increased by verapamil by blocking the efflux pump. Accordingly, intracellular 
concentrations and the immunosuppressive effect can be affected by the inter-individual 
variability in the ABCB1 pump. Kimchi-Sarfaty et. al. 13 have found that the 3435C>T 
transition affects the timing of co-translational folding and insertion of ABCB1 into the 
plasma membrane, thereby altering the structure of the substrate interaction sites and 
differentiates verapamil specificities to the ABCB1 pump. The genetically determined 
differences in ABCB1 correlate with the activity of the pump; different studies have shown 
that 3435CC carriers had a higher ABCB1 pump activity than those with the 3435TT 
genotype. 7, 35-36. The current study showed in tacrolimus-treated renal transplant patients 
with the 3435CC genotype, the more active ABCB1 variant, that verapamil decreased the 
IL-2 production by T cells i.e. enhanced the biological effect of tacrolimus. In contrast, 
verapamil did not influence IL-2 production in patients with the TT genotype (figure 4). 
To relate the immunosuppressive effect of tacrolimus to the three genotypes, the 
ratio of tacrolimus trough concentration and percentage of IL-2 producing T cells, as a 
measure for the requirement of tacrolimus in renal transplant patients was compared. This 
ratio was significantly higher in CD8+ T cells of patients that have the 3435CC genotype 
compared to the ratio in TT genotype patients, showing that tacrolimus had a smaller 
effect in renal transplant patients with the CC genotype. This could be explained by the 
fact that in CC-genotype patients tacrolimus is more effectively pumped out of the cells, 
which leads to lower tacrolimus concentrations at its target. CC genotype patients needed 
higher tacrolimus concentrations to achieve the same IL-2 inhibition compared to the TT 
genotype, in line with the study of Hoffmeyer et. al. 11 that shows healthy volunteers with 
the 3435 ABCB1 TT genotype, after oral administration, have higher plasma concentrations 
of digoxin compared to subjects that have a CC genotype. In addition, Crettol et. al. 7 
have shown that carriers of the variant 3435T allele had higher intracellular cyclosporine 
concentrations, in line with our results. The importance of IL-2 production by CD8+ T 
cells for allo-reactivity was shown in liver transplant patients where it was undoubtedly 
associated with acute cellular rejection 37. Additional studies are necessary to confirm our 
preliminary findings and to relate haplotype polymorphisms of the ABCB1 genotype 13 to 
the pharmacodynamic effect of CNI, which needs higher patient numbers than used in the 
current study. 
The current study shows the ABCB1 3435C>T SNP affects the pharmacodynamic effect of 
tacrolimus in renal transplant patients. For clinical use these effects shed new perspectives 
for measurements of intracellular tacrolimus concentrations and are a move towards 
optimization of the immunosuppressive regimen after kidney transplantation.
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INTRODUCTION
The nephrotoxic side effects of cyclosporin A (CsA) were already recognized by Calne and 
co-workers when they prescribed the drug for the first time to human kidney transplant 
recipients in the late 1970s.1 The nephrotoxicity of CsA had not been apparent in their 
experiments in animals that were performed prior to the clinical introduction of CsA. However, 
it was soon discovered that the acute CsA-mediated nephrotoxic effects were reversible on 
dose reduction or cessation of the drug. It was not until CsA was used for prolonged periods 
in patients with autoimmune disease and in nonrenal transplant recipients that the chronic 
nephrotoxic effects of CsA became clear. After the clinical introduction of tacrolimus (Tac) 
in the early 1990s, this drug also turned out to have nephrotoxic side effects comparable 
to those associated with the use of CsA. At present, after more than 20 years of clinical 
use, the chronic nephrotoxicity of the calcineurin inhibitors (CNIs) CsA and Tac is one of the 
biggest challenges facing transplant physicians. Whether or not ISA247, a novel CsA analog, 
will be associated with less nephrotoxicity than CsA and Tac is unclear at present. A recent 
phase 3 trial with this drug in patients with psoriasis showed mild to moderate reductions 
in renal function in only 2% of the patients but only indirect comparisons with CsA can 
be made as this was a placebo-controlled study.2 In this review, we will describe recent 
advances in our understanding of CNI-mediated nephrotoxicity with a focus on the drug 
transporter adenosine triphosphate-binding cassette protein B1 (ABCB1) and cytochrome 
P450 3A (CYP3A) and the variability in their encoding genes.
Pathophysiology
Clinically, an acute and a chronic form of CNI-induced nephrotoxicity can be distinguished.3 
Acute nephrotoxicity usually occurs within several days after starting CNI treatment. It may 
present as an acute oligoanuric syndrome [delayed graft function (DGF)] or as a rise in serum 
creatinine that may resemble other causes of early graft dysfunction such as, for example, 
acute rejection. In general, acute CNI-induced nephrotoxicity is rapidly and completely 
reversible on dose reduction or CNI withdrawal.3 Pathophysiologically, it is characterized 
by constriction of the afferent glomerular arteriole, leading to a decreased renal plasma 
flow and a reduction of the glomerular filtration rate (GFR).4 This change in vascular tone 
seems to result from an imbalance in the secretion and metabolism of the vasodilatory 
nitric oxide and prostaglandins, and the vasoconstrictive thromboxane and endothelin and 
an increased activity of the sympathetic nervous system. Second, CNIs have been reported 
to cause mesangial cell contraction, thereby altering glomerular permeability. Finally, 
CNIs may interfere with normal tubular function causing sodium retention and edema, 
reduced excretion of potassium and uric acid, increased urinary magnesium excretion, and 
hyperchloremic metabolic acidosis.3,5,6
Chronic CNI-induced nephrotoxicity is associated with prolonged use of these agents and 
has been observed after all types of transplantation and during treatment of autoimmune 
disease.3,7-9 The clinical course is characterized by a slow decline in renal function that 
ABSTRACT
Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use 
of cyclosporine and tacrolimus and has been observed after all types of transplantation, 
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may progress to end-stage renal disease. In addition, most patients have hypertension. 
Although some patients with chronic CNI-induced nephrotoxicity may have proteinuria, 
most patients do not as a result of the vasoconstrictive effects of CNIs (thereby lowering 
glomerular filtration pressure). In fact, the absence of proteinuria in a patient with a failing 
transplant can be of help in distinguishing CNI-induced nephrotoxicity from other causes 
of chronic renal transplant failure such as chronic (humoral) rejection or recurrence of 
the primary kidney disease in the transplant. In contrast to the acute form, chronic CNI-
induced renal insufficiency improves little, if at all, after dose reduction or cessation of CNIs. 
Histologically, chronic CNI-induced nephrotoxicity is characterized by extensive alterations 
in the renal architecture that may include arteriolar hyalinosis, glomerular sclerosis and 
thickening of Bowman’s capsule, tubular atrophy (TA), and interstitial (striped) fibrosis and 
diagnostic pathologic criteria have been described.10-12 Nonetheless, it may be difficult to 
distinguish histologic changes associated with prolonged use of CNIs from those induced by 
for example, hypertension, diabetes, aging, or chronic humoral rejection, conditions that 
may coexist with CNI nephrotoxicity.13 
The pathogenesis of chronic CNI-induced nephrotoxicity is far from being understood, 
but hemodynamic changes leading to ischemia, direct toxic effects of CNIs on the tubules, 
and an increased expression of the profibrotic transforming growth factor-β are considered 
important etiologic factors. For an in-depth review of the pathogenesis of chronic CNI-
mediated nephrotoxicity, the reader is referred to the literature.12
The clinical problem
Although the use of CNIs has resulted in a dramatic decrease in the incidence of acute 
rejection and, consequently, a large improvement in short-term transplantation results, the 
long-term results of kidney transplantation have not improved to a similar degree over the 
last few decades.14 In fact, the long-term results of kidney transplantation may even have 
worsened in recent years.15 Although late kidney allograft loss has many causes, there is 
compelling evidence that the prolonged use of CNIs is an important contributing factor. 
Nankivell et al. prospectively followed a cohort of kidney-pancreas transplant recipients 
treated with CsA-based immunosuppression for up to 10 years after transplantation.16,17 
All patients received kidneys of pristine quality [defined as the absence of vascular 
changes, glomerulosclerosis and TA and interstitial fibrosis (IF) at time of implantation], 
and protocol kidney biopsies were obtained regularly after transplantation. Ten years after 
transplantation, the cumulative incidence of histologic changes in the kidney, indicative 
of chronic CNI-related nephrotoxicity, was nearly 100%.16,17 More recently, Naesens et 
al. described a cohort of 252 renal transplant recipients who all received Tac-based 
immunosuppression.18 In this study, protocol biopsies were obtained regularly from the 
time of implantation for up to 3 years post transplantation. In line with the observations 
made by Nankivell et al. in CsA-treated patients, in this cohort, the cumulative incidence 
of vascular intimal thickening, glomerulosclerosis, TA, and IF all increased with time after 
transplantation.16-18    
In addition, chronic renal dysfunction is common after nonrenal transplantation. Ojo et al. 
observed that chronic renal failure (defined as a GFR of 29 mL per minute per 1.73 m2 
of body surface area or less or the development of end-stage renal disease) developed 
in 11426 (16.5%) of 69321 patients 5 years after nonrenal transplantation.19 End-stage 
renal disease (defined as the initiation of dialysis or preemptive kidney transplantation) 
developed in 3297 (28.9%) of the patients with newly diagnosed chronic renal failure. The 
5-year risk of chronic renal failure varied according to the type of organ transplanted and 
ranged from 6.9% among recipients of heart-lung transplants to 21.3% among recipients 
of intestine transplants.19 In this registry study, the large majority of patients were treated 
with a CNI-containing immunosuppressive regimen and no (protocol) kidney biopsies were 
performed. Therefore, the cause of chronic renal failure was not established. Nonetheless, 
these observations do indicate that renal dysfunction in CNI-treated transplant recipients is 
a huge clinical problem.
Finally, studies in patients treated with CNIs for autoimmune disease such as uveitis and 
psoriasis have demonstrated that chronic renal dysfunction is a complication of prolonged 
CNI treatment.8,9,20 For example, among 41 patients treated with CsA for idiopathic uveitis, 
the GFR decreased from 102 mL/min per 1.73m2 at the start of treatment to 88 mL/min 
per 1.73m2 after 2 years of CsA therapy. Importantly, this decrease in renal function was 
accompanied by histologic changes over time with significant increases in glomerular 
sclerosis, thickening of Bowman’s capsule and TA and IF.9
Although the risk of developing chronic renal insufficiency has been associated with 
longer use and higher doses of CNIs, this has not been a universal finding (reviewed in 
Naesens et al.12). In fact, some authors have speculated that the risk of developing CNI-
induced nephrotoxicity depends on individual susceptibility and is not directly related to 
systemic exposure to CNIs if drug levels are kept within the current target ranges by use 
of therapeutic drug monitoring.12,21 In recent years, there has been an increasing interest 
in the role of drug transporters and drug-metabolizing enzymes and their possible roles 
in the pathophysiology of chronic CNI-induced nephrotoxicity. We will now discuss the 
evidence pointing towards a role of ABCB1 and CYP3A in the development of CNI-related 
nephrotoxicity.
ABCB1
ABCB1 (formerly known as permeability glycoprotein or P-gp) belongs to the family of the 
-binding membrane transporters (subfamily B).22 It is an 170 kDa adenosine triphosphate-
dependent transporter capable of pumping many endogenous substances and a wide 
variety of drugs (including CsA and Tac) from the cytoplasm or cell membrane to the 
extracellular space.23,24 Based on its specific expression in among others, the intestine, liver, 
and kidney, it has been postulated that ABCB1 functions as a protective barrier by actively 
extruding xenobiotics and metabolites from the cell interior into the gut lumen, bile, or 
urine. ABCB1 is also expressed on various leukocytes, including T and B lymphocytes and 
dendritic cells.25, 26 
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In the normal human kidney, ABCB1 is expressed in the brush border of proximal tubular 
epithelial cells.18,27-29 In addition, ABCB1 is expressed in epithelial cells of Bowman’s 
capsule, glomerular mesangial cells, on the apical membrane of the thick ascending limb of 
Henle’s loop, intracellularly in distal tubules, and on the apical membrane of the collecting 
duct.30,31 ABCB1 expression in endothelial cells of renal arteries, arterioles, and glomerular 
and peritubular capillaries was found to be absent or low.18,29,31 Intrarenal ABCB1 is thought 
to play an important role in the renal elimination of metabolic waste products and toxins. 
Interestingly, renal ischemia-reperfusion injury in mouse kidney resulted in an upregulation 
of Abcb1 expression, which may represent an adaptive response in the renal regeneration 
process after injury.32 
Evidence for a role of ABCB1 in the pathogenesis of CNI-related nephrotoxicity was first 
provided by García del Moral et al. who demonstrated that in vitro exposure of Madin-
Darby canine kidney tubule cells to CsA leads to an increased expression of ABCB1.33 In 
human arterial endothelial cells and rat proximal tubule cells, ABCB1 expression and 
activity was also induced by incubation with CsA.34 Treatment of these cells with Tac 
had the same effect, although this required supratherapeutic concentrations of the 
drug.34 In vivo, it was demonstrated that chronic treatment of rats with CsA induced the 
expression of ABCB1 in renal tubular cells, which increased with a longer duration of CsA 
treatment.35,36 This induction was shown to be reversible because after cessation of CsA 
treatment, ABCB1 expression levels decreased toward normal.35 Importantly, in these rat 
studies, ABCB1 expression was inversely related to the presence of hyaline arteriopathy 
and periglomerular -and peritubular atrophy.36
In human kidney transplant recipients, chronic CsA treatment has also been associated 
with upregulated ABCB1 expression.31,33 In a histological case-control study, Koziolek et 
al. observed that the intrarenal expression of ABCB1 was higher in CsA-treated kidney 
transplant recipients who suffered from acute tubular necrosis, acute rejection or chronic 
allograft nephropathy as compared with normal kidneys or kidney transplants from 
recipients treated with a CsA-free immunosuppressive regimen.31 By contrast, in kidney 
transplant biopsies from patients suffering from CsA-related nephrotoxicity, ABCB1 
expression was not upregulated when compared with controls.31 Similar observations 
were reported by Joy et al. in a small retrospective study.37 More recently, Naesens et 
al. observed that a lower ABCB1 expression (as determined by immunohistochemistry) 
in protocol kidney transplant biopsies was a risk factor for the development of chronic 
histologic damage in Tac-treated renal transplant recipients.18
 Taken together, these observations suggest that treatment with CNIs induces ABCB1 
expression both in vitro and in vivo. This upregulation of ABCB1 may serve to protect 
the kidney from the injurious effects of CNIs by facilitating their extrusion. Failure to 
adequately upregulate ABCB1 expression or a constitutively low ABCB1 expression in renal 
parenchymal cells could lead to intrarenal accumulation of CNIs and predispose patients 
to the occurrence of CNI-related nephrotoxicity. 
Although this hypothesis remains to be formally tested, experimental studies have 
provided evidence that ABCB1 inhibition does indeed cause increased intrarenal CNI 
concentrations, leading to renal dysfunction. In rats, it was demonstrated that sirolimus 
potentiated the nephrotoxic effects of CsA through a pharmacokinetic interaction, which 
caused increased intrarenal CsA concentrations.38 Anglicheau et al. demonstrated in 
vitro that this pharmacokinetic interaction likely results from sirolimus-mediated ABCB1 
inhibition.39 
CYP3A
The CYP enzyme family consists of more than 50 isoenzymes that are responsible for 
the oxidative metabolism of many endogenous and exogenous compounds.40 The CYP3A 
subfamily, which represents the majority of CYP proteins in human liver, metabolizes more 
than 50% of all drugs currently in use.40 The CYP3A isoenzymes CYP3A4 and CYP3A5 are 
responsible for the metabolism of CsA and Tac in adults.41-43 Both CYP3A4 and CYP3A5 are 
expressed in the small intestine and liver with CYP3A4 being the most important CYP3A 
isoenzyme in terms of expression and activity. By contrast, in the kidney, the expression 
and activity of CYP3A5 by far exceed that of CYP3A4.44-47 In normal kidney, the expression 
of CYP3A5 was highest in proximal tubular epithelial cells and collecting duct epithelium 
with a lower expression in distal tubular epithelial cells.45 
There exist large differences in the activity of intestinal and hepatic CYP3A between 
individuals, and this variability in enzyme activity is in part responsible for the marked 
interindividual variability in the pharmacokinetics of CNIs.48-52 Given the predominance 
of CYP3A5 in CYP3A-mediated metabolism in the kidney, it has been hypothesized that 
intrarenal CYP3A5 expression may be a risk factor for CNI-induced renal dysfunction. 
In a case-control study, Joy et al. compared CYP3A5 expression in kidney biopsies from 
renal transplant recipients with histological evidence of CNI-induced nephrotoxicity (n 
= 29) with biopsy specimens from patients with various renal diagnoses including acute 
interstitial nephritis, diabetes mellitus and acute cellular rejection (n = 30).53 Compared 
with controls, the expression of CYP3A5 in the apical membrane and cytoplasm of both 
proximal and distal tubules was found to be lower in nephrotoxic biopsies.53 These findings 
suggest that reduced CYP3A5 expression may be a risk factor for the development of 
structural nephrotoxicity secondary to CNI treatment, possibly by reduced intrarenal 
detoxification. However, this was a relatively small and retrospective study in which the 
control group appeared to consist of both renal transplant recipients and nontransplanted 
patients suffering from various kidney diseases. In addition, the type of CNI treatment (CsA 
versus Tac) was not specified, the use of drugs interacting with CNIs was allowed, and no 
genotyping for CYP3A5 was performed (see below). 
Genetic variability in ABCB1 and CYP3A and CNI-related nephrotoxicity
Both the ABCB1 and CYP3A4 and CYP3A5 genes are polymorphically expressed. More than 
25 single nucleotide polymorphisms (SNPs) have been discovered in ABCB1. The best-
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studied SNP is the 3435C>T transition located in exon 26, which leads to the formation of 
an ABCB1 protein with an altered conformation and function.54 The ABCB1 3435C>T SNP is 
in strong linkage disequilibrium with the 1236C>T (in exon 12) and the 2677G>T/A (in exon 
21; Ala893Ser/Thr) SNPs.55 With regard to CYP3A4 and CYP3A5, a large number of SNPs 
have been identified in their encoding genes (see http://www.imm.ki.se/CYPalleles).56 At 
present, the best-studied SNP is that in intron 3 of the CYP3A5 gene, genomic 6986A>G, 
which shows 100% linkage with the absence of CYP3A5 protein. This variant, referred to 
as the CYP3A5*3 allele, occurs homozygously in 80% of the white and 30% of the African 
American population.57-59
Over the past few years, there have been numerous studies investigating the 
association between the various SNPs in ABCB1 and CYP3A and the pharmacokinetics 
of CNIs. With regard to CsA, these SNPs appear to have only a limited, if any, effect on 
its pharmacokinetics (reviewed in de Jonge and Kuypers60). However, renal transplant 
recipients carrying the CYP3A5*3 allele require a significantly lower Tac dose to reach 
target concentrations compared with patients homozygous for the wild-type allele (6986A, 
designated as CYP3A5*1).60 A higher Tac dose requirement has also been observed for 
CYP3A5 expressers (individuals with the CYP3A5*1/*1 or CYP3A5*1/*3 genotype) receiving 
a heart, liver, or lung transplant. In contrast, the effect of SNPs in ABCB1 and CYP3A4 on Tac 
dose requirement seems to be much smaller when compared with the CYP3A5*3 SNP.60 
The focus of genetic association studies in transplantation has recently shifted from 
CNI pharmacokinetics to transplantation outcomes, including renal allograft dysfunction. 
Hauser et al. were the first to report on the influence of ABCB1 genotype on the occurrence 
of CsA-related nephrotoxicity after renal transplantation.61 In this case-control study, 
which included 97 patients, the ABCB1 genotype of both the acceptor and the donor was 
determined and the latter proved to be a major risk factor for the occurrence of clinically 
defined CsA-related nephrotoxicity.61 Among patients with CsA-related nephrotoxicity (n = 
18), kidney transplants with the ABCB1 3435TT genotype were overrepresented compared 
with patients without toxicity [odds ratio (OR) = 3.2; 95% confidence interval 1.4-7.6]. The 
donor’s but not the recipient’s ABCB1 genotype was highly predictive as 2½ years after 
transplantation, approximately 40% of all patients who received a kidney transplant from 
a donor homozygous for the 3435T allele developed CsA-related nephrotoxicity compared 
with only 10% of patients who received a kidney with the 3435CT or 3435CC genotype. To 
determine whether the ABCB1 genotype was an independent risk factor for CsA-related 
nephrotoxicity, a multivariate logistic regression analysis was performed. In the final model, 
which included several nongenetic factors, only the donor’s ABCB1 3435TT genotype was 
strongly associated with clinically defined CsA-related nephrotoxicity (OR = 13.4; 95% 
confidence interval 1.2-148).61 Because both the CsA dose and exposure to CsA were 
not significantly different between patients with and those without CsA nephrotoxicity, 
these observations were explained by a reduced ABCB1-mediated CsA elimination from 
renal tubular epithelium in patients with the ABCB1 3435TT genotype. Further evidence 
for a decreased renal elimination of CNIs in ABCB1 3435TT homozygotes comes from a 
recent Belgian study.18 A cohort of 252 adult renal transplant recipients, who received a 
kidney transplant from a deceased donor in 93% of cases and who were treated with Tac, 
mycophenolate mofetil (MMF) and glucocorticoids, was followed prospectively for 3 years 
after transplantation. During this period, a total of 744 kidney transplant biopsies (both 
protocol and indication biopsies) was obtained. A gradual increase in chronic histologic 
damage of renal allografts was observed during the follow-up period. Both donor 
and recipient homozygosity for the ABCB1 T allele at position 3435 were significantly 
associated with a higher grade of IF and TA. This association was most prominent when 
both donor and recipient had the ABCB1 3435TT genotype with and OR of 3.9 (donor plus 
recipient homozygous for ABCB1 T versus no homozygosity) of having a higher IF/TA score. 
Systemic exposure to Tac was not associated with the chronic histologic appearance of 
kidney transplants. Importantly, graft function at 3 years post transplant was also worse in 
individuals with the combined donor-recipient ABCB1 TT genotype, although graft survival 
was not associated with ABCB1 genotype.18 In a retrospective study including 832 renal 
transplant recipients treated with CNIs, kidney allograft survival at 1 year post transplant 
was also found not to be associated with ABCB1 genotype.62The incidence of DGF after renal 
transplantation was recently reported to be associated with recipient ABCB1 genotype.63 
Among 147 renal transplant patients who were followed prospectively and treated with 
CsA, glucocorticoids and mycophenolate mofetil or azathioprine as part of a randomized 
controlled clinical trial, carriers of ABCB1 T allelic variants at positions 2677 and 3435 
(in exons 21 and 26, respectively) had a more than 3-fold higher risk of developing DGF 
compared with noncarriers. After a median follow-up of 65.5 months, GFR was about 5 mL/
min per 1.73 m2 lower in carriers of the T allelic variants in exons 21 and 26 compared with 
noncarriers.63 This difference could not be explained by differences in systemic exposure 
to CsA. The authors speculated that the higher incidence of DGF in T allele carriers could 
have resulted from higher intracellular CsA concentrations in infiltrating leucocytes (which 
express ABCB1) causing a higher production of reactive oxygen species and more severe 
oxidative stress.63 In patients treated with Tac, however, ABCB1 genotype was not found 
to be a risk factor for DGF.18,64 In addition, in an animal study, mice deficient for Abcb1 
(mdr1a/1b(-/-)) were in fact protected against ischemia-reperfusion injury. It was suggested 
that the smaller degree of renal damage in mdr1a/1b(-/-) mice kidneys after ischemia was 
caused by a decreased number of apoptotic cells causing tubular obstruction.65 Obviously, 
more research is needed to clarify the exact role of ABCB1 in ischemia-reperfusion injury. 
Fewer data are available regarding the role of genetic variation in CYP3A in CNI-induced 
renal dysfunction. Kuypers et al. reported a higher incidence of (indication)biopsy-
proven Tac nephrotoxicity in 95 renal transplant recipients (not the donors) with the 
CYP3A4*1/CYP3A5*1 and CYP3A4*1B/CYP3A5*1 genotypes than among patients with the 
CYP3A4*1/CYP3A5*3 genotype.66 In contrast, Quteineh reported a nonsignificant trend 
between CYP3A5 genotype of the transplant recipient and the incidence biopsy-proven 
Tac nephrotoxicity (being highest in CYP3A5*3 homozygotes).67 Other studies did not find 
significant associations between CYP3A genotype and either renal function or allograft 
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survival after renal transplantation.62,64,68 Interestingly, in one study it was observed that 
kidney transplant recipients carrying a CYP3A5*1 allele had a better survival compared 
with noncarriers.69 
CNI-related nephrotoxicity after nonrenal transplantation
The association between CNI-induced nephrotoxicity and genetic variation in ABCB1 and 
CYP3A has not been extensively studied in recipients of a nonrenal organ transplant. In 
a case-control study including 120 white liver transplant recipients treated with CNIs 
(74% receiving CsA-based and 26% Tac-based immunosuppression), patients who were 
homozygous for the ABCB1 2677 T allele (which is in linkage disequilibrium with the 3435 
T allele) were less than 50% as likely to experience symptoms of chronic renal dysfunction 
(defined as a serum creatinine ≥ 141 μmol/L) compared with 2677GT or 2677GG individuals 
3 years after transplantation.70 In this study, a nonsignificant trend toward a lower incidence 
of chronic renal dysfunction was observed among 3435 T allele homozygotes.70 In contrast, 
in a recent study conducted among 51 pediatric liver transplant recipients, patients with 
an ABCB1 variant allele at positions 2677 or 3435 were found to be at an increased risk 
of developing renal dysfunction.71 In a case-control study including 106 heart transplant 
recipients (treated with CsA or Tac), the ABCB1 2677G>T/A SNP was not found to be 
associated with renal dysfunction.72 A recent retrospective single-center analysis including 
294 heart transplant recipients treated with CsA also found no association between the 
ABCB1 1236C>T, 2677G>T/A, and 3435C>T SNPs or ABCB1 haplotype and renal function 1 
year after transplantation.73 
With regard to the effect of CYP3A5 genotype on the incidence of renal dysfunction 
after nonrenal transplantation even fewer data are available. Recently, Fukudo et al. 
studied 60 adult liver transplant recipients who received Tac-based immunosuppression.74 
They observed that renal dysfunction was not associated with the CYP3A5 genotype of 
the transplanted liver. In contrast, recipients (and thus the native kidneys) homozygous 
for CYP3A5*3 had a significantly higher risk of developing nephrotoxicity compared with 
CYP3A5*1 allele carriers: 46% versus 17%; hazard ratio 3.16 (1.01 - 6.16).74 CYP3A5 genotype 
was not associated with renal dysfunction after cardiac transplantation.72
When interpreting the results of genetic association studies investigating the 
pharmacogenetics of CNI-related nephrotoxicity after nonrenal transplantation, several 
things should be kept in mind. First of all, and unlike transplanted kidneys, native kidneys 
are innervated. One of the possible mechanisms of CNI-induced nephrotoxicity is the ability 
of these drugs to stimulate the sympathetic nervous system which in turn may lead to an 
increased renal vascular resistance and reduced glomerular filtration.12 Second, patients 
receiving a heart or liver transplant already may have (undiagnosed) renal disease (e.g. 
immune-complex glomerulonephritis) at the time of transplantation or may develop renal 
insufficiency because of causes other than CNI-induced nephrotoxicity.75 In many of the 
above-mentioned studies investigating renal insufficiency after nonrenal transplantation, 
kidney biopsies were not routinely taken to firmly establish the cause of renal failure. 
As such, cases of renal insufficiency attributed to the use of CNIs may in fact have been 
misdiagnosed. Finally, the pharmacokinetics of CNIs in liver transplant recipients is complex 
and influenced by both donor and recipient genotype. Fukudo et al. demonstrated that 
in the early phase after liver transplantation, intestinal ABCB1 expression and intestinal 
CYP3A5 genotype contributed to the interindividual variation in the oral clearance of 
Tac.74 After the first month, however, it was the CYP3A5 genotype of the grafted liver that 
significantly affected Tac dose requirement. These findings suggest that the major organ 
influencing Tac disposition changes from the native intestine in the early phase after 
transplantation to the transplanted liver in the stable phase when the metabolic function 
of the graft has recovered.74
Conclusions and future directions 
There is substantial evidence that intrarenally expressed ABCB1, and to a lesser extent 
CYP3A5, is implicated in the pathogenesis of CNI-induced renal dysfunction. In addition, 
genetic variation in the ABCB1 and CYP3A5 genes explains some of the interindividual 
differences in the susceptibility to the nephrotoxic effects of CNIs. 
However, at present many questions are left unanswered and problems unsolved. 
First of all, we should improve our ways to diagnose true CNI-induced nephrotoxicity 
and distinguish it from other diseases and conditions that may also cause histologic 
damage of the kidney transplant and lead to renal insufficiency (such as, e.g., chronic 
antibody-mediated rejection and polyomavirus infections). Studies using gene expression 
profiling or newly-identified biomarkers for renal damage have shown promising 
results.76-78 Second, there is no direct evidence in humans that the association between 
ABCB1 expression/genotype and CNI-induced nephrotoxicity is indeed caused by higher 
intrarenal concentrations of CNIs. It is therefore to be expected that future studies will 
pursue this hypothesis by measuring intrarenal CNI concentrations in animal models of 
CNI-related nephrotoxicity and possibly also in human studies. Such investigations would 
also allow a further study of the role of various CsA and Tac metabolites in CNI-induced 
nephrotoxicity.79 In addition to this “pharmacokinetic hypothesis”, alternative explanations 
for the association between ABCB1 and chronic CNI-related nephrotoxicity will likely be 
studied further. Such alternative explanations include the role of ABCB1 in proximal tubular 
epithelial cell apoptosis.80 Moreover, the role of other polymorphically expressed genes 
such as, for example, transforming growth factor-β, vascular endothelial growth factor, 
and caveolin-1 requires further study.81-83 Finally, there is at present only limited evidence 
that ABCB1 and CYP3A genotype ultimately influence graft (or patient) survival. 
Nonetheless, we feel that in the near future interventional trials will be initiated to 
investigate whether patients who are predicted to be at increased risk of CNI-induced 
nephrotoxicity will indeed benefit from CNI-free immunosuppressive protocols or CNI-
sparing regimens. 
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ABSTRACT
Background The risk of long-term chronic allograft nephropathy and graft loss after kidney 
transplantation is increased in patients with a high intra-patient variability of tacrolimus 
(Tac) clearance. 
Methods To test whether this intra-patient variability is associated with an individual’s 
CYP3A5 genotype, we measured the intra-patient variability in Tac clearance in a cohort of 
208 kidney transplant recipients treated with Tac and mycophenolate mofetil. 
Results Tac dose requirement was significantly higher in patients expressing CYP3A5. 
However, intra-individual variability of Tac clearance was not related to CYP3A5 genotype. 
Conclusion Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. 
Other factors, including patient adherence, may explain the variability in Tac clearance 
within an individual patient over time.
INTRODUCTION
In a previous study, we observed that the risk of long-term chronic allograft nephropathy 
and graft loss after kidney transplantation is increased in patients with a high intra-
patient variability of tacrolimus (Tac) clearance.1 The causes of this variability in Tac 
clearance within individual patients are incompletely understood. An explanation could 
be an individual’s cytochrome P450 3A (CYP3A) genotype. Tac is metabolised by the CYP 
isoenzymes CYP3A4 and CYP3A5. Both enzymes are polymorphically expressed and several 
studies have demonstrated that patients homozygous for the CYP3A5*3 single-nucleotide 
polymorphism (SNP), which leads to the absence of functional CYP3A5 protein, require a 
lower Tac dose compared with patients who express CYP3A5 protein due to the presence 
of the CYP3A5*1 allele.2-6
Korean investigators have recently suggested that not only inter-patient variability but 
also intra-patient variability is correlated with CYP3A5 genotype.7 In healthy individuals 
taking Tac as part of a bioequivalence study, CYP3A5 expressers had less intra-patient 
variability as compared to CYP3A5 non-expressers. This observation was explained by the 
fact that in patients without functional CYP3A5 enzyme, the metabolism of Tac depends 
exclusively on the activity of CYP3A4.7,8 Because the CYP3A4 enzyme is more sensitive 
to induction and inhibition, CYP3A5 non-expressers could be more prone to variable Tac 
clearance over time.8
To investigate this hypothesis, we correlated the intra-patient variability in Tac clearance 
to the CYP3A5 genotype in a large cohort of renal transplant patients. 
MATERIALS AND METHODS
Study population
All patients who participated in our previous study and of whom the CYP3A5 genotype 
was known, were included.1 CYP3A5 genotyping and Tac whole-blood concentration 
measurement in these patients was previously performed as part of and as described 
in several studies investigating the genetic basis of inter-patient variability in Tac 
pharmacokinetics.9-11 Patients not carrying the CYP3A5*3 allele were assigned the 
CYP3A5*1/*1 genotype by default.
Study parameters
The primary outcome variable of the present study was the intra-patient variability in 
apparent oral Tac clearance (in the rest of this manuscript referred to as “clearance”). The 
Tac clearance of an individual was calculated by taking the reciprocal of the ratio of the 
whole-blood Tac concentrations (in nanogram per millilitre) obtained between 6 and 12 
months after transplantation and the corresponding Tac doses (in milligram per day). 
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The within-patient variability in Tac clearance was then calculated as described previously1 
using the following formula:
{[(Xmean –X1) + (Xmean –X2) …… + (Xmean -Xn)] / n} / Xmean * 100= intra-patient 
variability (%)
Where Xmean is the mean Tac clearance of the available samples, X1 is the first available 
Tac clearance, X2 is the second and so on. The patients were divided into low and high 
intra-individual variability groups using the median variability of Tac clearance as the cut-
off value.
Statistical analysis
To test the null hypothesis of no difference in CYP3A5 genotype frequency between 
patients with a high and low intra-patient variability in Tac clearance, we compared 
CYP3A5 expressers (patients with the CYP3A5*1/*1 or CYP3A5*1/*3 genotype) with non-
expressers (patients with the CYP3A5*3/*3 genotype). Statistical analysis was performed 
by use of the Chi square test, Fischer’s exact test or Student’s t test, as appropriate with an 
α of 0.05. All values are depicted as means (± SD) unless stated otherwise.
RESULTS
Of the 297 patients included in our original study cohort, DNA for CYP3A5 genotyping 
was available for 208 patients. For all patients there were at least 2 samples available for 
calculation of the intra-patient variability of Tac clearance with a mean number of 4.6 ± 
1.8 samples per patient. The baseline characteristics of these 208 patients are depicted in 
Table 1. We observed no differences in these characteristics between CYP3A5 expressers 
and non-expressers, except for mean body weight and ethnicity. In line with previous 
observations, the CYP3A5*1 allele was more prevalent among black transplant recipients 
compared with Caucasian patients.12 In addition, Tac dose requirement was 1.8-fold higher 
in patients expressing CYP3A5 compared with CYP3A5 non-expressers, confirming earlier 
observations.11 
Of the 208 patients included, 104 had a low intra-patient variability of Tac clearance, 
whereas 104 patients displayed a high within-patient variability in Tac clearance. Ethnicity 
was not related to intra-patient variability of Tac clearance. When comparing CYP3A5 
expressers with CYP3A5 non-expressers, no differences in the intra-patient variability of 
Tac clearance were observed (P = 0.28; Table 2). In addition, we observed no differences in 
the intra-individual variability of Tac clearance between patients with the CYP3A5*1/*1 vs. 
CYP3A5*1/*3 vs. CYP3A5*3/*3 genotypes (P = 0.43; Table 2) 
Depicted are the numbers of patients with a low or a high intrapatient variability in 
dose-corrected Tac predose concentration according to CYP3A5 genotype. The apparent 
oral clearance was calculated by taking the reciprocal of this ratio (for example, a dose-
corrected Tac predose concentration of 0.52 ng/ml per mg per day gives an apparent oral 
Table 1. Baseline characteristics.
CYP3A5 expressers 
(n = 59)
CYP3A5 non-expressers 
(n = 149)
P-value
Male / female 38 / 21 88 / 61 0.48
Mean age recipient at 
transplantation (years)
45.7 ± 13.1 44.3 ± 14.4 0.50
Mean transplant number 1.3 ± 0.7 1.2 ± 0.5 0.25
Mean bodyweight (kg) 72.0 ± 14.0 77.9 ± 14.2 0.0075
Ethnicity
Asian
Black
Caucasian
Other
Unknown
9 (15.3%)
16 (27.1%)
19 (32.2%)
4 (6.8%)
11 (18.6%)
8 (5.4%)
2 (1.3%)
114 (76.5%)
5 (3.4%)
20 (13.4%)
Mean number of HLA mismatches 2.6 2.5 0.60
Living donor 40.7% 58.4% 0.22
Primary kidney disease
Chronic pyelonephritis
Diabetes mellitus
Glomerulonephritis 
Hypertensive nephropathy
IgA nephropathy
Polycystic kidney disease
Reflux/obstructive nephropathy
Unknown
Other
2 (3.4%)
8 (13.6%)
4 (6.8%)
15 (25.4%)
5 (8.5%)
3 (5.1%)
3 (5.1%)
5 (8.5%)
14 (23.7%)
7 (4.7%)
8 (5.4%)
7 (4.7%)
21 (14.1%)
11 (7.4%)
22 (14.8%)
11 (7.4%)
23 (15.4%)
39 (26.2%)
Tac C
0
 (ng/ml)
t = 6 months
t = 12 months
7.5 ± 2.5
7.0 ± 2.4
8.0 ± 2.8
6.8 ± 2.4
0.15
0.50
Tac C
0
/dose (ng/ml per mg per day)
t = 6 months
t = 12 months
1.08 ± 1.0
1.09 ± 0.6
1.92 ± 0.9
1.90 ± 1.0
<0.0001
<0.0001
Table 2. Intra-patient variability in Tac clearance and CYP3A5 genotype.
Low variability group High variability group
n (%)
Dose-corrected Tac 
predose concentration  
(ng/ml per mg per day)
n (%)
Dose-corrected 
Tac predose 
concentration (ng/
ml per mg per day)
CYP3A5 non-expressers (*3/*3) 78 (75.0%) 0.52 ± 0.27 71 (68.3%) 0.45 ± 0.30
CYP3A5 expressers (*1/*1 plus *1/*3) 26 (25.0%) 0.33 ± 0.30 33 (31.7%) 0.24 ± 0.15
CYP3A5 *1/*1
5 
(4.8%)
0.53 ± 0.45
9 
(8.7%)
0.20 ± 0.11
CYP3A5 *1/*3 21 (20.2%) 0.28 ± 0.24 24 (23.1%) 0.25 ± 0.16
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clearance of 1.92 L/day). These numbers are given as absolute values and as percentage 
of the total population (in parentheses). The median variability in Tac clearance of the 
whole population was 15.6% and this value was used to define patients as having either 
a high (above the cut-off of 15.6%) variability or a low (below the cut-off) variability. The 
mean Tac clearance of each genotype group is also shown. No differences were observed 
in the distribution of patients with the various CYP3A5 genotypes among the high and 
low variability groups (p = 0.28 for expressers vs. non-expressers and p = 0.43 for non-
expressers vs. CYP3A5 *1/*3 vs. CYP3A5 *1/*1, respectively). 
DISCUSSION
In the present study we found no significant association between intra-patient variability of 
Tac clearance and CYP3A5 genotype. Our findings are in contrast with the observations of 
Chung et al.7 who observed a higher proportion of CYP3A5 non-expressers among patients 
with a high intra-patient variability of Tac clearance. 
There could be several reasons for these seemingly conflicting data. First of all, the 
pharmacokinetic data of Chung et al. were more detailed than ours. For our study, only 
Tac pre-dose concentrations obtained during routine patient care at the outpatient 
clinic were available for the analysis, whereas Chung and colleagues performed detailed 
pharmacokinetic measurements over a twelve hour Tac dosing interval. The participants 
in the latter study were healthy volunteers (n = 29) who participated in a pharmacokinetic 
bioequivalence study. As these volunteers received two single doses of two different Tac 
formulations, the intra-patient variability in the study of Chung et al. may in part be due to 
differences between the two Tac formulations. 
Our study population consisted of transplanted patients using a number of drugs other 
than Tac. This co-medication was not systematically recorded but may have had an effect 
on intra-individual variability in Tac clearance by inducing or inhibiting CYP3A4-mediated 
Tac metabolism. Two recent studies13-14 have shown that CYP3A5 non-expressers are more 
susceptible to the inhibitory effects of fluconazole and ketoconazole on Tac metabolism. 
Obviously, this factor does not confound the results when studying a selected group of 
healthy volunteers participating in a cross-over pharmacokinetic study.15 Another possible 
explanation for the differences between our results and those of Chung et al., could be 
the different ethnic make-up of the study populations. Our study population was of mixed 
ethnic background, whereas the population of Chung et al. consisted exclusively of Korean 
subjects. We can not rule out the possibility that the CYP3A4 enzyme of Koreans is more 
susceptible to induction or inhibition than the CYP3A4 enzyme of Caucasians. Of the 208 
patients in our study less than 10% were of Asian descent and our study therefore lacks 
power to perform a meaningful analysis of Asian patients separately. 
Non-adherence to the immunosuppressive medication may be another cause for high 
within-patient variability in Tac clearance, especially in observational cohort studies. In 
our previous analysis1 we observed that the intra-patient variability for Tac clearance was 
poorly correlated with the intra-patient variability for mycophenolic acid clearance. We 
assumed that non-adherence would have resulted in a similar variability in clearance of 
both drugs. However, we cannot rule out the possibility that non-compliance did influence 
our results. Future studies using sensitive methods for medication adherence such as the 
Q-methodology are needed to resolve this matter.16
CONCLUSION
The intra-patient variability of Tac clearance is not associated with CYP3A5 genotype in 
stable kidney transplant patients. More research is needed to provide insights about what 
causes intra-patient variability of Tac clearance in patients using this immunosuppressive 
drug. 
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ABSTRACT
TDM for tacrolimus (Tac) is universally applied. However, the concentration-effect 
relationship for Tac is poorly defined. This study investigated whether Tac concentrations 
are associated with acute rejection in kidney transplant recipients. Data from three 
large trials were pooled. We used univariate and multivariate analysis to investigate the 
relationship between BPAR and Tac predose concentration at 5 time points (day 3, 10, and 
14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced 
BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations 
between Tac predose concentrations and the incidence of BPAR at the different time points. 
In the multivariate analysis, only Delayed Graft Function (DGF) and the use of induction 
therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8 
- 4.0; p < 0.001] for DGF and 0.66 [95% CI: 0.44 - 0.99; p = 0.049] for induction therapy. 
The other variables, including the Tac predose concentrations, were not statistically 
significantly associated with BPAR. We did not find an association between the Tac predose 
concentrations measured at 5 time points after kidney transplantation and the incidence 
of acute rejection occurring thereafter. Based on this study it is not possible to define the 
optimal target concentrations for Tac.
INTRODUCTION
Tacrolimus (Tac) has almost replaced cyclosporine A (CsA) as the drug of first choice for the 
prevention of graft rejection after kidney transplantation 1. Therapeutic Drug Monitoring 
(TDM) for Tac is universally applied. Requirements for a drug to implement TDM in clinical 
practice include a high between-patient variability in pharmacokinetics, a relatively low 
within-patient variability, and a concentration-effect relationship. In order to do TDM, 
assays to measure drug concentrations also need to be available and ideally, randomized 
trials should show an improvement in clinical outcome when a drug is dosed based on 
measured drug concentrations compared to a fixed-dose approach. For Tac several assays 
are available, but randomized trials showing a benefit of TDM are not available. However, 
it is not realistic to expect that for Tac such a trial will ever be performed. 
Contrary to the belief of many physicians and surgeons, the concentration-effect 
relationship for Tac is poorly defined. As the most important reason to prescribe Tac to a 
transplant recipient is the prevention of acute rejection, it is surprising that there are so 
few data on the concentration-effect relationship of Tac. Based on the current literature 
there is little support to promote the use of a specific therapeutic window and aim for 
certain target concentrations. 
Several investigators have attempted to identify the optimal Tac concentration range, 
i.e. the one which is associated with the lowest incidence of rejection and with acceptable 
toxicity, as shown in Table 1. 
Table 1. Literature 
Author, Year
Number of 
patients 
Conclusion
Borobia et al, 2009 15 57 kidney
The Tac predose concentrations within the first post-operative week  
are an important predictor of acute rejection
Staatz t al, 2001 16 29 kidney
Significant relationship between acute rejection and median  
Tac predose concentrations in the first month.
Bottiger et al, 1999 17 14 kidney
Concentrations below 10 ng/mL seem to be beneficial  
with respect to side effects
Kershner et al, 1996 18 92 kidney Significant relationship between the Tac concentrations and toxicity
Undre et al, 1999 19 56 kidney
Mean 12-hour Tac area-under the concentration vs. time-curve (AUC
0-12
) 
on day 2 after transplantation was significantly lower in 17 patients 
who experienced acute rejection than in the 39 patients who remained 
rejection-free
Kershner et al, 1996 18 721 liver No relationship between the Tac concentrations and toxicity
Laskow et al, 1996 20 92 kidney
No significant difference among three different Tac-ranges  
(5-14 ng/mL, 15-25 ng/mL, and 26-40 ng/mL) with respect  
to the incidence of rejection
Nashan et al, 2009 21 60 liver
Tac predose concentrations of 5-8 ng/mL in the first month  
of transplantation resulted in the same rejection rates as  
Tac concentrations of 10-15 ng/mL.
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The findings of many of these reports are conflicting and limited by the fact that they 
were of a retrospective design, included limited numbers of patients, and that the co-
immunosuppressive medication used was different from that which is currently considered 
the gold standard. For the interpretation of the studies that are available an important 
additional problem is the fact that not all investigators studied Tac concentrations at the 
same time point after transplantation. 
Rodriguez et al 2 recently performed a meta-analysis of 64 studies investigating the 
correlation between the Tac predose concentration and the incidence of rejection in liver 
transplant recipients. They concluded that the mean Tac predose concentration during 
the first month was not correlated with acute rejection. Nevertheless, they suggested that 
lower Tac predose levels would be more appropriate after liver transplantation to prevent 
Tac toxicity. 
Despite limited evidence for performing TDM for Tac and the exact predose concentrations 
to aim for, in most transplant centers considerable time and effort is spent on the precise 
dosing of Tac in order to reach the predefined Tac target concentrations rapidly. Once on 
target, maintaining patients within the target concentration range also requires careful 
monitoring. 
The aim of the present study therefore was to investigate whether the currently used 
and empirically-defined Tac target predose concentrations are indeed associated with 
the risk of developing acute rejection in kidney transplant recipients. We pooled the data 
of three large randomized-controlled trials (RCTs) and studied the relation between Tac 
exposure and the incidence of biopsy-proven acute rejection (BPAR). 
PATIENTS AND METHODS
Patients and clinical trials
For the present analysis we combined the data of three large, randomized-controlled 
clinical trials in kidney transplant recipients, the FDCC (3), Symphony 4 and OptiCept 5 trials. 
In brief, the main common elements of the three studies were the randomized, open-
label, parallel-arm, multicenter design, and the fact that they included a broad spectrum 
of patients. In general, these patients had a low-to-medium immunological risk and were 
treated under the respective protocols for at least one year after kidney transplantation. In 
addition to adults, the FDCC and OptiCept studies enrolled paediatric patients, who were, 
however, not included in our analysis.
Tac target concentrations
For the present analysis we included only the patients from these three RCTs who received 
Tac as part of their immunosuppressive regimen from the day of transplantation and had 
a minimum of 1 known Tac level. The Tac levels were targeted differently between the 
studies. For the FDCC study, Tac dosing was according to each center’s protocol, and on 
average was between 10 and 14 ng/mL in the first month, with gradual tapering thereafter. 
In the Symphony study, Tac levels were targeted at 3-7 ng/mL for the study period. In the 
OptiCept trial, the Tac predose concentrations were 8-12 ng/mL within the first month, 4-6 
or 8-10 ng/mL in the second and third months (depending on the randomization group), 
and 3-5 or 6-8 ng/mL from the fourth month onwards. Data on Tac dose and predose 
concentrations, as well as other demographic and clinical characteristics were collected 
from the databases of the three RCTs and pooled. Tac predose concentrations were studied 
at day 3 (± 2 days), day 10 (± 2 days), day 14 (± 3 days), month 1 (± 7 days), month 6 (± 4 
weeks). We changed the Tac levels that were higher than 30 ng/mL (24 measuring points 
in total) into missing values, to prevent that non-predose Tac concentrations would be 
included in the analysis. However, we also performed the analysis with all the Tac levels 
(including the ones that were higher than 30 ng/mL).
Acute rejection
BPAR was defined as any histologically-confirmed episode for which a Banff score of 1 (mild, 
grades IA and IIA), 2 (moderate, grades IB and IIB), or 3 (severe, grade III) was recorded. In 
all three trials, all biopsy samples were assessed by a local pathologist, and rejection was 
classified according to the revised Banff grading system 6. For the present analysis, only the 
first episode of BPAR was investigated. Ongoing or recurrent rejections were not studied. 
Statistical analyses 
The correlations between Tac concentrations and BPAR were done for BPARs occurring 
after the time of the Tac concentration measurement, within the remainder of the first 
post-transplant year tested with the non-parametric Mann Whitney U test at the five 
different time points. We also did the same analysis for BPARs occurring within the 
month following the Tac concentration measurement, again for all five time points. We 
also performed a similar analysis categorizing the patients as high-risk if they had one 
or more of the following characteristics: delayed graft function (DGF), second or third 
transplantation, panel reactive antibodies (PRA) of more than 15%, four or more human 
leukocyte antigen (HLA) mismatches, or were of African descent (black). All other patients 
were considered as low-risk. We have previously used the same definition for high and 
low risk 7. The significance level was stated at 5%. Induction therapy (yes/no)(either ATG 
of anti ILR monoclonal antibody induction), HLA mismatches (<4 / ≥4), DGF (yes/no), PRA 
(<15 / ≥15) and number of transplant (first / ≥second transplant) were correlated with 
the occurrence of BPAR within one month and one year after transplantation by using 
the Chi Square test. To identify independent risk factors for the development of BPAR, a 
binary logistic regression was performed, including all the above mentioned variables, plus 
median levels of Tac predose concentrations. Statistical analysis was carried out using SPSS 
version 19 (SPSS / IBM Inc., Chicago, Illinois, USA).
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RESULTS 
Pati ent characteristi cs 
In the three clinical trials a total of 1363 renal transplant pati ents were treated with Tac 
aft er transplantati on. Of these pati ents, 1304 met the inclusion criteria and were used for 
further analysis (Fig. 1). Of these 1304 pati ents, 358 (27%) parti cipated in the FDCC study, 
385 (30%) in the Symphony study, and 561 (43%) in the Opti cept study. 
Figure 1. Included pati ents from the three clinical trials and reasons for exclusion from the study.
Figure 2.
A B
A Boxplots depicti ng the Tac predose concentrati ons of all pati ents at the fi ve diff erent ti me points aft er 
transplantati on. 
B Boxplots depicti ng the Tac predose concentrati ons of pati ents experiencing BPAR (black boxes) and pati ents 
without BPAR (white boxes) at the fi ve diff erent ti me points aft er transplantati on. 
Bott om, middle, and top lines of each box correspond to the 25th percenti le, the 50th percenti le (median), and 
the 75th percenti le, respecti vely. The caps show the 5th and 95th percenti les. The points represent the outliers 
and the asterisks represent the extreme outliers (more than three ti mes the height of the boxes). 
The pati ent characteristi cs are listed in Table 2. A total of 4953 Tac predose concentrati ons 
of 1304 pati ents were available for the analysis (Total predose concentrati ons of 818 on 
day 3; 1127 on day 10; 804 on day 14; 1167 on month 1 and 1019 on month 6). 
The Tac predose concentrati ons show a substanti al range and are depicted in Figure 2A. 
Twenty-four Tac concentrati ons were >30 ng/mL (n =13 on day 3; n =4 on day 14, n = 4 on 
month 1 and n = 3 on month 6). As we were unable to check whether these concentrati ons 
were truly predose concentrati ons or in fact post-dose concentrati ons, these values were 
classifi ed as “missing values” and excluded from the primary analysis. 
 Relati onship between Tac and BPAR
In this cohort the overall incidence of BPAR was 10.4% (n = 136) within one year aft er 
transplantati on. The vast majority of BPARs occurred within the fi rst month aft er 
transplantati on (91/136 = 7%). We univariately tested the relati onship between median Tac 
predose concentrati ons and the occurrence of BPAR within the fi rst post-transplant year at 
5 diff erent ti me points, as shown in Table 3A and Figure 2B. We did not fi nd any signifi cant 
relati onship between the Tac concentrati on and the incidence of BPAR. The results for 
BPAR within the fi rst month aft er the Tac measurements did show similar results: again 
pati ents that developed a BPAR had Tac predose concentrati ons that were not diff erent 
compared to pati ents without a BPAR, as shown in Table 3B. As for only 61% of the pati ents 
a Tac predose concentrati on was available for day 3 (Table 3A), we have studied the mean 
Tac predose concentrati on for each pati ent, based on samples drawn between day 3 and 
day 14 and correlated this to BPAR. Again, these Tac concentrati ons were not signifi cantly 
diff erent between pati ents with BPAR and pati ents without BPAR (10.02 vs. 9.97; p = 0.90). 
The data were further analyzed by strati fi cati on into two groups: pati ents with a predose 
concentrati on < 5 ng/mL vs. pati ents with a predose concentrati on > 5 ng/mL, and pati ents 
with a predose concentrati on < 10 ng/mL vs. pati ents with a predose concentrati on > 10 
ng/mL. The results are shown in Table 4. There were no stati sti cally signifi cant associati ons 
between the Tac predose concentrati ons and the occurrence of BPAR within one month 
aft er the measurement or throughout the rest of the fi rst year aft er transplantati on. 
To analyse the risk of BPAR further, we divided the group into high and low immunological 
risk pati ents according to the defi niti on described above. The total number of pati ents 
defi ned as being low-risk was 499 (39%) whereas 786 (61%) pati ents were considered to 
be high-risk. Nineteen pati ents were not included in this analysis, because one or more of 
the variables needed to defi ne their immunological risk were not known. The incidence of 
BPAR was higher in pati ents in the high-risk group (100/786 = 12.7%) compared to the low-
risk group (36/499 = 7.2%), with an odds rati o of 1.9 for pati ents in the high-risk group vs. 
the low-risk pati ents [95% CI: 1.3 - 2.8; p < 0.05]. First we analysed the Tac concentrati ons 
at the diff erent ti me points for the high-risk group vs. the low-risk group. At all the ti me 
points the median Tac predose concentrati ons were not stati sti cally signifi cantly diff erent 
between the high and low risk groups. We further analysed the Tac concentrati ons at the 
diff erent ti me points within the high and low risk group separately, as shown in Table 5. 
Patients in the database
n = 1363
 
Included in the analysis 
n = 1304 (95.7%)
FDCC study 
n = 358 (27.5%) 
Symphony study 
 n = 385 (29.5%) 
OptiCept study 
n = 561 (43.0%) 
Excluded n = 59 (4.3%)
 - Age unknown (n = 5) 
 - Age < 18 years (n = 9)
 - Tac concentrations unknown (n = 45)
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Again no significantly differences could be found between the patients that developed 
BPAR and patients without BPAR for the low (Table 5A) as well as for the high risk patients 
(5B). 
We have changed the Tac levels that were higher than 30 ng/mL (24 measuring points 
in total) into missing values, to prevent that non predose Tac concentrations would be 
included in the analysis. However, we have also performed the analysis with all the Tac 
levels (including the ones that were higher than 30 ng/mL), but the results did not change 
(data not shown). 
Explaining BPAR
Next to the Tac predose concentrations, in the univariate analysis, induction therapy, 
HLA mismatches, DGF, PRA and number of transplants were tested with the occurrence 
of BPAR within one year after transplantation. Of all 1304 patients 68% used induction 
therapy, and 9.6% of these patients suffered from a BPAR whereas this percentage was 
12.3% in patients who did not use induction therapy after transplantation (p = 0.13). We 
also correlated the incidence of BPAR and the mean Tac concentration of day 3 to day 14 
only within patients that did not use induction therapy. The Tac concentration in this group 
was not statistically different between patients with BPAR and patients without BPAR (p 
= 0.53). To test the influence of HLA mismatching we divided the group into patients that 
had 0-3 HLA mismatches vs. patients that had more than 3 HLA mismatches. There was 
a significant correlation between the number of HLA mismatches and the occurrence of 
BPAR. In patients with more than 3 HLA mismatches 12.3% had BPAR vs. 8.9% in patients 
that had 0-3 HLA mismatches (p = 0.046). Also for DGF we found a significant correlation 
with the occurrence of BPAR (19.7% in patients with DGF vs. 8.3 % in those without DGF), p 
< 0.001). The PRA status was not significantly related to the development of BPAR. PRA was 
separated into patients that had a PRA < 15% and patients with a PRA > 15%, in the first 
group 10.5% developed BPAR and in the last group 8.6% (p = 0.54). We have also studied 
the development of BPAR within patients that had a first kidney transplantation and 
compared this to patients that had one or more transplants before. Patients who had been 
transplanted before had a higher risk of developing BPAR (17.9%) compared with patients 
who received their first kidney allograft (9.9%; p = 0.021). The variables are listed in Table 
6A. Because of the different designs of the studies we have also tested the incidence of 
BPAR within the different studies (Symphony, Opticept and FDCC). The patients in the 
Opticept trial suffered significantly less from a BPAR than in the other studies (7.5% vs. 
12.2% (Symphony) and 13.1% (FDCC); p = 0.01. 
In order to exclude the possibility that some of the other factors associated with the 
incidence of BPAR have confounded the relationship between Tac concentrations and 
BPAR we have adjusted for observed confounders and we performed a multivariate 
analysis which included these variables, as well as the Tac concentrations. Multivariate 
analysis demonstrated that only DGF and the use of induction therapy were independently 
correlated to BPAR, with an odds ratio of 2.7 [95%-CI: 1.8 - 4.0; p < 0.001] for DGF, and 
0.66 [95%-CI: 0.44 - 0.99; p = 0.049] for the use of induction therapy. The other variables, 
including the Tac predose levels, were not significantly associated with the risk of 
developing BPAR as shown in Table 6B. 
DISCUSSION
We did not find a correlation between the Tac predose concentration measured at 5 time 
points after transplantation and the occurrence of acute rejection in the period thereafter, 
within the first post-transplant year. The same was true for BPARs within the first month 
following the Tac measurement. We investigated a large and heterogeneous study 
population, and the Tac concentrations measured showed a substantial range, despite 
rather tight target concentrations defined in the protocols. 
The situation for Tac seems to be quite different from mycophenolic acid (MPA). For 
MPA, a concentration-effect relationship has been shown repetitively 8-9 and for MPA 
it was also shown that in contrast to patients at low-risk for BPAR for high-risk patients 
there was a significant difference in the incidence of BPAR depending on the MPA 
concentrations reached 7. In the present study, in neither the high-risk nor in the low-
risk patients the incidence of acute rejection was dependent on the Tac concentrations. 
A bit to our surprise the mean Tac concentrations in high risk patients were not different 
from the Tac concentrations found in the low risk population. We had expected that 
physicians responsible for dosing Tac would aim for higher Tac concentrations in patients 
considered to be at presumed higher risk for BPAR, and that they would allow for lower 
concentrations in patients with a lower risk of rejection. Also in the multivariate analysis 
the Tac concentrations did not surface as predictor for BPAR. 
TDM is generally considered to be required for managing Tac therapy. Often transplant 
centers have specified the target concentrations for Tac, depending on time post-transplant, 
on co-medication and presumed risk of rejection. One would think that for a drug so 
extensively used the evidence for the optimal Tac concentration would be compelling. We 
show that this is not the case. In the past 15 years we have seen a substantial change in 
the target Tac concentrations, with targets as high as 20 ng/mL in the early years, and with 
targets as low as 3-7 ng/mL in the Symphony study. This change in target concentrations 
was largely reached empirically, and there is only limited evidence for the different targets. 
This does not imply that TDM for Tac is useless. Without TDM the large between-patient 
variability in Tac pharmacokinetics would go unnoticed, and extremes in Tac exposure 
would occur, exposing some patients to toxic levels and others to very low levels. Based 
on our analysis however it is not possible to conclude that the Tac target concentrations 
should be above for example 5 or 10 ng/mL. Possibly the threshold for efficacy is at a 
concentration that is even lower than the currently applied targets, and it is possible that 
only when concentrations reach values as low as 1 or 2 ng/mL the incidence of BPAR starts 
to increase. The same was suggested by Rodriguez 2 who proposed to further lower the Tac 
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concentration in liver transplantation. They even recommended the regulatory authorities 
and pharmaceutical industry to change the regulatory drug information for lowering the 
target levels. 
This study is a combined analysis of three large clinical trials, and a large number of kidney 
transplant recipients was included. In spite of the considerable number of patients studied, 
we could not show an association between the development of acute rejection in 1 month 
or 1 year after transplantation and the Tac whole blood concentrations. Also adjusting for 
confounders in a multivariate analysis the results stayed negative. Recently Capron et al. 
10 also showed that there is no correlation between Tac whole blood concentrations and 
rejection after liver transplantation. However, they did find a strong correlation between 
Tac concentrations within peripheral blood mononuclear cells (PBMCs), the site of action of 
Tac, and the staging of rejection in liver transplant recipients. However, as indicated above, 
the currently clinically employed assays measure the Tac concentration in whole blood, 
which is determined to a large extent by the Tac concentration in the erythrocyte fraction. 
Tac concentrations in PBMCs are not 1:1 correlated with whole blood (or erythrocyte) 
concentrations, for example due to the presence of drug transporting enzymes in the 
cell membranes of PBMCs. Therefore Tac concentration within PBMCs might be a better 
marker of immunosuppressive efficacy than the whole blood predose concentration. 
Future studies should study the relationship between intracellular Tac concentrations and 
rejection risk in kidney transplant recipients in more detail.A limitation to this study is that 
donor specific anti-HLA antibodies were not routinely measured, and therefore we have 
no data on correlations between tacrolimus exposure and DSA. Next to this, we had only 
access to Tac concentrations drawn at predefined time points. These Tac concentrations 
might not be the last measured concentration prior to diagnosing BPAR and we cannot 
exclude the possibility that a similar analysis with the last levels drawn would show an 
association. However, intrapatient variability of Tac is limited and we do not think that we 
would have achieved another outcome by using the last levels drawn. Another limitation 
is that the pre-dose concentrations that were investigated in this study do not adequately 
reflect the exposure to Tac. Kuypers et al. in 2004 showed that in contrast to Tac predose 
concentrations the Tac area under the concentration curve from 0 to 12 hours [AUC(0-
12)] was correlated with clinical efficacy, at different time points after transplantation 
11. However, a good correlation between Tac predose concentrations and AUC has been 
demonstrated. In clinical practice predose concentrations are the preferred method to 
monitor Tac treatment 12. In a multivariate analysis also Australian investigators 13 did not 
find a correlation between Tac pre-dose concentrations or Tac AUC and incidence of acute 
rejection, whereas in their study MPA-AUC was correlated to BPAR. 
Another explanation might be that other mechanisms, such as innate immunity, which 
are not calcineurin driven might play a role in the development of acute rejections. These 
rejections could not be prevent by the use of calcineurin inhibitors, such as Tac and for 
these type of rejections it is therefore not useful to aim for a specific Tac target. Although 
T-cells, inhibited by Tac, have a critical role in acute rejection it is known that there is an 
upregulation of proinflammatory mediators in the allograft before the T cell response, this 
is due to innate immunity and it is independent of the adaptive immune system 14.
In this study we have focused only on efficacy, as the incidence of nephrotoxicity was 
not prospectively collected. Therefore it is not possible form this study to define the upper 
threshold for Tac treatment. 
In conclusion, we did not find an association between the Tac predose concentrations 
and the incidence of acute rejection after kidney transplantation. Even though it is generally 
accepted that TDM is essential to maintain the efficacy of Tac, the analysis in this study 
does not show that TDM, at the used whole blood target ranges, adds to lowering the risk 
of acute rejection. We do not want to suggest that TDM for Tac can be abolished, but a 
more critical perception on the relevance of the presumed optimal target concentrations 
is recommended. 
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Table 2. Patient Characteristics
Gender (female / male) 450 (34%) / 854 (66%)
Age (yr; mean (SD) 48 (13.8)
Ethnicity (%):
     - Black
     - Non- Black 
161 (12%)
1143 (88%)
Transplantation (1st / ≥2) 1219 (94%) / 84 (6%)€
Delayed Graft Function: Yes / No 238 (18%) / 1066 (82%)
Panel reactive antibodies (< 15% / ≥ 15%) 1124 (91.5%) / 105 (8.5%)€
HLA-mismatches (< 4 / ≥4) 709 (54%) / 595 (46%)
Living related / living unrelated / deceased donor 338 (26%) / 183 (14%) / 783 (60%)
Induction therapy: Yes / No 890 (68%) / 414 (32%)
€: For transplantation and PRA there were missing values in 1 and 6 patients, respectively. 
Table 3A. Median Tac predose concentrations and their association with BPAR occurring within the remainder 
of the first posttransplant year after the Tac concentration measurement.
Post-transplant 
Time point
Median predose Tac concentration (ng/mL) 
in patients with BPAR 
Median predose Tac concentration (ng/mL) 
in patients without BPAR
Day 3
Tac: 10.3 [6.5; 17.1; 27.6]Ω
n = 135 (61%)¥
Tac: 9.5 [6.0; 14.5; 29.5]Ω
n = 1168 (63%)¥
Day 10
Tac: 9.0 [7.0; 11.8; 25.8]Ω
n = 92 (85%)¥
Tac: 9.1 [6.6; 12.2; 28.2]Ω
n = 1013 (87%)¥
Day 14
Tac: 7.8 [5.6; 10.4; 26.2]Ω
n = 65 (72%)¥
Tac: 8.1 [6.2; 11.4; 29.7]Ω
n = 722 (62%)¥
Month 1
Tac: 8.7 [5.8; 12.7; 20.2]Ω
n = 45 (84%)¥
Tac: 9.7 [7.0; 12.5; 27.6]Ω
n = 1050 (90%)¥
Month 6
Tac: 7.5 [6.3; 10.5; 11.0]Ω
n = 15 (80%)¥
Tac: 6.8 [5.3; 8.6; 23.6]Ω
n = 924 (79%)¥
¥  The percentage of patients of whom the Tac levels were available for analysis at this post-transplant 
time point. Tac concentrations were related to BPAR occurring after the date of the Tac concentration 
measurement. 
Ω  The numbers show the 25th percentile, 75th percentile and the range respectively. For all comparisons no 
statistically significant differences were found, all p-values were > 0.05.
Table 3B. Median Tac predose concentrations and their association with BPAR occurring within 1 month after 
the Tac concentration measurement. 
Post-transplant 
Time point
Median predose Tac concentration 
(ng/mL) in patients with BPAR 
Median predose Tac concentration  
(ng/mL) in patients without BPAR
Day 3
Tac: 11.1 [6.3; 10.5; 11.0]Ω
N = 60 (66%)¥
Tac: 9.5 [6.3; 10.5; 11.0]Ω
N = 1212 (62%)¥
Day 10
Tac: 9.0 [6.3; 10.5; 11.0]Ω
N = 51 (86%)¥
Tac: 9.1 [6.3; 10.5; 11.0]Ω
N = 1047 (87%)¥
Day 14
Tac: 8.5 [6.3; 10.5; 11.0]Ω
N = 24 (71%)¥
Tac: 8.1 [6.3; 10.5; 11.0]Ω
N = 1209 (62%)¥
Month 1
Tac: 8.0 [6.3; 10.5; 11.0]Ω
N = 7 (71%)¥
Tac: 9.7 [6.3; 10.5; 11.0]Ω
N = 1206 (90%)¥
Month 6
Tac: 7.4 [6.3; 10.5; 11.0]Ω
N = 5 (100%)¥
Tac: 6.8 [6.3; 10.5; 11.0]Ω
N = 1178 (79%)¥
¥  The percentage of patients of whom the Tac levels were available for analysis at this post-transplant 
time point. Tac concentrations were related to BPAR occurring after the date of the Tac concentration 
measurement. 
Ω  The numbers show the 25th percentile, 75th percentile and the range respectively. For all comparisons no 
statistically significant differences were found, all p-values were > 0.05.
Table 4. Numbers of patients with Tac concentrations below or above 5 ng/mL (Table 4A) and numbers of 
patients with Tac concentrations below or above 10 ng/mL (Table 4B) at 5 post-transplant time points, and 
incidence of BPAR in these patients following that time point. 
4A. Tac predose concentrations < / > 5 ng/mL
Time point Tac < 5ng/mL BPAR Tac > 5ng/mL BPAR P -value
Day 3 146 10 (6.8%) 671 73 (10.9%) 0.14
Day 10 129 7 (5.7%) 962 71 (7.4%) 0.42
Day 14 92 8 (8.7%) 677 39 (5.8%) 0.27
Month 1 86 2 (2.3%) 1002 36 (3.6%) 0.54
Month 6 185 2 (1.1%) 751 10 (1.3%) 0.79
4B. Tac predose concentrations < / > 10 ng/mL
Time point Tac < 10ng/mL BPAR Tac > 10ng/mL BPAR P -value
Day 3 426 40 (9.4%) 391 43 (11%) 0.48
Day 10 619 49 (7.9%) 472 29 (6.7%) 0.26
Day 14 495 32 (6.5%) 274 15 (5.5%) 0.58
Month 1 573 22 (3.8%) 515 16 (3.1) 0.58
Month 6 797 9 (1.1%) 139 3 (2.2%) 0.32
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 Table 5. Median Tac predose concentrations at different time points after transplantation in patients with 
BPAR and in patients without BPAR divided into low (5A) and high risk patients (5B).
5A Low Risk patients
LOW-RISK PATIENTS (n = 499)
(Total BPAR incidence: 36/499 (7,2%))
Post-transplant  
Time point
Median predose Tac concentration  
(ng/mL) in patients with BPAR 
Median predose Tac concentration  
(ng/mL) in patients without BPAR 
p-value
Day 3
Tac: 10.3 [6.3; 10.5; 11.0]Ω
n = 17 ¥
Tac: 10.1 [6.3; 10.5; 11.0]Ω
n = 269 ¥
0.46
Day 10
Tac: 9.5 [6.3; 10.5; 11.0]Ω
n = 20 ¥
Tac: 9.0 [6.3; 10.5; 11.0]Ω
n = 394 ¥
0.68
Day 14
Tac: 8.9 [6.3; 10.5; 11.0]Ω
n = 11 ¥
Tac: 7.9 [6.3; 10.5; 11.0]Ω
n = 302 ¥
0.73
Day 3- day 14
Tac: 9.2 [6.3; 10.5; 11.0]Ω
n = 36 ¥
Tac: 9.2 [6.3; 10.5; 11.0]Ω
n = 454 ¥
0.63
Month 1
Tac: 10.1 [6.3; 10.5; 11.0]Ω
n = 10 ¥
Tac: 9.3 [6.3; 10.5; 11.0]Ω
n = 421 ¥
0.64
¥ The patients from whom the Tac levels were available for analysis at this post-transplant time point. For 
month 6 after transplantation the number of patients was too low to perform the analysis and this time 
point is therefore excluded from the analysis. 
Ω The numbers show the 25th percentile, 75th percentile and the range respectively
5B. High Risk patients
HIGH-RISK PATIENTS (n = 786)
(Total incidence of BPAR: 100/786 (12,7%))
Post-transplant 
Time point
Median predose Tac concentration  
(ng/mL) in patients with BPAR 
Median predose Tac concentration 
(ng/mL) in patients without BPAR
p-value
Day 3
Tac: 10.6
n = 66 ¥
Tac: 9.4
n = 454 ¥
0.26
Day 10
Tac: 8.7
n = 58 ¥
Tac: 9.1
n = 600 ¥
0.98
Day 14
Tac: 7.8
n = 36 ¥
Tac: 8.1
n = 402 ¥
0.28
Day 3- day 14
Tac: 9.1 
n = 99 ¥
Tac: 9.3
n = 673 ¥
0.63
Month 1
Tac: 8.7
n = 28 ¥
Tac: 9.9
n = 614 ¥
0.24
¥ The patients from whom the Tac levels were available for analysis at this post-transplant time point. For 
month 6 after transplantation the number of patients was too low to perform the analysis and this time 
point is therefore excluded from the analysis. 
Ω The numbers show the 25th percentile, 75th percentile and the range respectively. 
Table 6A. Other variables related to BPAR (univariate analysis). 
Patients (%) Patients with BPAR (%) P-value
DGF 18.3 19.7 < 0.001
No DGF 81.7 8.3
HLA mismatches > 4 46 12.3
HLA mismatches < 4 54 8.9 0.046
Number transplantation > 1 6.4 17.9 0.021
Number transplantation = 1 93.6 9.9
PRA > 15% 13.8 8.6 0.54
PRA < 15% 86.2 10.5
Induction therapy 68 9.6 0.13
No Induction therapy 32 12.3
Table 6B. Multivariate analysis 
OR (95% CI) P-value
DGF 2.7 (1.8 – 4.0) 0.0001
Induction 0.66 (0.44 – 0.99) 0.049
Mean Tac concentration day 3 – day 14 0.98 (0.94 – 1.03) 0.48
HLA mismatches < 4 1.47 (1.02 – 2.13) 0.07
Number transplantation > 1 1.71 (0.91 – 3.23) 0.09
PRA > 15% 0.51 (0.17 – 1.53) 0.23
DGF = Delayed graft function; PRA = panel reactive antibody
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ABSTRACT
Objective We investigated the association between genetic polymorphisms in ABCB1 and 
SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and 
leucopenia in 338 kidney transplant recipients.
Methods 338 patients participating in an international, randomized-controlled clinical trial 
were genotyped for ABCB1 and SLCO1B. The patients were all treated with mycophenolate 
mofetil plus either ciclosporine (CsA) or tacrolimus (Tac). MPA-AUCs, MPA-glucuronide 
(MPAG) AUCs and acylglucuronide (AcMPAG)-AUCs were measured on days 3 and 10, and 
months 1, 3, 6, and 12 after kidney transplantation.
Results The risk of developing diarrhea was 1.8-fold higher in patients co-treated with Tac 
as compared with patients co-treated with CsA (95% CI: 1.03-3.13; P = 0.038). ABCB1 and 
SLCO1B SNPs were not associated with dose-adjusted exposure to MPA, MPAG or AcMPAG 
nor with the incidence of diarrhea or leucopenia. 
Conclusion Genotyping for ABCB1 or SLCO1B pre-transplantation is unlikely to be of clinical 
value for individualization of MPA therapy.
INTRODUCTION 
Mycophenolate mofetil (MMF) is the most frequently used antiproliferative agent for the 
prevention of acute rejection after kidney transplantation 1. MMF is a pro-drug and is 
itself not pharmacologically active. After oral administration, MMF is rapidly hydrolyzed 
to form mycophenolic acid (MPA). MPA is immunologically active and is inactivated by 
uridine diphosphate glucuronosyltransferase (UGT)-mediated glucuronidation to form 
7-hydroxy-glucuronide mycophenolic acid (MPAG) 1-2. In addition, two minor metabolites 
are formed: the inactive phenolic glucoside and the acylglucuronide (AcMPAG), which has 
immunosuppressive properties in vitro. MPAG is the main MPA metabolite and is excreted 
into bile through multidrug-resistance protein (MRP)-2 mediated transport 3-4. In the gut, 
bacterial deconjugation transforms MPAG back into MPA, which is absorbed from the 
colon. Because of this enterohepatic circulation, the initial MPA plasma concentration 
peak at 1-2 h is followed by a second increase in the MPA plasma concentration, occurring 
6-12 h after oral administration. Finally, the majority of the absorbed MMF is eliminated 
by the kidneys as MPAG 2, 4.
The clinical use of MPA is complicated by its large inter-individual pharmacokinetic 
variability. Exposure to MPA may vary up to 10-fold in transplant recipients 5. This 
variability in MPA pharmacokinetics is in part explained by both non-genetic and genetic 
factors 6. With regard to the latter, it was recently demonstrated that single-nucleotide 
polymorphisms (SNPs) in the MPA-metabolizing enzymes UGT1A8 and UGT1A9, as well as 
in the drug transporter MRP2, explain part of the variability in MPA pharmacokinetics 7-9). 
The use of MPA is further complicated by the frequent occurrence of gastrointestinal 
adverse effects, such as nausea, abdominal cramps and especially diarrhea. Diarrhea has 
been shown to reduce the quality of life of transplanted patients and is an important 
reason for non-compliance or discontinuation of MPA therapy 10. In daily clinical practice 
the MMF dose is reduced in patients suffering from diarrhea. Although this does lead to 
less gastrointestinal discomfort in most patients, MPA dose reduction is not without risk as 
it may result in acute rejection 11-13.
The pathogenesis of MPA-related diarrhea in renal transplant recipients is unknown. 
Some authors have speculated that AcMPAG may cause an erosive enterocolitis by 
covalently binding to villous proteins in the intestinal mucosa 14. However, data from 
the Fixed-dose (FD) versus Concentration-controlled (CC) trial have shown that AcMPAG 
plasma-concentrations were not different between patients with and those without 
diarrhea 15. Moreover, no association was found between the occurrence of diarrhea and 
genetic polymorphisms in UGT2B7 which is responsible for the formation of AcMPAG 16-17. 
A direct toxic effect of MPA or MPAG on enterocytes may be an alternative explanation. 
Differences in the expression or function of drug transporting enzymes present in the 
apical membrane of the intestine could lead to high local concentrations of MPA or MPAG 
at the level of the intestinal epithelium and thus predispose certain patients to develop 
gastrointestinal side effects. Membrane transporters play a critical role in the absorption 
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and disposition of many drugs. However, at present there are only limited data considering 
the role of membrane transporters, such as ABCB1 and SLCO1B1 in the pharmacokinetics 
of MPA and MPAG. 
ABCB1 (P-glycoprotein; encoded by ABCB1) is an adenosine triphosphate (ATP) binding 
cassette (ABC) transmembrane transporter that is expressed in the intestinal epithelium 
where it limits the absorption of many drugs by actively extruding them back into the gut 
lumen 18-19. More than 25 SNPs have been discovered in ABCB1, some of which have been 
associated with interindividual variability in drug disposition 20-21. In an in vitro study, by use 
of a transfected cell line, Sawamoto et al. demonstrated that MPA is a substrate for ABCB1 
22. More recently, these in vitro findings were corroborated by an experimental in vivo 
study in mice. Studying ABCB1 knockout mice, Wang et al. observed that the MPA levels in 
plasma and tissue of these mice were markedly increased as compared to wildtype mice, 
again suggesting that MPA is an ABCB1 substrate 23. Among the organic anion transporting 
polypeptide (OATP) transporters, encoded by SLCO (solute carrier organic anion) genes, 
OATP1B1 (SLCO1B) and OATPB3 (SLCO1B3) are the major OATPs expressed on hepatocytes. 
In addition, OATPs are also expressed in the kidney and intestine 24. The OATPs are believed 
to be involved in the uptake of MPAG from the blood into hepatocytes 25. Polymorphisms 
leading to altered OATP activity may therefore affect MPA pharmacokinetics. Miura et al. 26 
demonstrated that the MPA AUC in carriers of the SLCO1B3 334G allele was higher compared 
with TT carriers in 87 Japanese patients who had undergone renal transplantation. Picard 
et al. also investigated this SNP in renal transplant recipients but reported the contrary, 
namely a higher MPA exposure in SLCO1B3 334T allele carriers compared with patients 
with the SLCO1B3 334 GG genotype. 
The aim of this study was to investigate whether genetic polymorphisms in ABCB1 
and SLCO are related to MPA pharmacokinetics and the occurrence of MPA-related 
diarrhea after kidney transplantation. In addition, we studied the relation between these 
polymorphisms and the occurrence of leucopenia (another common side effect of MPA), 
an association which was recently observed in a paediatric kidney transplant population 
27. To this end, we performed a subgroup analysis of patients who participated in the FDCC 
clinical trial 28. The current pharmacogenetic substudy was performed as an integral part 
of this immunosuppressive drug trial. 
METHODS
Patients and study design
The patients in this study were de novo kidney transplant recipients who participated 
in a phase IV, open, prospective, randomized, controlled, international, multicenter trial 
comparing Fixed-Dose MMF (Cellcept™, Roche Pharmaceuticals, Basle, Switzerland) 
treatment with Concentration-Controlled MMF treatment (the so-called “FDCC trial”). The 
primary outcomes of the FDCC trial have been presented in a separate publication 28. At 
the initiation of the study a pharmacogenetic substudy was planned, and in the centers 
participating in this substudy, all patients provided two written informed consents, one for 
the FDCC study and one for the pharmacogenetic substudy. The ethics committees of all 
participating centers and the relevant authorities in the participating countries approved 
the study protocol.
In the FDCC study, immunosuppressive therapy consisted of MMF, a calcineurin inhibitor 
and glucocorticoids. The choice for ciclosporine (CsA) or tacrolimus (Tac), was according 
to each centre’s protocol. Standard calcineurin inhibitor and glucocorticoids tapering 
regimens were left to the discretion of the investigators. Induction therapy with either 
anti-interleukin-2 receptor monoclonal antibody treatment or antithymocyte globulin 
was allowed. From the patients participating in the pharmacogenetic substudy, a single 
3 mL EDTA blood sample was collected during one of the pharmacokinetic assessments. 
Samples were shipped to the Erasmus MC in Rotterdam, the Netherlands, where DNA was 
isolated and stored. 
Diarrhea was defined as a frequency of more than four loose stools per day, if this was 
a change from the patient’s normal pattern. Diarrhea was defined as a secondary safety 
objective in the FDCC-trial. A possible infectious etiology of diarrhea was not systematically 
investigated. Leucopenia was defined as a total leukocyte count below 3.0 x 109/L. 
Drug concentration measurements
In all patients, a mini area-under the concentration versus time-curve (AUC; three samples 
within the first two hours after administration) was measured to calculate the corresponding 
AUC
0-12h
 on day 3, day 10, week 4 and months 3, 6 and 12 after transplantation and 
whenever deemed necessary by the attending physician 28. Tac pre-dose concentrations 
and CsA pre-dose and two-hour post-dose concentrations were measured on day 3, day 
10, week 4 and months 3, 6 and 12 after transplantation and whenever deemed necessary 
by the attending physician. The CsA-treated patients were analyzed separately from the 
Tac-treated patients, as CsA is a known inhibitor of ABCB1 and CsA is also known to interact 
with MPA pharmacokinetics through inhibition of MRP2-mediated excretion of MPAG in 
the gut lumen 29-30. 
DNA isolation and genotyping 
For the present analysis, patients were genotyped for 3 ABCB1 SNPs 21: 1236C>T (exon 12), 
2677G>T/A (exon 21) and 3435C>T (exon 26), for 2 SLCO1B1 SNPs (521T>C and 388A>G) 
and 2 SLCO1B3 SNPs (344T>G and 699G>T). 
Genotyping for the ABCB1 1236C>T, 2677G>T/A and 3435C>T was performed using 
Taqman allelic discrimination assays on the ABI Prism 7000 Sequence detection system. 
Each assay consisted of two allele-specific MGB probes, labelled with the fluorescent 
dyes VIC and FAM. The primer and probe sequences, designed by Applied Biosystems 
(Assay-by-Design service) are listed in Table 5. For the tri-allelic variant 2677G>T/A two 
separate assays were designed, one detecting G2677A and one detecting G2677T. PCRs 
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were performed in a reaction volume of 12 µL, containing assay-specific primers, allele-
specific Taqman MGB probes, Abgene Absolute QPCR Rox Mix and genomic DNA (5 ng). The 
thermal profile consists of an initial denaturation step at 95oC for 15 minutes, followed by 
40 cycles of denaturation at 92oC for 15 seconds and annealing and extension at 60oC for 
1 minute. Genotypes were scored by measuring allele-specific fluorescence using the SDS 
1.2.3 software for allelic discrimination (Applied Biosystems). 
The SLCO1B1 388A>G, 521T>C and the SLCO1B3 334T>G, 699G>A genotyping was done 
using predesigned DME Taqman allelic discrimination assays on the ABI Prism 7000 HT 
Sequence detection system. The assay ID’s are listed in Table 5. Each assay consisted of two 
allele-specific minor groove binding (MGB) probes, labeled with the fluorescent dyes VIC and 
FAM. PCR were performed in a reaction volume of 10 µL, containing assay-specific primers, 
allele-specific Taqman MGB probes, Abgene Absolute QPCR Rox Mix and genomic DNA 
(15 ng). The thermal profile consists of an initial denaturation step at 95oC for 15 minutes, 
followed by 40 cycles of denaturation at 92oC for 15 seconds and annealing and extension at 
60oC for 1 minute. Genotypes were scored by measuring allele-specific fluorescence using 
the SDS 1.2.3 software for allelic discrimination (Applied Biosystems). 
Statistical analysis
As the distribution of the data followed a normal distribution, MPA-AUCs are expressed as 
means ± SD. Statistical significance between the different genotype groups was assessed 
using ANOVA. The association between the occurrence of diarrhea/leucopenia and different 
SNPs was analyzed using the Chi-square test or Fisher’s exact test, where appropriate. In 
all analyses the significance level was 5%. We used a binary logistic regression model to 
investigate predictive factors for MPA-related leukopenia and diarrhea. When a consistent (a 
minimum of five of six time points) pattern in MPA AUC
0-12hr 
or MPAG/MPA ratio difference 
was observed for one genotype group, multivariate analyses were performed, using mixed-
model analysis of variance. In these models, the overall difference in MPA AUC
0-12hr 
or MPAG/
MPA ratio was analyzed after logarithmic transformation, adjusted for FD/CC arm, gender, 
age, enzyme-multiplied immunoassay technique/high-performance liquid chromatography 
analysis, delayed graft function, and creatinine clearance. Explanatory variables in the linear 
model were: study visit as within-patient categorical variable with six levels and various 
between-patient variables that were considered constant in time, such as gender and age 
at transplantation. No structure was imposed on the variances per visit and covariances 
between visits of repeated measurements of the outcome variables considered. Coefficients 
estimated from the mixed-model analysis of variance were back-transformed (antilog) to 
become interpretable as percentage changes in geometric mean values of the untransformed 
outcome variable. All statistical analyses were performed by use of SPSS version 16.0 
software (Chicago, IL, USA). 
For the haplotype analysis we performed a PHASE analysis 31. The program PHASE implements 
methods for estimating haplotypes from population genotype data. All the haplotypes that 
were estimated with > 98% and had a frequency of > 5% were included in the analysis 32. 
RESULTS 
The baseline characteristics of the 338 patients included in this study are summarized in 
Table 1. 
Table 1. Patient characteristics 
Gender (female / male) 130 / 208
Age mean yr (range) 49 (18-78)
Ethnicity (%):
- Caucasian
- Black 
- Asian 
- unknown
297 (88) 
10 (3)
14 (4)
17 (5)
Transplantation (1st, 2nd, 3rd, unknown) 298 (88%) /30 (9%) / 5 (2%) / 5 (2%)
Fixed-dose / Concentration-controlled MMF 180 / 158 
Delayed Graft Function: Yes / No  77 / 260
Tacrolimus / Ciclosporine 157 / 172
Panel reactive antibodies (< 10% / ≥ 10%)  308 / 26 
HLA-mismatches 
A
B
DR
0.91
1.12
0.86
Living / deceased donor 110 / 228 
Induction therapy: Yes / No 154 / 184 
MPA Pharmacokinetics
ABCB1 
The genotype frequencies of the various ABCB1 SNPs are shown in Table 2. The frequencies 
were all in Hardy-Weinberg equilibrium (Chi-Square test). The daily MMF dose was not 
significantly different between the different ABCB1 genotype groups. The ABCB1 1236C>T, 
2677G>T/A and 3435C>T SNPs were not associated with dose-adjusted MPA-AUC, as 
shown in Table 3 (co-medication Tac) and Table 4 (co-medication CsA). Next, we studied 
the effects of the ABCB1 haplotypes on the MPA-AUCs. Only 5 of the 18 estimated ABCB1 
haplotypes were observed with high frequency (>5%). These haplotype frequencies were: 
ABCB1 TT-TT-TT (13%), CC-GG-CC (17%), CT-GG-CC (12%), CT-GT-CT (31%), TT-GT-CT (8%). 
Each of the 13 remaining genotypes represented less than 3% of the patients’ combined 
ABCB1 genotypes. None of the MPA pharmacokinetic parameters was significantly 
associated with one of the ABCB1 genotypes (data not shown). 
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SLCO1B
The allelic frequencies of the SLCO1B1 and the SLCO1B3 polymorphisms are shown in 
Table 2. The frequencies were all in Hardy-Weinberg equilibrium. SLCO1B3 699G>A and 
SLCO1B3 344T>G have been reported to be in linkage disequilibrium and carriers of 
SLCO1B3 699A are often also carriers of the SLCO1B3 344G allele [25]. The same was seen 
in our study population (data not shown). For this reason and also because in the literature 
the most data exist on the SLCO1B3 344T>G genotype only the results of this genotype 
are provided. The daily MMF dose was not significantly different between the different 
SLCO1B3 genotypes. We analyzed the dose-adjusted MPA-AUC for patients co-treated 
with CsA and co-treated with Tac separately. In the CsA group no significant associations 
were found with regard to dose-adjusted MPA-AUC and the different polymorphisms in 
SLCO1B1 and SLCO1B3 (Table 4). For the patients co-treated with Tac no differences in 
dose-adjusted MPA-AUC were found in relation to SLCO1B1. On the other hand, when 
studying the SLCO1B3 SNP, we observed a significantly lower dose-adjusted MPA-AUC in 
patients with the SLCO1B3 344 TT genotype at month 1 and 3 compared with patients 
with the SLCO1B3 344 GT genotype (Table 3). At month 6 there was a trend to significance 
(P = 0.072). When we studied the corresponding MPAG/MPA metabolic ratio, there was 
a significant difference. The patients with the 344 TT genotype had a 24% lower MPAG/
MPA metabolic ratio (P = 0.038) compared to the 344 GG genotype and the patients with 
the 344 GT genotype had a 21% lower (P < 0.0001) MPAG/MPA metabolic ratio compared 
the 344 GG genotype. Next, we performed a mixed model analysis, adjusting for FD/CC 
arm, gender, age, enzyme-multiplied immunoassay technique/high-performance liquid 
chromatography analysis, delayed graft function, UGT and MRP2 SNPs and creatinine 
clearance. This did not result in identifying the SLCO1B3 genotype as a risk factor for lower 
MPA-AUCs, nor for the MPAG/MPA metabolic ratio. 
Incidence of diarrhea
Diarrhea was observed in 77 of the 338 patients, giving an overall incidence of 23%. The 
mean time to the first episode of diarrhea among these patients was 21 days after kidney 
transplantation (range 3 to 323 days). In 49 of the 77 patients (64%) the MMF dose was 
reduced, whereas no dose reduction was necessary in 28 episodes of diarrhea (36%). 
Mean daily MMF doses and MPA exposure were not different between the patients that 
experienced diarrhea compared to patients who did not suffer from diarrhea. This was 
observed when we analysed the whole follow-up period, or only the month 1 and month 
3 post-transplantation time points. 
However when we split up the group into Tac and CsA treated patients we observed a 
difference: in the Tac treated patients 45 patients (29%) suffered from diarrhea, while in 
the CsA group 33 patients (19%) suffered from diarrhea. As a result a 1.8 higher risk (OR: 
1.79, 95% CI 1.03 – 3.13; P = 0.038) of diarrhea was observed for patients co-treated with 
Tac compared with patients co-treated with CsA. 
In the Tac group the MPA AUCs were not different at any time point for patients suffering 
from diarrhea and patients that did not suffer from diarrhea. However, the MPAG/MPA 
metabolic ratio on day 3 in the Tac group was significantly lower for the patients that 
suffered from early diarrhea (diarrhea within the first 3 months after transplantation) 
compared to patients that did not suffer from diarrhea: 7 (diarrhea) vs. 5 (no diarrhea); 
P = 0.03. The MPAG/MPA ratio on days 3 or day 10 did not show any differences between 
patients with or without diarrhea that occurred within month 1 posttransplantation. 
When we compared the incidence of diarrhea in the Tac group between the different 
ABCB1 genotypes, the incidence of diarrhea was comparable between these groups (Table 
2). In the CsA group 33 of the 172 patients (19%) developed diarrhea with no significant 
difference between the different ABCB1 genotype groups (Table 2). Next, we investigated 
the effects of the ABCB1 haplotypes on incidence of diarrhea. In the unambiguous haplotype 
ABCB1 CC-GG-CC group, 11 (19%) patients developed diarrhea and in the ABCB1 TT-TT-TT 
group, 11 (26%) of the patients had diarrhea (Table 2). For the other ABCB1 haplotypes the 
following incidences for diarrhea were observed: CT-GG-CC: 9 (23%), CT-GT-CT: 22 (21%), 
TT-GT-CT: 7 (26%). None of the haplotypes was associated with the occurrence of diarrhea 
(P = 1.0).
Table 2. Frequencies of the genotypes, incidence of diarrhea and leukopenia.
Genotype No Diarrhea Diarrhea p-value No Leucopenia Leucopenia p-value
ABCB1 (n)
1236C>T
CC 117 (35%) 80% 20%
0.786
94 (80%) 23 (20%)
0.546CT 155 (47%) 77% 23% 131 (85%) 23 (15%)
TT 60 (18%) 75% 25% 51 (85%) 9 (15%)
2677G>T/A
GG 110 (34%) 79% 21%
0.868
88 (80%) 22 (20%)
0.589GT/TT 200 (62%) 77% 24% 168 (84%) 31 (16%)
GA 14 (4%) 79% 21% 12 (86%) 2 (14%)
3435C>T
CC 81 (24%) 79% 21%
0.683
70 (86%) 11 (14%)
0.172CT 173 (52%) 79% 21% 138 (80%) 35 (20%)
TT 78 (24%) 74% 26% 68 (88%) 9 (12%)
Haplotype* CGC 58 (17%) 81% 19%
0.999
48 (83%) 10 (17%) 0.433
Haplotype TTT 43 (13%) 74% 26% 38 (88%) 5 (12%)
SLCO1B1 (n)
T521C
CC 11 (3%) 80% 20%
0.654
9 (90%) 1 (10%)
0.395TC 91 (27%) 75% 25% 67 (79%) 18 (21%)
TT 234 (70%) 80% 20% 183 (85%) 33 (15%)
A388G
AA 102 (30%) 79% 21%
0.246
72 (81%) 17 (19%)
0.497AG 147 (44%) 75% 25% 116 (83%) 24 (17%)
GG 76 (23%) 85% 15% 64 (88%) 9 (12%)
SLCO1B3 (n)
T344G
GG 224 (66%) 78% 22%
0.007¥
176 (85%) 32 (15%)
0.336GT 100 (30%) 84% 16% 74 (82%) 16 (18%)
TT 13 (4%) 46% 54% 9 (69%) 4 (31%)
¥: significant (p < 0.05), between 344GG and 344TT
* Also the other ABCB1 haplotypes did not show any differences in incidence of diarrhea or leucopenia
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To study the influence of the MMF treatment arm on the incidence of diarrhea we analyzed 
the patients that received MMF in a fixed-dose separately from patients that received 
MMF in a concentration-controlled form. Again no statistically significant differences were 
found between the different ABCB1 genotypes (data not shown). 
When studying the SLCO1B SNPs, no association between diarrhea and SLCO1B1 
genotype was observed. However, patients with the SLCO1B3 344 TT genotype had a 
significantly higher incidence of diarrhea (54%) compared to patients with the SLCO1B3 
344 GG genotype (22%; P = 0.007; Table 2) and to patients with the GT genotype (16%; P 
= 0.006). 
To identify the risk factors for the development of diarrhea within one month, a logistic 
regression was performed. The following variables were included: ABCB1 genotype and 
haplotype, SLCO1 genotype, gender, age, MMF treatment (FD vs. CC), living/deceased 
donor, type of calcineurin inhibitor, creatinine values at day 10 and finally AcMPAG-AUC, 
MPAG-AUC, MPA-AUC, MPAG/MPA ratio (all day 10 levels). We did not identify any risk 
factors for the development of diarrhea. When leaving the AcMPAG out of the analysis (as 
this metabolite was only measured in 66 patients), this did not alter the results and we still 
could not identify any risk factors for diarrhea. 
Table 3. Dose adjusted MPA-AUC in patients using tacrolimus as co-medication according to ABCB1 and SLCO 
genotype
Dose-adjusted MPA-AUC (mg.h/L) ± SD 
Day 3 Day 10 Month 1 Month 3 Month 6 40 ± 80
ABCB1 (n)
1236C>T
CC 61 (39%) 50 ± 23 50 ± 32 61 ± 33 74 ± 47 80 ± 49 40 ± 80
CT 65 (41%) 46 ± 21 41 ± 21 55 ± 23 65 ± 22 69 ± 27 40 ± 73
TT 31 (20%) 44 ± 14 40 ± 18 53 ± 19 79 ± 27 24 ± 74 21 ± 78
2677G>T/A
GG 55 (36%) 53 ± 23 ¥ 50 ± 32 62 ± 32 71 ± 34 81 ± 45 84 ± 48
GT/TT 89 (59%) 44 ± 19 40 ± 20 55 ± 23 72 ± 30 74 ± 34 76 ± 45
GA 8 (5%) 36 ± 14 40 ± 14 41 ± 11 82 ± 83 53 ± 23 52 ± 16
3435C>T
CC 44 (28%) 49 ± 24 48 ± 33 58 ± 33 75 ± 48 76 ± 48 78 ± 52
CT 76 (48%) 47 ± 20 43 ± 21 55 ± 23 66 ± 28 73 ± 34 71 ± 36
TT 37 (24%) 45 ± 18 42 ± 22 58 ± 26 77 ± 27 76 ± 29 86 ± 51
SLCO1B1 (n)
T521C
CC 3 (2%) 72 ± 0.7 44 ± 17 57 ± 7 63 ± 8 49 ± 7 43 ± 11 
TC 40 (25%) 49 ± 24 47 ± 31 55 ± 32 83 ± 52 82 ± 43 77 ± 45 
TT 117 (73%) 46 ± 19 43 ± 23 57 ± 25 68 ± 27 72 ± 35 77 ± 45 
A388G
AA 53 (33%) 46 ± 22 46 ± 29 60 ± 30 74 ± 34 79 ± 41 79 ± 50 
AG 77 (48%) 46 ± 19 44 ± 24 57 ± 26 71 ± 30 74 ± 36 81 ± 46 
GG 26 (16%) 48 ± 20 43 ± 21 50 ± 24 69 ± 52 62 ± 34 55 ± 20 
SLCO1B3 (n)
T344G
GG 107 (66%) 49 ± 22 42 ± 25 54 ± 25 66 ± 31 70 ± 36 79 ± 50 
GT 46 (29%) 44 ± 18 52 ± 25 68 ± 31 88 ± 43 86 ± 40 73 ± 31 
TT 8 (5%) 44 ± 16 37 ± 17 44 ± 14 ¥ 60 ± 20 ¥ 62 ± 24 62 ± 16 
¥: significant (p < 0.05), but only for GT vs. TT
Incidence of leucopenia
In this study, 56 patients (17%) developed leucopenia. The daily MMF dose on days 3 and 
10, month 3, 6 and 12 was comparable between patients suffering from leucopenia and 
patients who did not experience leucopenia. Only at month 1 did we observe a significant 
difference in MMF dose: 2541 mg (95% CI: 2264-2817) vs. 2088 mg (95% CI: 1998-2178); 
P < 0.001 for patients suffering from leukopenia (n = 55) and those not suffering from 
leukopenia (n = 245), respectively. However, the corresponding MPA-AUC at day 3, month 
1, 3 and 6 was not different between patients with and those without leucopenia. Only at 
month 12 did we observe a significant difference in MPA-AUC between patients with (n 
= 32) and those without leucopenia (n = 164): (77 mg*h/L [95% CI: 60-95] vs. 61 mg*h/L 
[95% CI: 55-66; P = 0.03]), respectively. No differences were found when we analysed 
the incidence of leucopenia separately in Tac-treated patients and CsA-treated patients. 
In order to identify the relationship of ABCB1 SNPs and SLCO SNPs with leucopenia we 
investigated the different SNPs in relation to the incidence of leucopenia. No relationship 
between SNPs in these genes and the risk of developing leucopenia was identified as 
shown in Table 2. 
To identify other risk factors for leucopenia we performed a logistic regression. The 
following variables were included: ABCB1 genotype and haplotype, SLCO1 genotype, 
gender, age, MMF treatment (FD vs. CC), living/deceased donor, type of calcineurin 
inhibitor, induction therapy, creatinine values at day 10 and finally AcMPAG-AUC, MPAG-
AUC, MPA-AUC, MPAG/MPA ratio (all day 10 levels). We did not identify any risk factors for 
the development of leucopenia. Again when leaving the AcMPAG out of the analyses we 
still did not identify any risk factors for the development of leukopenia. 
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Table 4. Dose adjusted MPA-AUC in patients using ciclosporine as co-medication according to ABCB1 and SLCO 
genotype 
                Dose-adjusted MPA-AUC (mg.h/L) ± SD 
Day 3 Day 10 Month 1 Month 3 Month 6 Month 12
ABCB1 (n)
1236C>T
CC 55 (33%) 31 ± 10 29 ± 13 34 ± 12 41 ± 15 48 ± 14 46 ± 16
CT 84 (51%) 31 ± 10 31 ± 12 34 ± 17 44 ± 23 49 ± 24 48 ± 21
TT 27 (16%) 36 ± 16 30 ± 10 32 ± 11 41 ± 16 46 ± 14 45 ± 16
2677G>T/A
GG 53 (31%) 32 ± 10 30 ± 14 35 ± 13 43 ± 17 50 ± 15 45 ± 16
GT/TT 111 (65%) 32 ± 12 31 ± 12 33 ± 16 43 ± 21 48 ± 21 48 ± 19
GA 6 (4%) 30 ± 5 23 ± 3 27 ± 9 25 ± 10 35 ± 5 49 ± 10
3435C>T
CC 36 (22%) 32 ± 8 28 ± 9 32 ± 10 41 ± 15 48 ± 15 43 ± 16
CT 90 (54%) 31 ± 11 30 ± 12 35 ± 17 43 ± 23 48 ± 22 47 ± 18
TT 40 (24%) 33 ± 14 33 ± 14 33 ± 11 43 ± 16 48 ± 17 49 ± 20
SLCO1B1 (n)
T521C
CC 8 (5%) 38 ± 15 29 ± 8 37 ± 24 47 ± 19 54 ± 10 45 ± 13 
TC 49 (29%) 31 ± 12 29 ± 12 33 ± 19 43 ± 29 50 ± 25 50 ± 26 
TT 110 (66%) 32 ± 10 31 ± 13 34 ± 12 42 ± 15 47 ± 17 47 ± 17 
A388G
AA 48 (29%) 30 ± 9 27 ± 8 30 ± 12 36 ± 12 42 ± 15 45 ± 16 
AG 67 (40%) 33 ± 13 32 ± 14 35 ± 17 44 ± 17 49 ± 16 48 ± 17 
GG 46 (27%) 32 ± 9 32 ± 13 35 ± 15 45 ± 25 51 ± 24 45 ± 20 
SLCO1B3 (n)
T344G
GG 111 (66%) 31 ± 10 29 ± 12 33 ± 15 41 ± 17 45 ± 18 49 ± 21 
GT 51 (31%) 33 ± 13 33 ± 13 36 ± 14 48 ± 26 56 ± 22 46 ± 17 
TT 5 (3%) 37 ± 14 33 ± 8 26 ± 9 39 ± 17 52 ± 5 43 ± 14 
G699A AA 110 (66%) 31 ± 10 29 ± 12 33 ± 15 41 ± 17 45 ± 18 ¥ 48 ± 19 
GA 50 (30%) 33 ± 14 33 ± 13 37 ± 14 49 ± 26 56 ± 22 46 ± 17 
GG 5 (3%) 37 ± 14 33 ± 8 26 ± 9 39 ± 17 52 ± 5 43 ± 14 
¥: significant (p < 0.05) 
Table 5. Primer and probe sequences of ABCB1 and SLCO1B SNPs
SNP Sequence
ABCB1 C1236T Forward primer TCTCACTCGTCCTGGTAGATCTTG
Reverse primer CACCGTCTGCCCACTCT
VIC probe TCAGGTTCAGGCCCTT
FAM probe TCAGGTTCAGACCCTT
ABCB1 G2677A Forward primer AATACTTTACTCTACTTAATTAATCAATCATATTTAGTTTGACTCA
Reverse primer GTCTGGACAAGCACTGAAAGATAAGA
VIC probe TTCCCAGCACCTTC
FAM probe CTTCCCAGTACCTTC
ABCB1 G2677T Forward primer CTTAGAGCATAGTAAGCAGTAGGGAGT
Reverse primer GAAATGAAAATGTTGTCTGGACAAGCA
VIC probe TTCCCAGCACCTTC
FAM probe TTCCCAGAACCTTC
ABCB1 C3435T Forward primer ATGTATGTTGGCCTCCTTTGCT
Reverse primer GCCGGGTGGTGTCACA
VIC probe CCCTCACGATCTCTT
FAM probe CCCTCACAATCTCTT
Rs-number Assay ID
SLCO1B1 388A>G Rs 2306283 C__1901697_20
SLCO1B1 521T>C Rs 4149056 C__30633906_10
SLCO1B3 334T>G Rs 4149117 C__25639181_40
SLCO1B3 699G>A Rs 7311358 C__25765587_40
DISCUSSION
This study provides evidence that the pharmacokinetics of MPA is not influenced by the 
investigated SLCO1B or ABCB1 SNPs. Although, in the univariate analysis we found that 
patients homozygous for the SLCO1B3 344T allele had significantly lower dose-adjusted 
MPA-AUC compared to the SLCO1B3 344GT genotype, the multivariate regression did not 
identify the SLCO1B3 genotype as a risk factor for lower MPA-AUCs. The same was shown 
for the corresponding MPAG/MPA metabolic ratio.
In a study from Miura et al. the dose-adjusted MPA-AUC
6-12
 was significantly higher in 
patients with the SLCO1B3 344GG genotype compared to the 334TT genotype 26. Miura 
et al. however studied only 87 patients for a shorter time period. Conversely, Picard et 
al. reported a higher MPA exposure in SLCO1B3 344T allele carriers compared with 
patients with the SLCO1B3 344GG genotype, which was attributed to a probably reduced 
enterohepatic cycling in these patients. These conflicting results were not confirmed by 
our study as we observed no significant association between MPA exposure and SLCO1B3 
SNPs. Recently Jacobson et al. 33 also found no association with MPA toxicity and SLCO1B3 
SNPs.
We did not find associations between the different genotypes and the incidence of 
diarrhea. However, a 1.8 higher risk (OR: 1.79, 95% CI (1.03 – 3.13 P = 0.038)) of diarrhea 
was observed for patients co-treated with Tac compared with patients co-treated with 
CsA. This is in line with the literature. The lower incidence of diarrhea in patients receiving 
CsA, confirmed in this study, may be due to inhibition of biliary excretion of MPAG or the 
AcMPAG metabolite in the gut 14, 34-35. Other pathophysiological mechanisms however 
may also play a role. For example, recently, Liu et al. 36 have shown that MPA dramatically 
increased the secretion of IL-1ß. This increased IL-1ß concentration could result in more 
diarrhea through an increased apoptosis of gastrointestinal cells. Alternatively, MPA is a 
selective inhibitor of IMPDH, which is involved in de production of purines for lymphocytes 
and is also involved in the replication of gastrointestinal epithelial cells. If IMPDH would be 
inhibited, the replication of gastrointestinal epithelial cells would decrease, which could 
result in disruption of fluid absorption and in diarrhea 37-38. However, IMPDH activity was 
not measured routinely in the FDCC cohort.
In the literature there is not so much evidence for the relationship between polymorphisms 
in ABCB1 and the development of leucopenia. Fukuda et al. reported a trend for patients 
that were homozygous for ABCB1 3435CC genotype and the development of leucopenia. 
However, only 8 pediatric kidney transplant recipients developed leucopenia in that 
cohort after receiving MMF, whereas there were only three patients with the ABCB1 
3435CC genotype. We studied a larger cohort prospectively and could not replicate the 
findings of Fukuda et al. 27. We also did not find a relationship for the SLCO1B genotype and 
leucopenia. Other genes, such as UGT might be associated with leucopenia. In a study in 38 
pediatric renal transplant recipients an association between the UGT1A9 polymorphism 
and leucopenia was identified. The patients that were homozygous for UGT1A9 -331T>C 
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developed leukopenia 39. However, after studying 2724 SNPs by Jacobson et al. 33 none of 
these SNPs were associated with leucopenia. 
In the present study, SLCOB1 and ABCB1 genotype was not found to be associated with 
changes in the MPA pharmacokinetics nor with the incidence of diarrhea or leucopenia 
in MMF-treated renal transplant recipients. Sawamoto et al. and also Wang et al. 22-23 
previously showed in vitro and in an animal study, that MPA is a substrate for ABCB1. 
However, they both studied the expression and function of the ABCB1 protein and not 
the effect of polymorphisms in the ABCB1 gene 22-23. The latter may have only a limited 
effect on ABCB1 protein expression and function. Another explanation for the absence of 
any significant association between MPA pharmacokinetics and ABCB1 SNPs in this study 
could be that the relative contribution of the ABCB1 transporter to MPA disposition is 
limited compared to that of other transporter proteins. Diarrhea is a frequent side effect 
of MMF, and as this frequently results in a MMF dose reduction, diarrhea may lead to 
graft loss because of under-immunosuppression. For that reason it is important to initiate 
studies that aim to find risk factors for this side effect. Based on the present findings, 
genotyping for ABCB1 or SLCO1B pre-transplantation is unlikely to be of clinical value for 
individualisation of MPA therapy. 
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With great interest we read the article by Jacobson et al. 1 who observed that single-
nucleotide polymorphisms (SNPs) in IL12A (rs568408G>A), CYP2C8 (rs11572076G>A), and 
HUS1 (rs1056663C>T) are associated with the occurrence of mycophenolic acid (MPA)-
related anemia but not leucopenia. These SNPs were identified by studying 978 renal 
transplant recipients by use of customized, commercially available gene chips that included 
a total of 2724 polymorphisms. Although the exact pathophysiological mechanism of these 
genotype-phenotype associations are not known, IL-12 mRNA levels were previously 
shown to be elevated in patients with aplastic anemia, HUS1 appears to be involved in 
the cellular response to DNA damage, and CYP2C8 may produce the 6-O-desmethyl-MPA 
metabolite.
However, the data of Jacobson et al. 1 were not confirmed in an independent cohort. The 
aim of our study was to investigate whether these SNPs are indeed associated with the 
occurrence of MPA-related anemia and leucopenia after kidney transplantation.
The patients described herein were de novo kidney transplant recipients who 
participated in a trial comparing Fixed-Dose (FD) mycophenolate mofetil (MMF) treatment 
with Concentration-Controlled (CC) MMF treatment. The primary outcomes of this so-
called FDCC trial were reported previously 2. Immunosuppressive therapy consisted of 
MMF combined with ciclosporine or tacrolimus, and prednisolone according to local 
practice. Anemia was defined as a hemoglobin level <11.3 g/dL (7.0 mmol/L) occurring 
after day 28 post-transplantation. Leucopenia was defined as a total leukocyte count 
<3.0 x 109/L. Of the total of 901 patients participating in the FDCC trial, 338 agreed to 
participate in a pharmacogenetic substudy. Genomic DNA was isolated from 200 µL EDTA 
whole-blood using a MagnaPure LC (Roche Diagnostics GmbH, Mannheim, Germany). 
Allelic discrimination reactions were realized using TaqMan® (Applied Biosystems, CA, 
USA) genotyping assays (C___2423981_10, C___1825446_20 and C__31658115_10) for 
rs568408G>A in IL12A, rs1056663C>T in HUS1, and rs11572076G>A in CYP2C8 on a ABI 
PRISM 7500® fast real-time PCR System (Applied Biosystems) using 20 ng genomic DNA 
according to the manufacturer’s instructions. For this analysis, data on the incidence of 
anemia and leucopenia of 332 of the 338 patients were available. Patients who received 
fixed-dose MMF (n=178) were analyzed separately from those that received concentration-
controlled MMF (n=154). Only in the concentration-controlled group was the MMF dose 
adjusted on the basis of repetitive pharmacokinetic sampling results 3.
The allele frequencies of the various SNPs were as follows: CYP2C8 G 99.5%, CYP2C8 A 
0.5%, IL12A A 15.1% and IL12A G 84.9%, and HUS1 C 51.1% and HUS1 T 48.9%. They were all 
in Hardy-Weinberg equilibrium. When we studied the allele frequencies in the fixed-dose 
and the concentration-controlled group separately, comparable allele frequencies were 
observed, with the exception of the distribution of the CYP2C8 SNP in the concentration-
controlled group: In this group all patients had the GG genotype. 
Anemia occurred in 65 patients (37%) in the fixed-dose group and in 61 patients (40%) 
in the concentration-controlled group, which was not significantly different (P=0.56). No 
significant differences in the frequency of the investigated IL12A and HUS1 SNPs were found 
between patients with and those without anemia in the fixed-dose and concentration-
controlled groups (Table 1). For the CYP2C8 SNP a significant association (P=0.021) was 
observed in the fixed-dose group with 100% of patients with the CYP2C8 rs11572076GA 
genotype having anemia (Table 1). However, only three patients (2%) had the GA genotype, 
yielding low statistical power. In fact, based on the reported (ref Jacobson) increased 
relative risk (2.1) of developing anemia in association with the CYP2C8 A variant allele, a 
sample size of 2200 patients (22 patients with anemia and 2178 control subjects) would 
have been necessary to have an 80% power with an alpha of 0.05% to reject the null 
hypothesis. However, this being a substudy of the completed FDCC trial, we feel that one 
should be cautious about performing such posthoc sample size calculations
The incidence of leucopenia was comparable in the fixed-dose and concentration-
controlled groups: 24 patients (14%) versus 32 patients (21%), respectively (P=0.10). No 
significant associations were observed between the different IL12A and HUS1 SNPs and the 
incidence of leucopenia, both in the concentration-controlled and the fixed-dose groups 
(Table 1). However, a significant association between the CYP2C8 rs11572076G>A SNP 
and leucopenia was observed in the fixed-dose group with patients carrying the variant 
allele having a higher risk of developing this adverse event: 67% (n=2) versus 13% (n=22), 
respectively (P=0.007; Table 1). 
Our results support the observation made by Jacobson et al. 1 that CYP2C8 rs11572076A 
allele carriers have a higher risk to develop anemia. However, the actual number of 
patients carrying this variant allele was rather small and therefore -despite the fact that 
this association was confirmatory- the possibility of a spurious finding remains. The 
association of the CYP2C8 rs11572076A allele with anemia was observed in the fixed-dose 
MMF group. In contrast to patients who received a concentration-controlled MMF dose 
(where any effects of genetic variation may be obscured by therapeutic drug monitoring), 
no dose adjustment based on plasma MPA concentrations was made in the fixed-dose 
group, allowing for the full expression of the clinical consequences of this SNP. A similar 
difference on the impact of pharmacogenetics between fixed-dose and concentration-
controlled treated patients was reported previously 3. We could not confirm the association 
with anemia and the IL12A rs568408G>A and the HUS1 rs1056663C>T SNPs. This may be 
explained by the fact that the size of the population we studied was smaller than that 
studied by Jacobson et al. 1 (n = 332 versus n = 978, respectively) and the resulting lower 
statistical power to detect such an association 4-6.
In addition, we found a significant association of the CYP2C8 genotype with the 
incidence of leucopenia. However, the frequency of the CYP2C8 rs11572076A variant allele 
was only 0.5% and is therefore alone insufficient to explain the much higher incidences of 
anemia and leucopenia that frequently complicate the use of MPA 7. Other factors, such as 
exposure to MPA, are in our view much more important determinants of hematologic MPA 
toxicity 8. Moreover, following transplantation, blood counts are frequently monitored 
and after a MMF dose reduction, anemia and leucopenia are often rapidly reversible. We 
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therefore conclude that although the CYP2C8 genotype appears to be associated with the 
risk of developing anemia and leucopenia, a pharmacogenetic approach is at present not 
helpful to reduce the risk MPA-related hematologic toxicity.
Table 1. Incidence of anemia and leucopenia in relation to SNPs in the CYP2C8, IL12A, and HUS1 genes in 332 
patients (fixed-dose group = 178 and concentration-controlled group = 154) receiving MMF as part of the FDCC trial. 
SNP and number of 
patients (frequencies)
Fixed-Dose group  
(n = 178)
Concentration-controlled  
group (n = 154)
Anemia P-value Leucopenia P-value Anemia P-value Leucopenia P-value
CYP2C8 (rs11572076)
GA
GG
3 (100%)
62 (35%)
0.021# 2 (67%)
22 (13%)
0.007# 0 (0%)
61 (40%)
Not 
tested
0 (0%)
32 (21%)
Not 
tested
IL12A (rs568408)
AA
GA
GG 
0 (0%)
20 (44%)
45 (35%)
0.31 0 (0%)
7 (15%)
17 (13%)
0.80 4 (50%)
17 (50%)
40 (36%)
0.27 2 (25%)
3 (9%)
27 (24%)
0.15
HUS1 (rs1056663)
CC
CT
TT
16 (41%)
31 (32%)
18 (44%)
0.31 8 (21%)
12 (12%)
4 (10%)
0.32 11 (26%)
34 (43%)
16 (49%)
0.10 9 (21%)
16 (20%)
7 (21%)
0.99
# = significant; P < 0.05
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Kidney transplantation is the preferred therapy for patients with end-stage renal disease 1.
Unfortunately, there is a shortage in donor kidneys, resulting in long waiting times for 
kidney transplantation. Waiting time is on average more than 4 years in the Netherlands 
(Nederlandse Transplantatie Stichting). Transplantation is not a cure, it’s an on-going 
treatment and the patients are required to take immunosuppressive drugs for the rest 
of their lives. Transplanted kidneys have a limited life span and many patients require 
a re-transplantation. These re-transplantations further contribute to the shortage in 
available kidneys. Optimizing longevity of the kidney transplant and using ‘the right’ 
immunosuppressive treatment after transplantation is essential. But what is ‘the right’ 
immunosuppressive treatment? ‘The right’ immunosuppressive treatment could be 
different for every patient. Individualization of immunosuppressive therapy after organ 
transplantation remains a challenge for every clinician. Individualization or personalization 
of drug treatment involves the implementation of clinical pharmacological technology 
to adjust for the differences between individuals. This includes the application of 
pharmacogenetics and therapeutic drug monitoring.
In chapter 2 we have studied the pharmacogenetics of calcineurin inhibitors. In chapter 
2.1 we have studied whether the polymorphisms in CYP3A5, CYP3A4 and ABCB1 affect 
clinical endpoints in kidney transplant recipients treated with ciclosporine. This study 
has shown that determination of CYP3A and ABCB1 SNPs before transplantation are not 
helpful in identifying patients at high risk of experiencing acute rejection or nephrotoxicity. 
A pharmacokinetic association with ciclosporine and the already mentioned genes could 
also not be found in this study. The genetic polymorphisms in CYP3A5, CYP3A4 and ABCB1 
are therefore not useful in determining the appropriate dose of ciclosporine for individual 
patients. Possibly a study of the pharmacogenetics of the donor might be more promising, 
especially with respect to the risk of developing severe nephrotoxicity 2, 3. One could 
imagine that the activity of the ABCB1 protein (P-glycoprotein) would determine the intra-
cellular accumulation of ciclosporine, and thus be linked to nephrotoxicity. In chapter 2.2 
we conclude that CYP3A4*22 T-variant allele significantly affects the pharmacokinetics of 
tacrolimus. Although there is a statistically significant association between genotype and 
pharmacokinetics this does not necessarily mean that using the genotype for individualized 
dosing of the drug will improve the clinical outcome. How much of the variability between 
patients will the genotype explain and what is the clinical benefit from the use of this 
genotype? The ultimate goal is not a better pharmacokinetic profile of tacrolimus, but a 
better clinical outcome, i.e. less toxicity or more efficacy of the drug. However, CYP3A4*22 
might be a guide to reach this goal. So far, CYP3A5*1 stays the strongest predictor for tailoring 
tacrolimus treatment, but also for CYP3A5, before implementation into the routine clinical 
care of transplant recipients, prospective clinical trials are needed to decide whether such 
a pharmacogenetic dose approach will improve the clinical outcomes. We are currently 
performing a randomized-controlled clinical trial (Dutch trial registry number NTR2226, 
www.trialregister.nl). In this trial patients are randomized to receive either a tacrolimus 
dose based on their CYP3A5 genotype of a standard tacrolimus dose only based on their 
body weight. However, not all the pharmacokinetic variability is explained by the CYP3A5 
genotype 4. The CYP3A4*22 T-variant allele might help to explain the additional variation. 
We have found that kidney transplant patients carrying the CYP3A4*22 T allele had a lower 
tacrolimus dose requirement. This effect was independent of CYP3A5. So the CYP3A4*22 
allele might be useful to fine-tune the tacrolimus starting dose after transplantation. 
Recently Elens et al. 5 confirmed this with a more detailed pharmacokinetic analysis in a 
Belgium population. She provided evidence for refining the genotype-based tacrolimus 
dosage by adding the CYP3A4*22 genotype to the CYP3A5*3 genotype. Using the algorithm 
for tacrolimus dosing of Passey et al. (6 2011) and incorporating the CYP3A4*22 allele 
improved the precision of this algorithm 5. In chapter 2.3 we have shown that this recently 
identified CYP3A4*22 SNP is also a risk factor for developing delayed graft function and for 
impaired renal function, although, these were renal transplant patients who were treated 
with ciclosporine. This adds more evidence to incorporate the CYP3A4*22 genotype into a 
genotype-based dosage guideline.  
In chapter 2.4 we have tested whether the ABCB1 3435C>T genotype influences the 
intracellular IL-2 production (as a measurement for the immunosuppressive effect of 
tacrolimus) in T-cells. We have found that the ABCB1 3435C>T SNP influences ABCB1 
activity and therefore the pharmacodynamic effect of tacrolimus in kidney transplant 
patients. We have performed in vitro experiments and show that if we block the ABCB1 
pump with a ABCB1 blocker verapamil the cytokine production was enhanced in patients 
with the ABCB1 3435CC genotype (the active form of the ABCB1 pump), but not in patients 
with the ABCB1 3435TT genotype. These results show that tacrolimus has a smaller effect 
in patients with an active ABCB1 pump, as the intracellular tacrolimus will be pumped out 
to the extracellular fluid by the ABCB1 pump. The evidence is supported by a study from 
Capron et al. 7 who described that renal transplant recipients carrying the ABCB1 3435T 
allele had higher tacrolimus concentration within the lymphocytes. While these results are 
promising, more studies are needed to conclude whether the ABCB1 3435C>T genotype 
will be a biomarker for the tacrolimus dose. 
An already extensively used tool to individualize the immunosuppressive therapy 
is therapeutic drug monitoring (TDM) 8. As part of clinical practice in the vast majority 
of transplant centers the tacrolimus concentrations are monitored. A drug should fulfill 
certain criteria to be suitable for therapeutic drug monitoring 9. These criteria include 
availability of a cost-effective drug assay, established target concentration range, a 
narrow therapeutic window, significant inter-individual pharmacokinetic variability and 
a reasonable relationship between the plasma (or whole-blood) concentration and the 
clinical effect. For tacrolimus, which is often used, one would think that a ‘reasonable 
relationship between the whole-blood concentration and the clinical effect’ and therefore 
an ‘established target concentration range’ has been shown extensively. Surprisingly this is 
not the case. In chapter 4 we studied whether the tacrolimus predose concentrations are 
related to the risk of acute rejection after transplantation. A large cohort of 1304 transplant 
recipients was used. No clear concentration-effect relationship was found. For example, 
Chapter 6
182 183
Chapter
6
patients with lower tacrolimus concentration did not have more rejections. One could 
argue that the lack of a clear concentration-effect relationship would be a strong argument 
to stop with TDM. Our study however does not imply that TDM for tacrolimus is useless. 
Without TDM the large between-patient variability in tacrolimus pharmacokinetics would 
go unnoticed, and extremes in tacrolimus exposure would occur, exposing some patients to 
toxic levels and others to very low levels. Based on our analysis however it is not possible to 
conclude that the tacrolimus target concentrations should be above, for example, 5 or 10 
ng/mL. Possibly the threshold for efficacy is at a concentration that is even lower than the 
currently applied targets, and it is possible that only when concentrations reach values as 
low as 1 or 2 ng/mL the incidence of BPAR starts to increase. Probably the used tacrolimus 
doses nowadays are too high. Unfortunately, in the dataset used for this study we could 
not investigate the correlation between toxicity and tacrolimus exposure. With the current 
dosing regimen, toxicity of tacrolimus might be a larger problem than underexposure. 
Recently however, Israni et al. 10 did find an association with risk of rejection in the first six 
months and tacrolimus trough levels after month 3. The tacrolimus concentrations which 
are measured for TDM purposes in daily practice are in whole blood. However, the site 
of action of tacrolimus is within the lymphocyte. Tacrolimus concentrations in peripheral 
blood mononuclear cells are not 1:1 correlated with whole blood (or erythrocyte) 
concentrations, for example, due to the presence of drug transporting enzymes in the cell 
membranes of lymphocytes 11, (see also chapter 2.4). Therefore tacrolimus concentrations 
within lymphocytes might be a better predictor of immunosuppressive efficacy than the 
whole blood predose concentration. Assays to measure tacrolimus in lymphocytes have 
been described 12. Capron et al. 13 have studied the correlation between acute rejection and 
the tacrolimus concentration within the lymphocytes. They have found that the tacrolimus 
concentration in the lymphocytes is inversely correlated to the risk of acute rejection in 
liver transplant recipients; lower intracellular tacrolimus concentration means a higher 
incidence of acute rejection. Interestingly, they also concluded that the whole-blood 
tacrolimus concentrations were not related to the rejection risk. Future studies should 
study the relationship between intracellular tacrolimus concentrations and rejection risk 
in kidney transplant recipients in more detail and the tissue concentration of tacrolimus in 
relation to its toxicity should also be included. 
The general opinion regarding the need for TDM for tacrolimus is different for 
mycophenolic acid (MPA). For MPA a concentration–effect relationship has been shown 
repetitively and in a randomized-controlled clinical trial it was also shown that with TDM it 
is possible to reduce the incidence of acute rejection in kidney transplant patients at low 
to moderate immunological risk 14. Despite compelling evidence for the added value of 
TDM for MPA, many transplant centers do not perform TDM for MPA. In chapter 5 we have 
performed studies on the pharmacogenetics of MPA, with a focus on its toxicity. In clinical 
practice the use of MPA is complicated by the frequent occurrence of gastrointestinal 
adverse effects, especially diarrhea. The gastrointestinal side effects are an important 
reason for noncompliance 15. In chapter 5.1 we have studied whether polymorphisms in 
SLCO1B and ABCB1 are associated with MPA-related diarrhea. On the basis of our findings, 
genotyping for ABCB1 or SLCO1B pre-transplantation is unlikely to be of clinical value for 
individualization of MPA therapy. Hematologic side effects, such as anemia and leucopenia 
are another common side effect of MPA. Jacobson et al. 16 found that SNPs in IL12A, CYP2C8 
and HUS1 are associated with the occurrence of MPA-related anemia but not leucopenia. 
In chapter 5.2 we tried to confirm these findings. Our results support the observation 
made by Jacobson et al. that CYP2C8A (rs11572076G>A) allele carriers have a higher risk 
to develop anemia. However, the actual number of patients carrying this variant allele was 
small and therefore the possibility of a spurious finding remains. We could not confirm 
the association with anemia and the IL12A (rs568408G>A) and HUS1 (rs1056663C>T). This 
may be explained by the fact that the size of the population we studied was smaller than 
that studied by Jacobson et al. (n = 332 vs. n = 978, respectively) and the resulting lower 
statistical power to detect such an association. Although the CYP2C8A allele carriers have a 
higher risk to develop anemia, blood counts are frequently monitored after transplantation 
and after a MMF dose reduction, anemia and leucopenia are often rapidly reversible. 
Therefore the conclusion form this study is that although the CYP2C8 genotype seems 
to be associated with the risk of developing anemia and leucopenia, a pharmacogenetic 
approach is at present not helpful to reduce the risk of MPA-related hematologic toxicity. 
It is therefore not recommended to dose the MPA differently or to choose for example for 
azathioprine in transplant patients with the CYP2C8A allele. 
The studies mentioned above investigated the inter-patient variability, i.e. the differences 
in pharmacokinetic between patients. However, tacrolimus pharmacokinetics is also 
characterized by intra-patient variability, the variability within one patient over time. In 
daily practice this is visualized by fluctuating tacrolimus concentrations in patients with 
a stable tacrolimus dose. Recently, Borra et al. 17 demonstrated that a high variability in 
tacrolimus predose concentrations was a risk factor for graft loss in renal transplant patients. 
A determinant for higher intra-patient variability could be an individual’s cytochrome P450 
3A (CYP3A) genotype. Korean investigators 18 have suggested that not only inter-patient 
variability but also intra-patient variability is correlated with CYP3A5 genotype. This was 
explained by the fact that in patients without functional CYP3A5 enzyme, the metabolism 
of tacrolimus depends exclusively on the activity of CYP3A4. Because the CYP3A4 enzyme 
is more sensitive to induction and inhibition, CYP3A5 nonexpressers could be more prone 
to variable tacrolimus clearance over time. In chapter 3.1 this hypothesis was investigated, 
by correlating the intra-patient variability in tacrolimus clearance to the CYP3A5 genotype 
in the renal transplant patient used by Borra et al. 17 A relationship between the CYP3A5 
genotype and the tacrolimus clearance was not found. The study from Yong Chung et al. 
who did find a relationship performed a more detailed pharmacokinetics analysis and 
the study population was different. Our study population (N = 208) consisted of renal 
transplant patients, whereas Yong Chung studied healthy volunteers (N = 29) with no co-
medication and who used two different formulations of tacrolimus. Moreover the study 
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population by Yong Chung et al. consisted exclusively of Korean subjects and we had mainly 
Caucasian subjects and only 10% Asian subjects. We cannot rule out the possibility that the 
CYP3A4 enzyme of Koreans is more susceptible to induction or inhibition than the CYP3A4 
enzyme of whites. 
Another factor that might explain a higher intra-patient variability in tacrolimus 
pharmacokinetics is poor adherence to medication in timing and/or frequency of ingestion. In 
chapter 3.2 we have also studied the influence of intra-patient variability in heart transplant 
patients. In the heart transplant recipients, in contrast to the renal transplant recipients, a 
relationship between the intra-patient variability in tacrolimus pharmacokinetics and the risk 
on cardiac allograft vasculopathy was not found. This discrepancy between renal and heart 
transplant patients might be explained by the use of more control visits in heart transplant 
recipients compared to renal transplant recipients. Although the main immunosuppressive 
regimen in both groups consists of MPA and tacrolimus and prednisolone, the heart 
transplant patients use the prednisolone for a longer period of time and they have more 
out-patient visits in the first year compared to renal transplant patients. A progression in the 
disease might be noticed at an earlier stage, but also non-adherence to the therapy might 
be noticed earlier. This difference may have contributed to the contrasting outcomes of the 
two studies. Moreover, the number of investigated patients was relatively low, and therefore 
our study may not have enough statistical power to identify the association between intra-
patient variability and the progression of vascular disease. Studies focusing on the intra-
patient variability should be performed to clarify the causes for this phenomenon.
The promise of individualizing immunosuppressive drugs has not yet been realized. 
Some investigators have designed a dosing algorithm that incorporated all the factors that 
influenced the pharmacokinetics of the immunosuppressive drugs, in order to reach ‘the 
right immunosuppressive treatment’ after solid organ transplantation (6, 19, 20, 21 novel 
polymoprhimsms). However, a validation of the recently developed DeKAF algorithm for 
dosing tacrolimus failed to accurately predict the tacrolimus clearance 22. Using real time 
tacrolimus doses and blood concentrations from an independent cohort did not show 
a good performance of the algorithm. The DeKAF algorithm took into account several 
clinical parameters, and for pharmacogenetics it only incorporated the CYP3A5 genotype. 
A polygenic algorithm incorporating also other genes known to influence the clearance of 
tacrolimus, including ABCB1, CYP3A4*22, POR*28 and PXR may be more predictive. However 
to conclude that the additional genetic variants (next to the CYP3A5 genotype) explain the 
residual variability in tacrolimus requirement, the reported associations should be confirmed 
in independent cohorts. It then may become possible to develop an accurate starting dose 
for tacrolimus and under- or overexposure to tacrolimus may be prevented. We should 
however also include the pharmacogenetics of the donor. After identification of the different 
polymorphisms that have an influence on the immunosuppressive pharmacokinetics and 
pharmacodynamics, we might have a better ‘dosing algorithm’ for the transplanted patients. 
However even when we use this pharmacogenetic dosing approach, a large proportion 
of overall variability will remain unexplained. Therefore the pharmacogenetics must go 
hand in hand with TDM, which is used to correct for the remainder of variability in the 
pharmacokinetics. As already mentioned intracellular tacrolimus concentrations might 
be more valuable to measure, and assays applying LC-MS are being developed, also in 
our center. However also here randomized clinical trials should be performed to define 
the optimal intra-cellular tacrolimus therapeutic window. When we would genotype the 
transplanted patients before their transplantations and after the transplantation we follow 
them with the right TDM measurements, we might help physicians to adapt the daily dose 
of the immunosuppressant to avoid major episodes of under- or overdosing and aspire to 
the ‘right immunosuppressive treatment’ after transplantation. 
CONCLUSION OF THIS  THESIS
· The SNPs in CYP3A and ABCB1 do not influence the ciclosporine pharmacokinetics 
and pharmacodynamics.
· The tacrolimus dose-adjusted trough blood concentration is higher in CYP3A4*22 T 
variant allele carriers.
· The CYP3A4*22 T variant allele carriers have also more delayed graft function and a 
poorer renal function when patients are treated with ciclosporine. 
· The SNPs in CYP3A and ABCB1 do not influence the ciclosporine mediated 
nephrotoxicity.
· The ABCB1 3435C>T variant allele causes increased intralymphocytic tacrolimus 
accumulation.
· CYP3A5 expressers do not have a higher within patient variability in the apparent oral 
clearance of tacrolimus.
· A high within-patient variability in the apparent oral clearance of tacrolimus is not a 
risk factor for the progression of cardiac allograft nephropathy.
· Tacrolimus predose concentrations do not predict the risk of acute rejection after 
renal transplantation. 
· Polymorphisms in the SLCO1B and ABCB1 do not influence the occurrence of MPA 
related diarrhea.
· CYP2C8A allele carriers have more MPA related anemia and leucopenia. 
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Scientific summary
Currently, immunosuppressive therapy for the prevention of acute rejection after kidney 
transplantation mostly consists of the combination of a calcineurin inhibitor (CNI), either 
cyclosporine or tacrolimus, plus mycophenolic acid (MPA), and glucocorticoids with or 
without induction therapy with an interleukin (IL)-2 receptor blocker or a T-lymphocyte 
depleting agent. With immunosuppressive drug combination therapy, patient and kidney 
allograft survival have greatly improved. 
Chapter 2 discusses the studies on the relationship between single-nucleotide polymorphisms 
(SNPs) in CYP3A and ABCB1 and the pharmacokinetics and pharmacodynamics of CNIs. In the 
first chapter (2.1) we have shown that the studied SNPs in CYP3A4, CYP3A5 and ABCB1 cannot 
explain the high interindividual pharmacokinetic variability of cyclosporine. In addition, 
the incidence of biopsy-proven acute rejection and the renal function were not associated 
with SNPs in these genes. In the next two chapters (2.2 and 2.3) we studied the recently 
discovered CYP3A4*22 SNP. In paragraph 2.2 we show that in kidney transplant recipients 
on cyclosporine therapy, the CYP3A4*22 T allele emerges as a risk factor for delayed graft 
function and impaired renal function. Chapter 2.3 describes the study of the CYP3A4*22 SNP 
with respect to tacrolimus PK. It is shown for the first time that the CYP3A4*22 SNP in kidney 
transplant recipients is associated with reduced tacrolimus clearance. We have demonstrated 
in this study that kidney transplant recipients who carry 1 or 2 T alleles require a 33% lower 
mean tacrolimus dose to reach their target predose concentration compared to wild-type 
patients. The fourth paragraph of this chapter studied the influence of the ABCB1 3435C>T 
SNP on the pharmacodynamics of tacrolimus. In an in vitro study it was demonstrated that 
the tacrolimus-mediated inhibition of cytokine production in T-cells was enhanced by the 
ABCB1 inhibitor verapamil. We show that in kidney transplant recipients who were on 
tacrolimus therapy and have the ABCB1 3435CC genotype, which encodes the active ABCB1 
variant, verapamil decreased IL-2 production. On the other hand, in patients with the ABCB1 
3435TT genotype, the inactive variant, verapamil did not influence cytokine production. 
We have also calculated the requirement of tacrolimus in renal transplantation, by using 
the ratio of tacrolimus trough levels and percentage of IL-2 producing T-cells. The ratio was 
significantly higher in CD8+ T-cells of patients who have an active ABCB1 pump (3435CC 
genotype) compared to 3435TT genotype. This implies that tacrolimus had a smaller effect 
in kidney transplant recipients with the 3435CC genotype. In the last paragraph (2.5) we 
have studied the literature to review whether pharmacogenetic factors explain part of the 
interpatient variability in susceptibility to develop calcineurin-induced nephrotoxicity. We 
have found evidence in the literature that ABCB1 and to lesser extent CYP3A5 is implicated in 
the pathogenesis of CNI-induced renal dysfunction. In addition, SNPs in ABCB1 and CYP3A5 
explain part of the interindividual differences in the susceptibility to the nephrotoxic effect 
of CNIs, although conflicting results have been published. 
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Next to the interindividual differences in the pharmacokinetics of immunosuppressive 
therapy we have studied in chapter 3 the intrapatient variability of tacrolimus 
pharmacokinetics. In the first paragraph (3.1) we studied kidney transplant recipients 
and found no significant associations between the intrapatient variability in tacrolimus 
clearance and the CYP3A5 genotype. In the second paragraph we have studied the 
intrapatient variability in tacrolimus clearance in heart transplant recipients. We have 
studied whether a high within-patient variability in tacrolimus clearance is associated 
with more rapid progression of cardiac allograft vasculopathy. However, the study shows 
that the intrapatient variability in tacrolimus pharmacokinetics is not correlated with graft 
vascular disease at 4 year after transplantation nor to acute rejection in heart transplant 
recipients.
Chapter 4 is dedicated to therapeutic drug monitoring. After treatment with tacrolimus 
TDM is universally applied. However, the concentration-effect relationship for tacrolimus 
is poorly defined. We have investigated whether the tacrolimus concentrations are 
associated with acute rejection in kidney transplant recipients. We have pooled data 
from three large clinical trials and studied the relationship between biopsy proven acute 
rejection and tacrolimus predose concentration in 1304 patients. We did not find a 
significant correlation between tacrolimus predose concentrations and the incidence of 
biopsy-proven acute rejection. 
In chapter 5 we have reported the studies on mycophenolate mofetil. We have studied 
whether polymorphisms in the SLCO1B gene and in the ABCB1 gene in renal transplant 
patients are related to MPA pharmacokinetics or to the occurrence of MPA-related diarrhea. 
We have found that the pharmacokinetics of MPA are not influenced by the investigated 
SLCO1B nor by the ABCB1 SNPs. Moreover, the incidence of diarrhea in the MPA treated 
patients could not be explained by the differences in the SLCO1B or the ABCB1 genotypes. 
In chapter 5.2 we have studied if the polymorphisms in the IL12A, CYP2C8 and HUS1 genes 
are associated with the occurrence of MPA related anemia and leucopenia. We concluded 
that the CYP2C8A allele carriers have a higher risk to develop anemia and leucopenia, 
but the IL12A and HUS1 gene polymorphisms were not associated with the incidence of 
anemia. 
Samenvatting
Het huidige immunosuppressieve regime voor de preventie van acute afstoting na 
niertransplantatie bestaat voornamelijk uit de combinatie van een calcineurineremmer 
(CNI), hetzij ciclosporine of tacrolimus, met mycofenolaat mofetil ( MMF ) en glucocorticoïden 
met of zonder inductie therapie. Met de ontwikkeling van deze combinatietherapie is de 
overleving van zowel de getransplanteerde nier als van de patiënt sterk verbeterd.
Hoofdstuk 2 beschrijft de resultaten van de studies over de relatie tussen genetische 
polymorfismen (“single-nucleotide polymorphisms; SNPs) in het CYP3A en ABCB1 gen 
en de farmacokinetiek en farmacodynamiek van calcineurineremmers. In de eerste 
paragraaf (2.1) hebben we aangetoond dat de polymorfismen in het CYP3A4, CYP3A5 
en ABCB1 gen de grote interindividuele farmacokinetische variabiliteit van cyclosporine 
niet kunnen verklaren. De nierfunctie en de incidentie van acute afstoting bleek ook niet 
geassocieerd met polymorfismen in deze genen. De volgende twee hoofdstukken (2.2 en 
2.3) beschrijven we het onderzoek naar het CYP3A4*22 polymorfisme. In paragraaf 2.2 
tonen we aan dat in niertransplantatie patiënten die behandeld worden met ciclosporine, 
het CYP3A4*22 T variant allel een risicofactor is voor een vertraagde transplantaat functie 
en een slechtere nierfunctie. In hoofdstuk paragraaf 2.3 hebben we het CYP3A4*22 
polymorfisme onderzocht in relatie tot de farmacokinetiek tacrolimus. In deze hfdts hebben 
we voor de eerste keer laten zien dat het CYP3A4*22 polymorfisme in niertransplantatie 
patiënten is geassocieerd met een verminderde klaring van tacrolimus. We hebben in 
deze studie aangetoond dat niertransplantatie patiënten die 1 of 2 T allelen hebben van 
het CYP3A4*22 gen, een 33% lagere gemiddelde dosis van tacrolimus nodig hebben voor 
de beoogde tacrolimus concentratie (C
0
) vergeleken met wild-type patiënten. De vierde 
paragraaf van hoofdstuk 2 bestudeerde de invloed van het ABCB1 3435C>T polymorfisme 
op de farmacodynamiek van tacrolimus. In een in vitro studie hebben wij aangetoond de 
cytokine productie in T cellen, die geremd wordt door tacrolimus, door de ABCB1 remmer 
verapamil verder wordt geremd, vermoedelijk doordat verapamil zorgt voor een hogere 
intra-cellulaire tacrolimus concentratie. We hebben laten zien dat in niertransplantatie 
patiënten die behandeld worden met tacrolimus en die het ABCB1 3435CC genotype 
hebben, de actieve ABCB1 variant, verapamil de IL-2 productie verlaagt. Daarentegen heeft 
verapamil bij patiënten met het inactieve ABCB1 genotype, ABCB1 3435TT, geen invloed 
op de IL-2 productie. Ook hier speelt de accumulatie van tacrolimus intra-cellulair een 
belangrijke rol. We hebben ook ‘de behoefte aan tacrolimus’ berekend, door de ratio te 
berekenen tussen tacrolimus dalspiegels en het percentage IL-2 producerende T-cellen. De 
ratio was significant hoger in patiënten met een actieve ABCB1 pomp (3435CC genotype) 
vergeleken met patiënten met het 3435TT genotype. Dit impliceert dat tacrolimus minder 
effect heeft in niertransplantatie patiënten met het 3435CC genotype. In de laatste 
paragraaf (2.5) hebben we de literatuur bestudeerd met betrekking tot farmacogenetische 
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factoren en calcineurin geïnduceerde nefrotoxiciteit. We hebben bewijs gevonden in 
de literatuur dat ABCB1 en in mindere mate CYP3A5 betrokken zijn bij de pathogenese 
van CNI geïnduceerde renale dysfunctie. Daarnaast zouden polymorfismen in het ABCB1 
en CYP3A5 gen een deel van de interindividuele verschillen in de gevoeligheid voor de 
nefrotoxische werking van calcineurineremmers verklaren, maar er worden tegenstrijdige 
resultaten gevonden.
Naast de interindividuele verschillen in de kinetiek van immunosuppressieve therapie 
hebben we in hoofdstuk 3 de intra-patiënt variabiliteit van tacrolimus farmacokinetiek 
bestudeerd. In de eerste paragraaf (3.1) hebben we onderzocht of het CYP3A5 genotype 
de intra-patient variabiliteit in tacrolimus farmacokinetiek kan verklaren. We hebben 
gevonden dat het CYP3A5 genotype geen invloed heeft op de intra-patient variabiliteit van 
tacrolimus. In de tweede paragraaf hebben we de intra-patiënt variabiliteit in tacrolimus 
klaring onderzocht na harttransplantatie. We hebben onderzocht of een hoge intra-
patiënt variabiliteit in tacrolimus klaring geassocieerd is met een snellere progressie van 
cardiale allograft vasculopathie. Uit deze studie blijkt dat de intra-patiënt variabiliteit in 
tacrolimus farmacokinetiek niet is gecorreleerd met cardiale allograft vasculopathie 4 jaar 
na transplantatie, noch met acute afstoting na harttransplantatie.
Hoofdstuk 4 is gewijd aan het meten van concentraties van geneesmiddelen in het 
bloed (TDM). Tijdens behandeling met tacrolimus wordt TDM universeel toegepast. De 
concentratie - effect relatie voor tacrolimus is echter slecht gedefinieerd. Wij hebben 
onderzocht of de tacrolimus concentraties een relatie hebben met acute afstoting na 
niertransplantatie. We hebben gegevens samengevoegd uit drie grote klinische studies 
en hebben de relatie tussen biopsie bewezen acute afstoting en tacrolimus predose-
concentraties in 1304 patiënten onderzocht. Wij zagen geen significante correlatie tussen 
tacrolimus predose concentraties en de incidentie van acute afstoting.
In hoofdstuk 5 zijn de studies gerapporteerd over mycofenolaat mofetil. Er is onderzocht of 
polymorfismen in het SLCO1B gen en in het ABCB1 gen bij niertransplantatiepatiënten zijn 
gerelateerd aan de farmacokinetiek van MPA en het optreden van de MPA-gerelateerde 
diarree. Wij hebben gevonden dat de farmacokinetiek van MPA niet wordt beïnvloed door 
de onderzochte SLCO1B noch door de ABCB1 SNPs. Bovendien wordt de incidentie van 
diarree in de MPA behandelde patiënten niet verklaard door de verschillende SLCO1B of de 
ABCB1 genotypes. In hoofdstuk 5.2 hebben we onderzocht of polymorfismen in het IL12A, 
CYP2C8 en HUS1 gen geassocieerd zijn met het optreden van MPA gerelateerde anemie 
en leukopenie. De conclusie luidt dat patiënten met het CYP2C8A allel een hoger risico 
hebben om anemie en leukopenie te ontwikkelen, maar de IL12A en HUS1 polymorfismen 
niet geassocieerd zijn met de incidentie van anemie of leukopenie.
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onderzoeken. 
Tevens wil ik professor Lindemans, professor Kuypers, professor Hilbrands en dr. Balk 
bedanken voor hun deelname aan de oppositie. 
Ik wil mijn dank uiten aan alle patiënten die deelgenomen hebben aan de onderzoeken. 
Mijn proefschrift is een resultaat behaald op verschillende afdelingen. Mijn dank gaat dan 
ook uit naar al deze diverse afdelingen. 
Het transplantatielaboratorium, waar ik vele uurtjes heb mogen doorbrengen. Beste Carla, 
dank dat je me deze mogelijkheid hebt geboden. Ramin, en alle anderen op het translab 
bedankt voor jullie gastvrijheid en alle uitleg over het FACSen, ficollen etc. 
De afdeling Klinische Chemie, onder leiding van professor van Schaik. Beste Ron, dank dat 
ik de genotyperingen bij jou heb mogen uitvoeren. Genetica is een belangrijk onderdeel 
van mijn proefschrift en zonder jouw hulp, was het uitvoeren van vele onderzoeken en het 
schrijven van de manuscripten niet mogelijk geweest. My gratitude also goes to professor 
Elens, dear Laure, thank you for all your help with the research! Beste Martin, bedankt dat 
jij mij het genotyperen hebt willen leren en dat je mij veel werk uit handen hebt genomen 
door menig patiënt zelf te typeren. 
De afdeling transplantatie, dank dat jullie bereid waren aan mijn onderzoek mee te 
werken! De transplantatie coördinatoren onder leiding van Willy Zuidema, dank voor 
al jullie werk met de patiënt-statussen. De researchverpleegkundigen, met name Anita 
Mathoera, Monique Cadogan en Nelly de Leeuw, bedankt dat jullie de logistiek rondom 
de mozaiek studie zo kundig hebben weten te coördineren! Saida Ibrahimi, bedankt voor 
alle administratieve zaken die rondom mijn promotie zijn geregeld door jou! Tevens wil 
ik op deze plek mijn dank uiten aan alle nefrologen die bereid waren mee te werken aan 
de studies: Beste Joke Roodnat, Jaqueline van de Wetering, Marcia Kho, Iris Noorlander, 
Ewout Hoorn, Ajda Rowshani, Stefan Berger, Bob Zietse en Michiel Betjes bedankt. 
De afdeling cardiologie dank voor hulp bij de analyses van de harttransplantatie patiënten. 
In het bijzonder mijn dank aan Alina Constantinescu.
Als laatste afdeling, de afdeling waar ik het meest te vinden was, de apotheek onder leiding 
van Dr. Roos. Beste Peter, bedankt dat ik onderdeel mag uitmaken van deze afdeling. 
Alle collega’s van de apotheek ben ik mijn dank verschuldigd voor de bijdrage aan mijn 
onderzoek in de bredere zin en de interesse in mijn onderzoek. 
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Alle jonge apo’s, bedankt voor jullie belangstelling in mijn onderzoek en de gezelligheid 
in de apotheek. Voor alle promovendi van de apotheek, veel succes met jullie onderzoek: 
Anna de Goede, Rianne Zaal, Roelof van Leeuwen, Iris van der Velde en Linda Franken. In het 
bijzonder Rianne Zaal, beste Rianne, dank dat ik straks jouw team mag komen versterken, 
ik heb er zin in! Tevens wil ik bij naam genoemd hebben Wassima Daoudi - Ajarai en Tilly 
Bol, onze secretaresses, dank voor al jullie hulp bij alle administratieve bezigheden! 
Nilufar Pashaee, als farmaciestudent heb je samen met mij onderzoek verricht en hebben 
we een mooi artikel als eindresultaat! Bedankt voor je inzet! Ivonne Buijt, beste Ivonne, als 
voor mij volwaardig statisticus heb je me vele statistische technieken bijgebracht. Bedankt 
dat je altijd bereid was om mijn statistische vragen te beantwoorden. Judith Kal, dank voor 
je hulp bij alle database taferelen!
Mijn paranimfen Nauras Shuker en Lisette Binkhorst wil ik bedanken dat jullie mij terzijde 
willen staan op de grote dag. Nog een jaartje en dan zijn jullie ook aan de beurt! Beste 
Lisette, dank voor al je motivatie gedurende het traject. Beste Nauras, ik ben jou veel 
dank verschuldigd voor de hulp die je hebt geboden bij mijn onderzoeken! Ik bewonder je 
ijverigheid en dank voor alle gezelligheid. Nog een keer binnen een dag heen en weer naar 
Spanje om te shoppen in Barcelona…?
Mijn dank gaat ook uit naar Fathia Kasmi en Rashida El-Barkany, lieve vriendinnetjes, al 
meer dan 10 jaar aan mijn zij, zoveel samen meegemaakt en ben nog steeds iedere dag 
dankbaar dat jullie in mijn leven zijn. Mijn andere vriendin die ik hier wil noemen, Jamila 
Lachhab, ik bewonder jouw kennis en bedank je voor je motiverende gesprekken! Hoewel 
ik je helaas niet meer zo vaak zie, uit het oog betekent zeker niet uit het hart. 
Mijn familie kan ik niet genoeg bedanken voor alles! Yema, lieve mama, shokran! Je bent 
een vrouw uit duizenden en ooit zei iemand: ‘noem me rijk, want ik bezit een moeder van 
goud’, voor mij geld hetzelfde. Wewa, lieve papa, helaas kan ik jou nu niet meer persoonlijk 
bedanken, maar ik weet dat jij trots op mij geweest zou zijn! Lieve (schoon) zussen en 
broers, malika, majid, malika, saida,fouad, caren, hayat, karima en latifa, bedankt voor 
jullie onvoorwaardelijke liefde! Ik prijs mij gelukkig met jullie als mijn familie. 
Mijn schoonfamilie, lieve schoonouders dank dat jullie mij zo openhartig hebben 
opgenomen in jullie familie! Shokran voor al jullie bereidheid om elke keer weer Obaida op 
te halen en om hem met zoveel liefde op te voeden. Shokran! Lieve schoonzusjes, Latifa, 
Lamia en Halima, dank jullie wel voor alles. Jullie zijn de beste schoonzusjes die een vrouw 
zich kan wensen! Bedankt voor al jullie gezelligheid!
Als laatste dank ik mijn twee mannen. Obaida, lieve zoon, jij hebt mij laten inzien wat echt 
belangrijk voor mij is in dit leven. Tevens heb je met jouw komst 'efficiënt werken' een 
echte betekenis gegeven. Abdelbasit, mijn gevoel voor jou rechtvaardig ik niet door alleen 
te zeggen bedankt... Jij bent onze steunpilaar en mijn alles, ik dank Allah (swt) dat jij in mijn 
leven bent gekomen. Ik hou zielsveel van je! 
Alhamdoulilah
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